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Abstract 
Fluorescent ligands have found numerous applications for studying interactions of drug 
molecules with their target and as a probe of biological systems. A common approach when 
designing and synthesising a fluorescent ligand is to separate the fluorophore and 
pharmacophore via a linker. One novel approach is to utilise click chemistry to allow the 
coupling of fluorophore to a pharmacophore. This thesis reports the results of an investigation 
into utilising click chemistry, specifically the alkyne-azide copper (I) cycloaddition to 
synthesis novel fluorescent GPCR ligands. Targets included the ȕ1, ȕ2 adrenoceptor and the 
muscarinic M3 receptor.  
Investigations into the introduction of a 1,2,3-triazole within the linker to the fluorophore 
resulted in 14 novel fluorescent antagonists active at the ȕ1 and ȕ2 adrenoceptor. The most 
promising ligand had log Ki values of -6.77 ± 0.20 (ȕ1) and -7.32 ± 0.05 (ȕ2). These ligands 
were used in a confocal microscopy studies to visualise the ȕ1 and ȕ2 adrenoceptors on the 
surface of CHO cells. However the ligands internalistion, and receptor visualisation was not 
possible. A range of structural modifications were made to reduce this with the introduction of 
a polar linker but this did not reduce the intracellular accumulation. The change to a longer 
wavelength fluorophore stopped intracellular accumulation but reduced the binding log Ki to -
5.16 ± 0.06 (ȕ1) -5.96 ± 0.20 (ȕ2). 
Twenty two novel fluorescent M3 ligands were synthesised and their inhibitory properties were 
investigated. An initial screen showed four promising ligands and further study into the 
binding affinities showed the ligands to have high potency (log Kb -7.97 ± 0.07 to -8.89 ± 0.11). 
These ligands were studied with confocal microscopy and intracellular accumulation did not 
occur. Structural changes to include a polar side chain or a sulfonic acid onto the fluorophore 
were investigated and led to three novel fluorescent ligands that had reduced lipophilicity. 
With this reduced lipophilicity, binding affinities were also reduced by ten fold compared to 
the original fluorescent ligand. The seven ligands were fully profiled physiochemically and 
kinetically. The physioschemical properties of these seven ligands gave a wide variety of 
lipophilic values. The kinetic profiles of the ligands exhibited very similar dissociation 
properties to those of the parent ligand with varying association rates. 
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The Muscarinic M3 ligands synthesised show great binding affinities for fluorescent ligands 
and kinetic profiles that are extremely similar to the parent ligand. These fluorescent ligands 
hold characteristics that can be used to further examine the pharmacology of muscarinic 
receptors and be used to replace radioligands for binding studies.  
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IC50  molar concentration which inhibits 50% of the maximal stimulatory response. 
IAM  immobilised artificial membrane 
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1. Introduction 
1.1. G-protein coupled receptors 
Guanine nucleotide binding protein coupled receptors (GPCRs) are the largest class of cell 
surface receptors. The amino acids of a GPCR protein molecule are wound into seven helices, 
which span the cell membrane and are often referred to as transmembrane domains.1 GPCRs 
consist of a single polypeptide chain of up to 1100 residues and compose the greatest single 
gene family, with approximately 800 genes in the human genome.2 The seven membrane-
spanning domains are connected by three intracellular and three extracellular loops. The N-
terminus resides outside the cell while the C-terminal domain is located inside the cell (Figure 
1.1).1 GPCRs play a critical role in the human body by controlling numerous biological and 
physiological functions, and can be activated by many different endogenous stimuli, including 
neurotransmitters, peptides and hormones, e.g. dopamine, adenosine, acetylcholine and 
glucagon.3 GPCRs are a major target area in pharmaceutical research and more than 60 new 
GPCR drugs have been launched in the past decade, representing approximately 24% of all 
drugs reaching the market.4 
 
Figure 1.1. Representation of a GPCR. The structure of the protein shows the seven transmembrane domains, the 
extracellular and intracellular loops, the NH2 and COOH termini. 
 GPCRs can be categorised into six families based on their activating ligands and sequence 
similarity. Three of these exist in mammals and are named ‘A’, ‘B’ and ‘C’.5 Group A is the 
largest subgroup, often known as the rhodopsin-like family, and contains receptors for odorants, 
  ?
small molecules such as biogenic amines, some small peptides, glycoprotein hormones and 
photons.6 This group is characterised by several conserved amino acids and a disulfide bridge 
that connects the first and second extracellular loop.5,7,8 The second largest subgroup is group 
B, also known as the secretin family, and its members are activated by hormones such as 
glucagon, gonadtropin-releasing hormones and parathyroid hormones.9 These peptides activate 
their receptors by a two-domain model in which the peptides bind at two sites before receptor 
activation.10 The final GPCR group found in mammals is Group C, also known as the 
metabotropic glutamate family, which contains receptors such as the metabotropic glutamate, 
Ca2+-sensing and Ȗ-aminobutyric (GABA)B. These receptors are characterised by a long amino 
terminus region and carboxy tail. The ligand-binding domain is located in the amino terminus, 
which has a large lobed structure.11 
1.1.1 G-proteins 
GPCRs are molecules that recognise external stimuli such as hormones, odorants and 
neurotransmitters. For this recognition to be transmitted to the cell, GPCRs are coupled to 
transducer molecules. These transducer molecules are heterotrimeric G-proteins that are 
capable of transferring the recognised external stimuli into an intracellular signal.12 Each G-
protein contains three subunits: Į, ȕ and Ȗ. Following receptor activation, GPCRs catalyse the 
exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on the GĮ 
subunit, which leads to a decreased affinity for ȕȖ and this results in dissociation.13 This allows 
subunits to activate a range of downstream signalling pathways, dependent on the G-protein. 
G-proteins belong to five different families (GĮs, GĮi, GĮq/11 GĮo and GĮ12/13) based on the Į 
subunit sequence identity and signaling activity.12,13  
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1.2.1 Molecular modelling 
 Molecular modelling is a collective term that refers to the theoretical methods and 
computational techniques used to model or mimic the behavior of molecules that can be 
applied for drug design and discovery. These techniques, such as de novo ligand design 
methods, use computational methods for designing molecules that complement a receptor or 
binding site structurally and energetically from X-ray crystal structures or receptors of similar 
nature.18 The aim of this approach is to design ligands that have high binding affinities for their 
respective target. De novo ligand design has been argued to be most successful when it benefits 
from established biological and experimental knowledge of the target and receptor.19 
Designing ligands from fundamentals can be applied from two approaches: molecular 
fragment20 and sequential growth.21  
 Sequential growth is a technique that ‘grows’ molecules into an active site, starting from a 
seed (small molecule or fragment) bound into the active site. The ligand can be grown via the 
addition of either a single atom or molecular fragment calculated as being complementary to 
the active site geometrically and/or energetically.22,23 The second molecular fragment approach 
docks molecular fragments on the active site to determine favourable positions based on 
energetically superior configurations. These fragments are then linked together. The initial step 
in this process is to discover the key locations of the active site and then bind small fragments 
to these positions. Once this is achieved, linking the fragments with a scaffold is carried 
out.19,20 Firth-Clark et al.24 used this process to develop lead compounds for the ATP-binding 
site of DNA gyrase.  
An in-depth review of GPCR de novo ligand screening was published by de Graaf and 
Rognan,25 and readers are directed to this publication.  
1.2.2 X-ray crystallography 
 In recent years, the study of GPCRs at the molecular level has developed significantly within 
X-ray crystallography that affords new dimensions to the use of computational chemistry. 
X-ray crystallography produces a three-dimensional molecular structure by X-ray diffraction. 
Unfortunately, members of the GPCR family possess attributes that are undesirable in relation 
to the classical techniques employed in crystallising proteins. GPCRs require the cell 
  ?
membrane for structural integrity and are generally unstable in detergent solutions.26 Since the 
first X-ray crystal structure of a human GPCR was solved in 2000 by Palczewski et al.27 there 
has been  large scope for development with more than 40 crystal structures of GPCRs entered 
in the protein data bank.4 Many of these crystal structures have been solved with a medium to 
high resolution, in most cases with a small molecule ligand incorporated into the structure. 
Examples of these include rhodopsin, adenosine A2A,
28 chemokine CXCR4,29 dopamine D3,
30
 
the ȕ1 and ȕ2 adrenoceptors,26,31,32 and the histamine H1 receptor.33  Some receptors have been 
engineered for stability using either point mutations of amino acids or the replacement of 
intracellular loops with lysozymes,34 and these modifications are shown not to affect ligand 
binding.26,35  
1.2.3.GPCR Pharmacology 
It is important to evaluate whether a new ligand is an agonist or antagonist and what the 
potency of the ligand is. It is critical to differentiate between an agonist and antagonist as these 
will give different effects on the receptor and the possible downstream effects. An agonist is 
defined as a ligand that binds to a receptor and alters the receptor state resulting in a 
pharmacological response. Agonists can be sub categorised into full agonists, partial agonists 
and inverse agonists. Full agonists activate the receptor and display full efficacy for the 
receptor, while a partial agonist will only have partial efficacy for the receptor relative to a full 
agonist. An inverse agonist is a ligand that binds to the orthosteric binding site but induces a 
pharmacological effect opposite to that of the agonist. This is usually shown with a decrease in 
basal level of activity of the receptor when no ligand is bound. An antagonist is ligand that 
does not induce a biological response when bound to the orthosteric binding site, but can block 
or dampen agonist-mediated responses. Figure 1.3 shows typical dose response curves for full, 
partial and inverse agonist as well as antagonists. 
  ?
 
Figure 1.3. Effect of various types of ligands on receptor response. (Effect is quote in %) 
 
 Some assays do not give functional results and just identify what that binding affinity of the 
ligand is while other assays give more accurate and comprehensive data of the compound 
targeting the GPCR. 
1.2.3.1.Radioligand binding experiments 
Radioligand based assays examine the binding of radioactive ligands to their counter-receptors. 
These assays are excellent for the determination of ligand affinity, but do not provide any 
information on the function of the ligand. There are three main types of radioligand binding 
assay: saturation assays, competition assays36 and kinetic assays.37 Saturation experiments can 
determine the affinity (Kd) of a radioligand and the maximal specific binding of a ligand (Bmax), 
while competition experiments are used to determine the affinity of unlabelled ligands (Ki).
36 
Receptor kinetic experiments allow the calculation of association and dissociation rates of 
radiolabelled ligands and non-labelled ligands. The drawbacks to using radioligands are the 
requirement of a large cell population (>104) if using whole cells. Radioligands are hazardous 
substances that need to be accounted for and must be disposed of in the correct manner, which 
can be expensive. When there is no commercially available radioligand for the receptor, 
synthesis of a radioligand is required, which is associated with drawbacks such as half-life of 
the radioligand and synthesis time. 
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1.2.3.2. GTPȖS binding assays 
 GTPȖS binding assays directly measure the guanine nucleotide exchange of G-proteins. 
Typically the acculimation of non hydrolysable GTP analogue, Upon receptor activation of the 
GPCR by an agonist, the receptor changes conformation exposing a binding site for a G-
protein complex. Once this G-protein complex is bound, the GĮ protein can release GDP and 
bind GTP. As the GTP is radiolabelled, usually [35S] GTPȖS, it is possible to measure the 
activation of the GPCR bing studied by measuring the amount of radiolabled GTP bound to the 
cell membrane,As this assay depends on receptor activation it is possible to determine whether 
a ligand is an agonist, antagonist or inverse agonist.38  
The disadvantages to this assay are that radioactive compounds are being used which have 
already been stated, and also a filtration step is required to separate the membrane bound [35S] 
GTPȖS to the unbound which can cause problems when using this as a high throughput assay.  
1.2.3.3. cAMP assays 
GĮs and GĮi/o G proteins when activated, affect andenylyl cylase and the production of cyclic 
adenosine monophosphate (cAMP). In cAMP assays, cAMP levels are typically measured 
using competition assays in which a cellular cAMP competes with an introduced labeled form 
of cAMP for binding to an anti-cAMP antibody.39 When GĮs is activated, a stimulatory effect 
of adenylyl cyclase is caused resulting in an increase in cellular cAMP which can be calculated. 
When GĮi/o is stimulated an inhibitory effect of adenylate cyclase occurs and a decrease in 
cAMP levels occur. 40 
This style of assay is only applicable to GPCRs that stimulate a cAMP response. GĮi/o 
dependent receptors can be difficult to screen as well as antagonists for both G-proteins.  
1.2.3.4. Reporter assays 
A reporter gene is a sequence of DNA that encodes for an easily measured protein product that 
is synthesised in response to the activation of a particular signalling cascade. The DNA 
sequence consists of three essential parts, a promoter, where transcription factors bind to 
control transcription, the reporter gene itself and a transcription stop signal.41 When a GPCR is 
activated, downstream signalling occurs and one response from a secondary messenger is gene 
transcription alteration. These secondary messengers are all located within the gene promoter 
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regions and can therefore be used for cell based assays for GPCR drug discovery.42  The 
reporter gene assays have the potential to determine the affinities, efficacies and potencies of 
respective antagonists and agonists. 
There are a range of disadvantages of the report gene assay. Firstly a long assay time is 
required, usually in the range of four to six hours, this is for the expression of the report gene 
product. Another disadvantage of the assay is the requirement of the cells to be transfected 
with the receptor gene and possible drugs used in the assay may effect other mechanisms 
further along the signal pathway. This could lead to the reporter readout becoming a mixture of 
activity at the receptor and a point elsewhere in the signalling cascade which generates false 
potencies for ligand-binding interactions.41 
1.2.3.5. Ca2+ assay 
Upon GPCR activation of a GĮq or GĮi coupled receptor, activation of phospholipase C to 
hydrolyse phosphatidylinositol biphosphate to form two secondary messengers, inositol 1,4,5-
triphosphate (IP3) and diacylglycerol. IP3 activates the IP3 receptors located on the 
endoplasmic reticulum resulting in an efflux of Ca2+ into the cytoplasm and an elevation of 
intracellular Ca2+.43 The Ca2+ assay utilises cell permeable Ca2+ sensitive fluorescent dyes that 
when bound to Ca2+ change their fluorescent properties that can determine whether a ligand is 
an agonist or an antagonist.  
This style of assay does have some disadvantages such as it cannot be used to screen for 
inverse agonists due to increase of basal Ca2+ is not observed. The assay is not suitable for 
ligands that have slow associate rates as calcium flux occurs rapidly and transiently.44   
1.2.4 Fluorescence 
Fluorescent probes have been used to study various receptors45-53 and these fluorescent probes 
offer many advantages over the conventional techniques currently used, and fluorescent probes 
are now being used in the assays previously mentioned. There are binding assays based on time 
resolved fluorescent resonance energy transfer, and homogenous time-resolved fluorescence 
technology.54 These assays remove the health and safety issues, synthetic problems and 
inconvenient short half lives of the radio isoptopes. Modifications to the cAMP assays has 
resulted in a fluorescent polarisation assay. This assay works in similar fashion but the 
  ?
competition is a between fluorescently labeled cAMP and non-labeled cAMP for a fixed 
number of antibody binding sites, again removing the hazardous radio isotope from the assay.55 
 Another benefit to using fluorescence for studying GPCRs is the conjugation of a fluorescent 
molecule to an established orthosteric ligand can be used to study ligand-binding interactions 
at the cellular level. They have the advantage of an easier less restrictive synthetic procedure as 
well as allowing direct visualisation using confocal microscopy, amongst other techniques, to 
determine the actual location of receptors within a single cell. This allows small numbers of 
cells to be used for each experiment and results can be obtained in real time.56 Fluorescent 
molecules can also be displaced by non-fluorescent ligands to examine specific and non-
specific binding. There are, however, some perceived disadvantages of using fluorescence-
based techniques. The addition of a fluorescent probe to a pharmacologically active ligand or 
indeed the receptor itself can alter their properties, and this needs to be considered. In addition, 
cells and tissues exhibit background fluorescence, which can cause problems when studying 
fluorescent receptors and ligands. When studying fluorescent proteins or ligands within a 
biological sample the signal of interest must be from the molecule or protein. Background 
fluorescence can add intensity to the signal of interest and it can be sourced from a range of 
cellular components, depending on the specimen being used. Examples consist of NADH, 
riboflavins and flavin coenzymes.57 Collagen, elastin and monomers of tubulin can also cause 
background fluorescence. If using cells, cell culture media that contain phenol red, vitamins 
and other components that fluoresce can cause issues if the samples are not washed 
thoroughly.58 Background fluorescence is known to be stronger at all wavelengths in the green 
and blue spectral region below 500 nm.59 
1.2.4.1 Principles of fluorescence  
Fluorescence is based on the properties of some molecules (generally polyaromatic 
hydrocarbons or heterocycles) that when excited by a photon can absorb the energy of that 
photon causing an excited electronic state (S1, S2). Upon relaxation from the excited state the 
same molecule releases a photon, this process is known as fluorescence emission.  The photon 
that is released from the molecule is of lower energy than the exciting photon. This is referred 
to as the Stokes shift, reducing the excited electronic state back to the ground state (S0). If a 
molecule that absorbs a photon does not emit a photon, it is regarded that the energy is lost 
  ? ?
through vibration and rotation of bonds. These processes are called radiation less transfer of 
energy.60 
 
Figure 1.4. Energy diagram for a fluorescent molecule (S0, electronic ground state; S1 and S2, electronic excited state.) 
1.2.4.2 Fluorescence techniques 
1.2.4.2.1 Confocal microscopy 
Confocal microscopy is a powerful tool for generating high-resolution images and 3-D 
reconstructions of a specimen. In confocal microscopy a laser light beam is focused onto a 
fluorescent specimen through the objective lens. The mixture of reflected and emitted light is 
captured by the same objective and is sent to the dichroic mirror. The reflected light is deviated 
by the mirror while the emitted fluorescent light passes through a confocal aperture (pinhole) 
to reduce the ‘out of focus’ light. The focused light then passes through the emission filter and 
proceeds to the photomultiplier.61 
Confocal microscopy can allow the study of ligand–receptor binding interactions at the single 
cell level and can capture biological processes such as localisation. Confocal microscopy has 
been used to visualise fluorescent probes on a range of receptors, including cannabinoid CB2,
62 
adenosine,63 adrenergic64 and mu opioid receptors.65  
1.2.4.2.2 Fluorescence polarisation 
Fluorescent polarisation (FP) is becoming an alternative to radioligand binding experiments and 
has many benefits over radioligand binding, such as low health and safety implications, 
homogenous format, high sensitivity and flexibility.66 FP uses polarised light to detect how 
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much fluorescent ligand is bound and not bound to a receptor. When polarised light is reflected 
from a bound ligand the light returns polarised as the bound ligand has little free rotation, unlike 
the free ligand, which can rotate freely in the extracellular media. This results in the return of 
non-polarised light.67 This can determine how much fluorescent ligand is bound when used in a 
competition assay, for example. 
1.2.4.2.3 Fluorescence correlation spectroscopy  
Fluorescence correlation spectroscopy (FCS) depends on small fluctuations in the fluorescence 
intensity as fluorescent particles move through a small defined volume.68 Statistical analyses of 
these fluctuations provide information regarding the diffusion coefficient of the labelled 
molecules being studied and their concentration. FCS is able to distinguish between bound and 
unbound species when studying receptor–ligand interactions.68 An unbound fluorescently 
tagged ligand in solution will show a fast diffusion coefficient, at a rate corresponding to its 
molecular mass. If that ligand subsequently binds to a slow-moving membrane-localised 
receptor, its diffusion coefficient will be significantly reduced, thus showing as a bound 
ligand.69 This reduction in the diffusion coefficient allows differentiation between free and 
bound ligand.  
1.2.4.2.4 Fluorescence resonance energy transfer  
Fluorescence resonance energy transfer (FRET) is a technique that utilises two separate 
fluorophores and the process of energy transfer. FRET uses the excited energy from one 
fluorophore (donor) to excite a separate fluorophore (acceptor) through a non-radiative process. 
This process is distance dependent and can be used to probe biological structures.70 FRET can 
allow the quantification of molecular interactions, such as between labelled receptors and 
ligands,71 protein conformational changes, and protein interactions.72  
For a more detailed review on fluorescence techniques, readers are directed to excellent reviews 
by Joo et al.73 and Hovius et al.71 
1.3 Current GPCR fluorescent ligands 
GPCRs have had a range of fluorescent ligands designed, synthesised and tested to investigate 
their pharmacology at the molecular level, and several thorough reviews have been published 
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covering fluorescent ligands and fluorescent imaging of GPCRs.66,68,74-77 McGrath et al.56 
published a comprehensive review of research on fluorescent ligands before 1996 and 
Middleton et al.74 provided a further review in 2005. There are also many examples of 
fluorescently labelled peptide ligands in the current literature; however, these will not be 
reviewed herein as our focus has been on small molecules. 
Xie et al.53 successfully developed an alternative for radioligand binding assay for histamine H2 
receptors by synthesising antagonists based upon the structure of aminopotentidine. These 
compounds were coupled with the commercially available fluorescent dyes S0536 or BODIPY 
650/665. The binding assays were performed on both human H2 receptors and guinea pig H2 
receptors. It was found that compound (1) bound with relatively high affinity (log Kb = í7.33) 
to the human H2 receptor as well as to the guinea pig H2 receptor (log Kb = í7.23). The coupling 
of the fluorophore to the pharmacophore was through amide bond formation. 
 
Figure 1.5. Structure of fluorescently labelled histamine H2 ligand. 
Cowart et al.78 synthesised and investigated eight benzofuran histamine H3 receptor antagonists. 
These compounds were based on ABT-239 and had a range of commercial fluorophores 
attached, including: nitrobenzofuran (NBD), benzo-2-oxa-1,3-diazole-4-sulfonate (SBD), 5-
(dimethylamino)naphthalene-1-sulfonyl chloride (dansyl chloride), 5-
carboxytetramethylrhodamine (5-TAMRA) and 6-carboxytetramethylrhodamine (6-TAMRA). 
The concept behind the fluorophores was to produce ligands with drug-like properties, such as 
good lipophilicity and no highly polar groups. The Ki values for the series of antagonists were 
in the range of log Ki = í10 to í8.22 at the human H3 receptor while the values were í9.92 to 
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í7.77 at the rat histamine H3 receptor, with the most potent antagonist (2) containing the NBD 
fluorophore.  
 
Figure 1.6. Structure of fluorescent histamine H1 ligand. 
Bonnet and co-workers synthesised fluorescent compounds through ‘click’ chemistry using 
Cu(I) catalysed 1,3-dipolar cycloaddition in an attempt to side-step some of the limitations of 
fluorescent probe synthesis; e.g. the requirement of excess reagents, and the generation of 
deleterious by-products that compromise both overall yield and purity. This approach focused 
on the insertion of a fluorophore onto a muscarinic antagonist scaffold that was derived from 
pirenzepine. The fluorophore incorporated into the scaffold was lissamine rhodamine B. The 
synthesis was performed in acetonitrile/water in the presence of CuSO4 and copper wire. This 
procedure afforded novel pirenzepine derivatives with nanomolar affinity for the muscarinic 
M1 receptor. The fluorescent ligand (3) was also examined in FRET based assays.
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Figure 1.7. Fluorescently labelled muscarinic M1 ligand. 
Lacivita et al.52 synthesised and developed a range of weakly fluorescent 5-HT1A ligands with 
nanomolar affinity for the receptor. Ligands were synthesised by a condensation reaction of the 
pharmacophore with the weakly fluorescent amine, 2-quinolinamine. The ligand with optimum 
binding (4) had a logKD = -9.39 and remained an antagonist. Within the same research group, 
red shifted 5HT-1A ligands were synthesised with the most potent ligand, 5, having a logKD -
7.20. Confocal microscopy was utilised and observed intracellular ligand accumulation. When 
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lower temperatures (4 °C) were used, less intracellular accumulation occurred and 
displacement of fluorescent ligand was achieved with serotonin.80  
 
Figure 1.8. Structure of weakly fluorescent and red shifted 5HT-1A ligands. 
Dopamine D3 fluorescent ligands were also synthesised within the same group. Two ligands (6 
& 7) were highly potent (logKD = -8.79 and -9.14). Epifluorescent microscopy was attempted 
but unfortunately visualisation was not possible.81  
 
Figure 1.9. Structure of fluorescent dopamine D3 ligands 
Briddon et al.47 describe FCS analysis of antagonist (8) with the adenosine A1 receptor. 
Confocal imaging allowed visualisation of the ligand at the receptor showing specific binding. 
The xanthine amine congener (XAC) derived fluorescent ligand had a binding affinity constant 
of -6.7 (logKb) calculated by cAMP accumulation and -6.5 (logKB) calculated by inositol 
phosphate accumulation. The ligand was readily synthesised by acylation of XAC by the 
commercially available BODIPY 630/650-X-succinimidyl ester.  
 
Figure 1.10. Structure of XAC-BODIPY 
Within the same research group Middleton et al.82 described the design and synthesis of a 
range of adenosine-A1 fluorescent agonists and the subsequent use of these in FCS-based 
studies of receptor- ligand interactions in live cells. The commercially available fluorophore 
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BODIPY 630/650 was again employed as the fluorophore of choice. FCS analysis allowed 
detection and quantification of receptor-ligand binding alongside confocal imaging 
demonstrating the specific nature of the receptor binding. The ligands displayed a range of 
pEC50 values ranging between 7.92 – 9.16.  
Further work in the group published by Cordeaux et al.83 described the use of FCS to 
investigate the diffusional characteristics of an agonist occupied A3 receptor using a 
fluorescent adenosine-A3 ligand. Studies included confocal microscopy utilising fluorescent 
ligands and fluorescent intracellular calcium detectors to visualise receptor binding and 
receptor activation. This allowed visualisation of both ligand and intracellular calcium 
production. The fluorescent ligand (9) utilised the commercially available BODIPY 630/650 
fluorophore.  
 
Figure 1.11. Structure of ABEA-X-BY630 
Baker et al.84 described a fuller investigation surrounding adenosine-A1 fluorescent ligands and 
how the linker and choice of fluorophore influences the pharmacology of the conjugated ligand. 
It was suggested from the results of two separate pharmacophores with different linkers and 
fluorophores that the physiochemical properties of the fluorophore and linker determine the 
ultimate utility of the fluorescent ligand. A range of fluorophores were investigated including 
Dansyl, Cy5, BODIPY 630/650, BODIPY FL and Texas Red with a range of linkers of 
differing length and chemical composition. 
Jones et al.85 developed a fluorescent muscarinic M3 antagonist based upon tolterodine. This 
scaffold had a commercially available BODIPY tag again attached through an amide bond and 
this resulted in a fluorescent M3 antagonist (10) with a log Ki = -8.33 calculated from 
radioligand binding experiments. It was later found that this ligand displayed poor stability and 
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degradation in solution with a t1/2 of one week. No other biological investigation was carried 
out on the ligand. 
 
Figure 1.12. Structure of fluorescent M3 ligand 
Baker et al.86 also described the use of a commercially available fluorescent ligand BODPIY-
TMR-CGP 12177 (11). Investigations into agonist activity through radioligand binding studies 
and confocal microscopy resulted in receptor visualisation and affinities to be calculated. 
Receptor binding could be reduced by pre-incubation with 3-(isopropylamino)-1-[(7-methyl-4-
indanyl)oxy]butan-2-ol (ICI 118551) or 4-[3-[(1,1-Dimethylethyl)amino]2-hydroxypropoxy]-
1,3-dihydro-2H-benzimidazol-2-one hydrochloride (CGP 12177). The fluorescent ligand had a 
low nanomolar affinity with values dependent upon on which assay was used.  
 
Figure 1.13. Structure of BODIPY-TMR-CGP 
A fluorescently labelled arterenol derived fluorescent ligand has been investigated by Hegener 
et al.87 The labelling of an arterenol pharmacophore with an alexa dye was used to study the 
ȕ2-adrenoceptor in living cells using FCS. It had respective log KD values of -8.88 and -8.22 at 
ȕ2 receptors of neurons (hippocampal neuron cells) and A549 cells (human cancer cells) 
respectively. It was calculated that the association rates were comparable in both cell types. 
Baker et al.64 recently published the synthesis and characterisation of high affinity BODIPY 
labelled ligands for the ȕ-adrenoceptors. Ligands were based on the orthosteric ligands 
propranolol, alprenolol and pindolol. These ligands had the commercially available BODIPY-
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630/650-X fluorophore tethered via a range of straight hydrocarbon or polyethylene glycol 
linkers. Binding affinities were calculated through radioligand binding experiments with [3H]-
4-[3-[(1,1-dimethylethyl)amino]2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one 
hydrochloride ([3H]-CGP 12177) and functional reporter gene assays. Confocal microscopy 
was used to visualise the binding of the fluorescent ligands at the ȕ2-adrenoceptor in single 
living cells. It was possible to prevent fluorescent ligand binding via pre-incubation with a 
non-selective antagonist. The most potent ligand was based on propranolol with a diethylene 
glycol linker (12); displaying log KD values of -9.53 and -8.46 at the ȕ2 and ȕ1 receptor 
respectively.  
 
Figure 1.14. Structure of fluorescent ȕ-adrenoceptor ligand 
It is clear from the above and other reports in the literature that fluorescently tagged ligands are 
now becoming a well-established practice for GPCR pharmacology with a range of different 
targets and different experiments being reported. The majority of fluorescent ligands 
synthesised have included a commercially available fluorophore attached by either amide bond 
formation or alkylation.   
1.4 Click chemistry 
To synthesise a fluorescent ligand, a fluorescent molecule needs to be attached to a biologically 
active molecule. As previously stated, this has been commonly achieved via either amide bond 
formation or alkylation reactions. These techniques can be troublesome if protecting groups 
need to be incorporated when synthesising novel fluorophores or connecting the fluorophore to 
the pharmacophore. One method to avoid the use of functional group protection to allow 
conjugation of a fluorescent molecule to an orthosteric ligand is through click chemistry. 
Bonnet and co-workers successfully achieved this when synthesising muscarinic M1 ligands.
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Click chemistry is a term defined by Barry K Sharpless to describe a style of chemistry that 
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joins small molecules together quickly.88 There are many types of click chemistry reactions, 
such as cycloadditions, olefin-based, and nucleophilic opening of rings. One of the most 
favoured reactions is the alkyne-azide copper (I) catalysed 1,3-cycloaddition which was 
evolved by the Sharpless and Meldal research groups.88,89 The original reaction was first 
developed by Rolf Huisgen with other 1,3-dipolar cycloadditions.90 It was noted that formation 
of triazoles from azides and acetylenes was first discovered 60 years earlier by O. Dimroth.91 
This reaction uses an azide functionalised molecule and a molecule with an alkyne functionality 
to form a five membered ring known as a 1,2,3-triazole shown in scheme 1.1, with the 
mechanism shown in figure 1.14. The original Huisgen 1,3-cyclo-addition did not use catalysts, 
and used high temperatures that resulted in a mixture of 1,4 and 1,5-adducts while the work of 
Sharpless and Meldal ultilised copper catalysis to optimise the regio-isomerism. The reaction 
time was decreased without the need for high temperatures which was also a reason for mixed 
isomerism, which is still true with the catalysed reaction.92 Another catalyst that can be used is 
a ruthenium metal catalyst, which results in a 1,5-regioisomer.93 
 
Scheme 1.1. Synthesis of a triazole from an azide and an alkyne using click chemistry. 
  ? ?
 
Figure 1.15 Mechanism for the click chemistry 1,3-cycloaddtion. 
A mechanism has been proposed for the click reaction using density functional theory 
calculations and is shown in figure 1.15.94 The mechanism begins with (1) the alkyne 
coordinating with the copper (I) species, displacing one ligand from the copper and results in 
the conversion of the alkyne to an acetylide. The next step (2) involves the replacement of one 
ligand in the copper complex with the azide. This allows binding to the copper via the nitrogen 
proximal to the carbon (3). The distal nitrogen in the azide attacks the acetylene carbon 
forming an unsual six membered copper (III) metallacycle. Step (4) is a ring contraction 
resulting in the five membered triazolyl-copper derivative and final protonation of the five 
membered ring releases the 1,2,3-triazole as the product and completing the cycle (5). 
 It has been noted that both azide and alkyne groups are very convenient functional groups due 
to the ease with which they can be introduced into a molecule, their stability under a variety of 
conditions and that they are stable in organic conditions that include molecular oxygen, water 
and the majority of common reaction conditions employed in modern-day synthesis.95-97 It is 
widely accepted that the two functional groups can be attached when needed for convenience 
and remain unaffected through a number of transformations unlike other reactive groups that 
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could be used to couple fluorophores to pharmacophores such as amines, carboxylic acids, 
alcohols and halides. When using azides and alkynes, side group modifications can be made 
without the need for protecting groups and this is also true when coupling the azide and alkyne 
together. Thus making the click chemistry reaction highly reliable, with the reaction being 
experimentally straightforward.98 Whilst the reaction (to form the 1,4 adduct) can be performed 
using commercial sources of copper (I) such as cuprous bromide or iodide, it has also been 
reported that the reaction works much better using a mixture of copper (II) usually in the form 
of copper (II) sulfate and a reducing agent with common agents being sodium ascorbate or 
copper wire; which produces Cu (I) in situ.79 The reaction can be performed in a range of 
solvents and a mixture of solvents are common, usually water and a partially miscible organic 
solvent such as acetone, methanol, ethanol and acetonitrile. In many cases, the product can be 
simply be filtered from the solution.99 
 
1.5 Research aims 
Fluorescent ligands have found numerous applications for studying the interactions of drug 
molecules and probes with biological systems.74 For a large proportion of these applications 
the use of fluorescently labelled molecules offers potential for a unique insight into following 
the course of cellular processes, or a more efficient and safer alternative to radio-labelled 
derivatives for routine applications such as for those used in ligand binding assays. The aims of 
this research are to identify an efficient and broadly applicable route to fluorescently labelled 
ligands and then demonstrate their effectiveness in a pharmacological setting.  
For this approach to be suitable for a range of applications it requires chemistry that is widely 
applicable, from readily available starting materials, that proceeds in a reliable and efficient 
manner and that is tolerant of a wide range of functionality, ideally without the need for 
protecting groups. 
 The aims are to establish the chemistry to produce key fluorescently-labelled synthons for use 
in a click chemistry labelling step and then to explore their introduction into pharmacophores. 
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In addition these ligands will be investigated in a pharmacological manner at the receptor 
target through a number of processes. 
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2. Design and synthesis of fluorescent beta-
adrenoceptor ligands  
2.1 Adrenoceptors 
One GPCR receptor subtype that is of interest is the adrenoceptor family. These receptors have 
been the target for numerous drug discovery projects and have been established as key 
therapeutic targets for cardiovascular and respiratory diseases.64 There are two types of 
adrenoceptor: Į and ȕ. The Į-adrenoceptors are subdivided into Į1 and Į2; the ȕ-adrenoceptors 
(ȕAR) are subdivided into ȕ1, ȕ2 and ȕ3. Generally, when activated Į1-adrenoceptors cause 
relaxation of smooth muscle in the gut, glycogen breakdown in the liver and vasoconstriction.1 
Į2-Adrenoceptors can pre-synaptically inhibit the release of neurotransmitters, affect platelet 
aggregation and inhibit the release of insulin.1 ȕ1-Adrenoceptors (ȕ1AR) are primarily located 
in the heart and their activation results in an increase in the heart rate and force of contraction. 
ȕ1-AR are also found in the kidneys where activation can lead to an increase in blood pressure 
by activation of the renin-angiotensin-aldosterone system. ȕ2-Adrenoceptors (ȕ2AR) are 
primarly found in the airways and in blood vessels. Activation of ȕ2AR can result in 
vasodilation and also leads to more rapid contraction of skeletal muscle and an increased rate 
of  glycogenolysis in the liver.1 ȕ3-adrenoceptors (ȕ3AR) are predominantly found in adipose 
tissue and are involved in thermogenesis and lipolysis.1 
 
2.1.1 ȕ Adrenoceptor 
The ȕ-adrenoceptors are primarly found in the heart (ȕ1AR), airways and blood vessels (ȕ2AR). 
All ȕ-adrenoceptors signal through the Gs G-protein. On activation the Įs-subunit and ȕȖ-
subunit can activate separate signaling pathways. The Įs-subunit causes activation of adenylyl 
cyclase, resulting in coversion of adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP).100 Amplification of the signal can arise from multiple molecules of 
cAMP being produced by each adenylyl cyclase. The secondary messenger cAMP has a range 
of diverse signaling targets that include cyclic nucleotide-gated ion channels, protein kinase A 
and exchange protein activated directly by cAMP.100 It has been noted that the ȕȖ-subunit can 
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2.2.1.1 Hypertension 
Hypertension is chronic cardiac condition in which the systemic blood pressure is elevated.1 
Causes include stress, obesity, smoking and potassium deficiency.107-109 A range of treatments 
are available for hypertension, including weight loss, dietary changes, calcium channel 
blockers, angiotensin-converting enzyme inhibitors and ȕ-blockers.110-112 Antagonists of ȕ1AR 
diminish the effect of adrenaline and other stress hormomes. Antagonists that are used for 
hypertension are propranolol (13), metoprolol (14) and nadolol (15).  
 
Figure 2.2. Structures of propranolol, metoprolol and nadolol. 
2.2.1.2 Angina pectoris 
Angina pectoris occurs when the oxygen supply to the cardiac muscle is insufficient for its 
needs, often resulting in severe pain for the patient.1 The pain has a characteristic distribution 
in the chest, arm and neck and is usually brought on by exertion or excitement. There are three 
types of angina pectoris: stable angina, unstable angina and microvascular angina.1 Stable 
angina is characterised by predictable pain on exertion. It is produced by an increased demand 
on the heart and is caused by the fixed narrowing of the coronary artery. Unstable angina is 
characterised by pain with less exertion, cumulating in pain at rest. Microvascular angina is 
characterised by angina-like chest pain but has different causes.113 Contributory factors 
associated with angina pectoris are smoking, diabetes, hypertension and obesity. The range of 
treatments for angina pectoris include nitroglycerin, a potent vasodilator that reduces blood 
pressure in the arteries and dilates the veins. Calcium blockers and ȕ-blockers are used to 
decrease the workload of the cardiac muscle. ȕ1AR antagonists that are currently used 
therapeutically include; bisoprolol (16), metoprolol (14), carvedilol (17) and nebivolol (18).114 
 
  ? ?
 
Figure 2.3. Structures of bisoprolol, carvedilol and nebivolol. 
2.2.1.3 Myocardial infarction 
Myocardial infarction, more commonly known as a heart attack, results in the interruption of 
the blood supply to a part of the heart, which causes heart cells to die. The most common cause 
of myocardial infarction is the occlusion of a coronary artery following the disturbance of an 
atherosclerotic plaque.1 It is accepted that the risks associated with atherosclerosis are 
generally the same as those for myocardial infarction and these are age, high blood pressure, 
obesity, prolonged exposure to high quantities of alcohol and smoking.115,116 ȕ-blocker therapy 
is used in the prevention of myocardial infarction and has been demonstrated to be beneficial 
in high-risk patients. ȕ1AR antagonists such as metoprolol and carvedilol have been 
successfully used clinically to prevent the reoccurrence of myocardial infarction.117 
2.2.1.4 Arrhythmia 
Arrhythmia also known as cardiac dysrhythmia, is the name given to the large group of 
conditions related to the abnormal electric activity of the heart. This involves an increased or 
decreased heart rate, and can be a regular or irregular heart beat. The most common heart 
arrhythmia is heart palpitations. The classification of arrhythmia is related to the site of the 
abnormality and whether there is an increase (tachycardia) or decrease (bradycardia) in the 
heart rate.1  
Anti-arrhythmic agents include fast inward sodium channel blockers (quinidine), slow channel 
blockers (verapamil) and ȕ-blockers. The ȕ1AR agents used include atenolol, esmolol and 
propranolol. Using antagonists decreases myocardial infarction mortality and prevents 
recurrence of tachyarrhythmia.118  
2.2.2 Respiratory targets 
Many adrenergic compounds are currently in widespread clinical use to treat asthma and 
chronic obstructive pulmonary disease.106  
  ? ?
2.2.2.1 Asthma 
Asthma is an inflammatory disorder in which there is a recurrent reversible obstruction of the 
airflow in the airways in response to stimuli that themselves are not noxious and do not effect 
non asthmatics.1 Asthma is thought to be caused by a combination of genetic and 
environmental factors.119 Asthma can be acute or chronic. In chronic asthma, the sufferer has 
intermittent attacks of dyspnoea, wheezing and coughing, which can be reduced by drug 
treatment. Acute asthma, also known as status asthmaticus, is not easily reversed by 
medication, can be fatal and requires prompt treatment.1 Two types of ȕ2AR agonists are 
commonly used for the treatment of asthma: short acting and long acting. Short acting agonists 
include salbutamol (19), levosalbutamol (20) and terbutaline (21).120 
 
Figure 2.4. Structures of salbutamol, levosalbutamol and terbutaline. 
The long-acting agonists include salmeterol (22), formoterol (23) and bambuterol (24), are 
used for moderate to persistant asthma. 
 
Figure 2.5. Structures of salmeterol, formoterol and bambuterol. 
2.2.2.2 Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is the co-occurrence of chronic bronchitis and 
emphysema, which results in the narrowing of the airways in the lung. Chronic bronchitis is 
the inflammation of the bronchi and bronchioles. Emphysema is distention and damage of the 
lung beyond the respiratory bronchioles and it supervenes after years of coughing. This 
  ? ?
combination results in limited airflow to the lungs, causing shortness of breath.1 Causes of 
COPD include smoking, occupational exposure, air pollution and genetics.121,122 There is 
currently no cure for COPD, however COPD is a preventable and treatable disease. Treatments 
include anticholinergics, corticosteroids and bronchodilators such as ȕ2AR agonists, e.g. 
salbutamol and an ultra-long-acting agonist, indacaterol (25).123 
 
Figure 2.6. Structure of indacaterol 
2.2.3 Aims 
This chapter describes the design, synthesis and pharmacological evaluation of a series of 
fluorescent ligands, which bind to ȕ-adrenoceptors.  The aim of this work was to synthesise a 
range of fluorescently labelled ȕ-adrenergic antagonists to use as tools to study ligand-receptor 
interactions through radioligand binding assays, confocal imaging and kinetic experiments. 
The technique that was used to conjugate a fluorescent probe to the orthosteric ligand was click 
chemistry. This was utilised to remove the need for functional group protection and 
deprotection steps that are commonly required for other conjugation methods.  
2.3. Design and synthesis of fluorescent ligands 
The design of novel fluorescent ligands for ȕ-adrenoceptors required an active pharmacophore 
for the receptor and the connection of a fluorescent molecule. The addition of this fluorophore 
cannot compromise the functional groups essential to receptor binding. The addition of a linker 
bearing a terminal group that can be utilised in a copper (I) catalysed azide-alkyne 
cycloaddition could prove a quick and convenient way of tethering a fluorescent molecule to 
an active pharmacophore. 
 Two known pharmacologically active and therapeutically used ligands, propranolol, a non-
selective antagonist, and metoprolol a E1 inverse agonist, were chosen as the orthosteric 
ligands.124 It was found that almost all of the hydrophobic regions of the 7-TMs influence the 
binding with agonists, while antagonist-binding specificity is mainly controlled by TMs six 
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The incorporation of a linker for fluorophore attachment can be tolerated beyond the amine 
group. It is known that branching and extension from the amine can be tolerated. Previous 
work within the group has also attached fluorescent moieties through linkers adjacent to the 
amine and they have been well tolerated.64,86 
For initial investigations into the copper (I) catalysed azide-alkyne cycloaddition between a 
fluorophore and pharmacophore, the synthesis of a non-commercially available fluorophore 
afforded many potential benefits such as individual functionalisation and individual fluorescent 
properties. Fluorophores based on boron-dipyrromethene (BODIPY) dyes were chosen (figure 
2.9), due to their excellent properties of high quantum yields with sharp excitation and 
emission spectra. BODIPY dyes have the ability to be individually functionalised for the 
required emission and excitation characteristics and functional groups for attachment.129 
Previous work within the group has utilised BODIPY dyes to great success. 45,82,86,130  
 
Figure 2.9. BODIPY core structure 
2.3.1. Retrosynthesis of fluorescent ligands 
 
 
Scheme 2.1. Retrosynthetic analysis of ȕ-adrenoceptor fluorescent ligand based on propranolol 
As described above, the alcohol and amine group are essential for pharmacological activity; 
thus, extension of the molecule adjacent to this motif was required. Incorporation of the linker 
into the secondary amine would extend the molecule and enable connection of the fluorophore.  
This allowed investigation to whether the triazole can be tolerated in the binding site or if it 
  ? ?
would have an effect on binding. Synthesis of the fluorescent ligands would be separated into 
two parts, pharmacophore/linker synthesis and fluorophore/linker synthesis. The two synthons 
would then be conjugated together by click chemistry to yield the final fluorescent ligand. 
2.3.2 Synthesis of pharmacophore and linker 
Syntheses of the two orthosteric headgroups were initiated with the deprotonation of the 
requiste phenol with sodium hydride in DMF, and addition of racemic epichlorohydrin (26), 
which after stirring at room temperature, yielded the epoxides 27a and 27b after column 
chromatography (83 and 64% yield) as confirmed by mass spectroscopy and nuclear magnetic 
resonance spectroscopy (NMR).  
 
Scheme 2.2. i) NaH, 1-napthol, DMF, 16 hr (83%). ii) NaH, 4-(2-methoxyethyl)phenol DMF, 16 hr (64%). 
Synthesis of a short azide linker was achieved by refluxing 2-bromoethylamine hydrobromide 
(28) with sodium azide to yield the azido-amine (29) as a free base after treatment with KOH 
(94% yield). Infra red spectroscopy (IR) was used to confirm the substitution with the azide 
with a peak at 2098 cm-1. This value is typical for a compound with azide functionality and 
there is usually an intense peak at ~2100 cm-1.131 
 
Scheme 2.3. i) NaN3, H2O, KOH, 21 hr (94%). 
 
  ? ?
 
Scheme 2.4. i) isopropanol, 18 hr, reflux (32-41%). 
 
Treatment of the epoxides 27a and 27b with the primary amine 29 yielded the secondary 
amines 30a and 30b.  
 
Scheme 2.5. i) isopropanol, reflux, 18 hr, (37-77%). 
An alkyne-functionalised pharmacophore was synthesised from commercially available 
propargylamine 31. The secondary amine was heated to reflux in isopropanol with the two 
separate epoxides 27a-b to yield alkyne-functionalised pharmacophores 32a and 32b in yields 
ranging from 37 to 77% after purification by column chromatography. 
The regiochemistry of the ethanolamines was confirmed by 1H NMR, 13C NMR and 1H-13C 
HSQC NMR spectroscopy. Epoxide opening occurred from the least hindered side, which is to 
be expected when the reaction is carried out in neutral or basic conditions. 132 Evidence for 
regioselective opening can be taken from 1H-13C HSQC NMR experiment of 30a for example 
(figure 2.10). The ‘C’ proton at 2.88-3.0ppm displays a chemical shift that is too low to be 
adjacent to an oxygen. The 13C experiment also supports this with a peak at 51.44. In addition, 
  ? ?
it would be expected that protons ‘C’ and ‘D’ would have similar shifts in signals in both 1H 
and 13C experiments, as shown in figure 2.10. Overlay of the linker with the product also 
helped determine regioselective opening. This configuration of the aryloxypropanolamines is 
present in all pharmacophores 30a-b and 32a-b.  
 
Figure 2.10. 1H-13C HSQC NMR of 30a in CDCl3. Spectral assignment using 
1H-13C HSQC experiment. The relevant 
1H proton and 13C carbon experiments are displayed on the x and y axis. 
2.3.3 Fluorophore synthesis 
Fluorophores were synthesised with terminal alkynes and azides to allow the desired copper (I) 
catalysed alkyne-azide cycloaddition with the linkers.  
 
 Scheme 2.6. i) SOCl2, toluene, DMF, 4 hr. ii) DCE, 2,4-dimethylpyrrole, 3 hr. iii) BF3.OEt2, DIPEA, 12 hr. 
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Synthesis of the acetylene-functionalised fluorophore began with the conversion of carboxylic 
acid (33) to its corresponding acid chloride (34) in quantitative yield confirmed by thin layer 
chromatography (TLC). Coupling of acid chloride 34 to 2,4-dimethylpyrrole at room 
temperature afforded the dipyrrin species 35, as comfirmed by TLC and mass spectroscopy. 
Due to the dipyrrin being unstable and difficult to isolate,129 both boron trifluoride diethyl 
etherate and N,N,-diisopropylethylamine (DIPEA) were added to the reaction mixture but this 
did not yield the desired fluorophore 36. TLC showed a number of fluorescent spots but 
unfortunately due to the large mixture of compounds in the crude, purification was not 
attempted and a similar synthesis was attempted to synthesise an azide-functionalised 
fluorophore.  
  
Scheme 2.7. i) NaN3, acetone/H2O, 60 °C, 7 hr (85%). ii) KOH, MeOH/H2O, 6 hr, (80%). iii) SOCl2, DMF, Toluene, 4 
hr. iv) 2,4-dimethylpyrrole, DCE, 3 hr. v) BF3.OEt2, DIPEA, RT, 12 hr. 
The synthesis commenced with an azide substitution of the bromo ester 37 in 85% yield. The 
hydrolysis of ester 38 with aqueous KOH yielded the carboxylic acid 39. This was confirmed 
by NMR with the loss of two peaks in the proton NMR corresponding to the ethyl group. The 
carboxylic acid 39 was converted to the acid chloride 40, which was used in-situ and coupled 
to 2,4-dimethylpyrrole at room temperature in quantitative yield as confirmed by TLC. Boron 
trifluoride diethyl etherate and DIPEA were added to the reaction mixture but the desired 
fluorophore was not purified from the reaction mixture due to the large amount of byproducts, 
which made column chromatography extremely difficult. As this reaction failed with two types 
of precursor (azide and alkyne), a different synthetic scheme was undertaken. BODIPY dyes 
have been synthesised from benzaldehydes in the prescene of trifluoroacetic acid (TFA) and 
2,3-dichoro-5,6-dicyano-1,4-benzoquinone (DDQ),98 therefore this was attempted. 
  ? ?
 
Scheme 2.8. i) Bromopropanol, DIAD, PPh3, THF, DCM, 12 hr (62%). ii) NaN3, DMF, 100 °C, 12 hr, (44%). iii) 2,4-
dimethylpyrrole, DCM, TFA, DDQ, Et3N, BF3.OEt2, RT, 16 hr, (17%). 
The synthesis of an azide-functionalised fluorophore required a Mitsunobu reaction between 4-
hydroxybenzaldehyde (43) and 1-bromo-3-propanol to yield the ether 44.  
There is still debate over the exact intermediates of the Mitsunobu reaction; however, the 
widely accepted mechanism is shown in figure 2.11.133 
 
Figure 2.11. Mechanism of the Mitsunobu reaction between 43 and 1-bromo-3-propanol. 
The bromo-ether was heated to reflux with sodium azide to create 4-(3-
azidopropoxy)benzaldehyde (45) without the need for purification. The azide was confirmed 
by IR spectroscopy and movement of a triplet signified the substitution. The azide-
functionalised benzaldehyde was coupled to 2,4-dimethylpyrrole with a catalytical amount of 
TFA, and finally reacted with boron trifluoride diethyl etherate, and triethylamine after being 
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oxidised by DDQ. The final step gave the azide-functionalised fluorophore 46 in 17% yield 
after purification. A similar literature procedure had a yield of 27%.98  
The alkyne derived fluorophore (48) followed the literature procedure of Li et al.134 starting 
with the commercially available 4-ethynylbenzaldehyde (47). 
 
Scheme 2.9. i) 2,4-dimethylpyrrole, DCM, TFA, DDQ, Et3N, BF3.OEt2, 16 hr (28%). 
2.3.4 Fluorescent spectroscopy 
With two fluorophores synthesised it was necessary to determine the excitation and emission 
profile of both. This would enable the correct filters and lasers to be employed when using and 
imaging the fluorescent ligands. As the fluorophores are similar in structure to BODIPY FL,135 
an approximate value of the emission was known. This was used to determine the excitation 
profile. 
 
Figure 2.12. Excitation profile with emission intensity measured at 515 nm. 
 
From the excitation scan, (Figure 2.12) both fluorophores were shown to have two main 
excitation wavelengths; one at 350 nm and the other at 480 nm. Both fluorophores were 
excited at each wavelength to give an accurate emission for the fluorophores and not a value 
based on BODIPY FL. 
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Figure 2.13. Excitation emission profiles when the fluorescent molecule was excited at a) 350 nm and b) 480 nm. 
The excitation at 350 and 480 nm showed a single emission at 517 nm. There was no 
difference between the two fluorophores as the conjugation within both fluorophores was very 
similar.   
2.3.5 Final pharmacophore fluorophore coupling reaction 
The final step in synthesising the fluorescent ligand was to form the five membered 1,2,3-
triazole ring by copper (I) catalysed 1,3-dipolar cycloaddition. Review of the relevant literature 
showed that the cycloaddition could be performed in many different solvent systems such as 
water/tert-butanol, water/acetonitrile and water/DCM.50,79,88,136,137 The cycloaddition can be 
achieved at room temperature or reflux and even with microwave irradiation.50,88,138,139  
The results of trial reactions between ethynylbenzene (49) and ethyl 4-azidobutanoate (38) 
with a range of different conditions are summarised in tables 2.1. and 2.2. Trial reactions 
established that water/DMF was the best solvent system. 
 
Scheme 2.10. Trial reaction for click chemistry 
 Procedures included different solvents systems; water/DCM, water/DMF, water/tert – butanol 
and water/acetonitrile. Different catalysts were also trialed, including copper wire/copper 
sulfate pentahydrate, and copper sulfate pentahydrate/sodium ascorbate. Sodium ascorbate and 
copper sulfate pentahydrate were found to be the best catalysts for the reaction.  
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Solvent Temperature Yield (%) 
H2O/tert-butanol RT 80 
H2O/tert-butanol 60 °C 83 
H2O/acetonitrile RT 68 
H2O/acetonitrile 60 °C 72 
H2O/DMF RT 83 
H2O/DMF 60 °C 89 
H2O/DCM RT 55 
H2O/DCM 60 °C 59 
 
Table 2.1. Trial click reactions. Reaction between ethynylbenzene and ethyl 4-azidobutanoate in the presence of 
copper wire and CuSO4.5H2O over 24 hr. 
 
Solvent Temperature Yield (%) 
H2O /tert-butanol RT 89 
H2O/tert-butanol 60 °C 92 
H2O/acetonitrile RT 74 
H2O/acetonitrile 60 °C 77 
H2O/DMF RT 88 
H2O/DMF 60 °C 93 
H2O/DCM RT 44 
H2O/DCM 60 °C 44 
 
Table 2.2. Trial click reactions. Reaction between ethynylbenzene and ethyl 4-azidobutanoate in the presence of 
sodium ascorbate and CuSO4.5H2O over 24 hr. 
Microwave (MW) irradiation provided high yields and low reaction times compared with room 
temperature reactions when actual fluorophores and pharmacophores were reacted compared 
with the trial reagents. The reaction temperature were kept low to avoid the possible formation 
of the undesired 1,5- adduct as well as the 1,4-adduct. NMR confirmed there was not a mixture 
  ? ?
of adducts by the presence of only one proton peak for the triazole. The final click reactions 
gave four final compounds with yields in the range of 24-70% after high performance liquid 
chromatography (HPLC) purification with an isocratic eluent of 40% water, 60% acetonitrile 
over 16 minutes. The crude and purified HPLC trace for 51a is shown in figure 2.15. 
 
Scheme 2.11. i) DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW, 80 min, 80 °C,  
40 W, (24-56%). 
 
Scheme 2.12. i) DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW, 80 min, 80 °C, 
 40 W ,(46-70%). 
  ? ?
 
Figure 2.14. Structures of first-generation ligands 
 
Figure 2.15. HPLC traces of crude (green) and purified (red) compound 51a. The HPLC method used: Kromasil 
reverse-phase C18 column (250 x 4.6 mm), a flow rate of 1.00 mL/min and UV detection at 254 and 366 nm. Linear 
gradient 5% - 95% solvent B over 16 min. Solvent A: 0.06% TFA in water; solvent B: 0.06% TFA in MeCN. 
2.3.6 Pharmacology 
The pharmacological activity of the fluorescent ligands was assessed by radioligand binding 
assays (RLB). Competitive radioligand binding was used to ascertain the binding affinity of the 
ligands. The affinity was determined by competitive displacement of the radioligand, [3H]-
CGP 12177 from chinese hamster ovary (CHO) cells expressing either E1- or E2-adrenoceptors. 
Radioligand binding was performed as previously described by Baker.106 At least three 
  ? ?
different experiments were conducted for each ligand in triplicate and the binding affinities of 
two standards, ICI 118,551 a E1-antagonist and CGP 12177 a E2-antagonist, were run in each 
experiment. The assays were run with a range of final concentrations from 1 × 10-4 M to 1 × 10-
10 M to produce the required dose-response curves. It was occasionally not possible to start at 1 
× 10-4 M due to the low solubility of the ligands. In addition at higher concentrations, the 
percentage of DMSO in the media would exceed 0.1% and this may harm the cells due to the 
toxicity of DMSO.140 Each ligand was diluted to 10-2 M using DMSO and the stock solution 
was stored at -20 qC until the ligand was tested. 
 
Figure 2.16. Fluorescent ligand displacement of [3H]-CGP 12177 specific binding at the human E-AR in whole CHO 
cells. Inhibition of [3H]-CGP 12177 specific binding to whole cells by compounds 51a, 51b, 52a and 52b in a) E1 cells 
and b) E2 cells. Nonspecific binding was determined by 10 µM propranolol. A concentration of 1 nM of [3H] CGP 
12177 was used in each experiment. Data points are a mean ± s.e.m of triplicate determinations. These single 
experiments are a representative of a minimum of three different experiments. 
 
Compound E1 Log Ki (n) E2 Log Ki (n)
51a -4.85 ± 0.01 (4) -4.86 ± 0.01 (4) 
51b -4.27 ± 0.01 (4) - 4.64 ± 0.06 (4) 
52a -4.27 ± 0.10 (4) -5.13 ± 0.05 (4) 
52b -4.24 ± 0.02 (3) -4.21 ± 0.13 (4) 
Propranolol -8.21 ± 0.12 (4) -8.93 ± 0.07 (4) 
 
Table 2.3. Log Ki values were obtained from [
3H]-CGP12177 binding in whole cells expressing either the human E1 or 
E2-AR. Values are mean ± s.e.m from n number of experiments. Ki refers to the equilibrium dissociation constant and 
the values were calculated from the IC50 values.  
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 Data from radio-ligand binding assays were used to calculate the IC50 values of the fluorescent 
conjugates. These values were used to calculate the respective binding affinities, Ki, using the 
Cheng-Prushoff equation.141 
D?H?ൌ D?D?H?H?  ? ൅ሾD?D?D?D?D?D?D?D?D?D?D?ሿD?H?  
Where [radioligand] = the concentration of free radioligand used in the assay, and KD = the 
dissociation constant of the radioligand for the receptor. IC50 is the concentration of the ligand 
that displaces 50% of the specific binding of the radioligand. 
The radioligand binding assays of the fluorescent ligands show that is it possible to synthesise 
a biologically fluorescent ligand with the alkyne-azide copper (I) catalysed cycloaddition. It is 
clear that the binding affinities are not comparable to that of propranolol or metoprolol. Ligand 
affinity values ranged from -4.24 to -5.13 and these values are significantly lower than those of 
the fluorescent ligands synthesised by Baker et al.64 The ligands synthesised by this group can 
be directly compared. All 14 ligands that Baker et al. synthesised had affinities greater than 
6.06 ± 0.07 for E1AR and -7.33 ± 0.09 for E2AR. The ligand with the lowest affinity 
synthesised by Baker et al. 53 is shown in figure 2.16. 
 
Figure 2.17. Structure of weakest adrenoceptor agonist synthesised by Baker et al.64 
The main differences between 53 and the ligands synthesised in this thesis excluding the 
pharmacophore, are the linker length and type as well as the fluorophore used. The fluorophore 
in 53 is BODIPY 630/650 X, a commercially available fluorophore that has a large linker 
attached. The fluorophore attached to ligands 51a-b and 52a-b has a BODIPY FL type 
fluorophore that does not come with such an extended linker. This could be one of the possible 
reasons that ligands 51a-b and 52a-b have poor affinity. The incorporation of a triazole into 
the linker is present in the ligands synthesised while ligand 53 does not. This triazole could 
  ? ?
reduce the binding affinity due to steric interaction. The movement of the triazole away from 
the pharmacophore could increase binding affinity. 
2.4 Synthesis of second-generation ligands 
Due to the poor binding affinity of each compound, the ligands required a second round of 
design and synthesis to improve receptor binding before any further receptor-ligand 
interactions could be investigated. Extension of the 1,2,3-triazole away from pharmacophore 
may achieve increased binding affinities as steric interactions from the triazole and fluorophore 
could be reduced. A second generation of ligands was designed with a longer linker between 
the pharmacophore and triazole, moving the triazole away from the amine and alcohol which 
are key for binding.  
This approach will increase the linker atom by atom to give more detail about the SAR of the 
molecules. The movement of the fluorophore away from the triazole was synthesised for a 
different approach of moving the fluorophore away from the triazole and the pharmacophore. 
The fluorescent ligands would be based on the propranolol pharmacophore due to the increased 
binding affinity over the metoprolol-based pharmacophore. The binding data suggest that the 
alkyne attached to the pharmacophore shows increased binding affinity over the azide 
functionalised pharmacophore. The second-generation ligands will have this orientation wih 
the fluorophore attached to the sp3-hybridised nitrogen of the 1,2,3-triazole.  
2.4.1 Linker synthesis 
Synthesis of the second-generation ligands started with the linker. Linkers varied in length 
from a two-carbon linker up to a four-carbon linker between the amine and the triazole. With 
the pharmacology results showing that alkyne-functionlised orthosteric ligands producing more 
potent fluorescent ligands, this orientation was kept. 
 
  ? ?
 
Scheme 2.13. i) Hydrazine monohydrate, isopropanol, sealed tube, 70 qC, 2 hr. ii) 1-(2,3-Epoxypropoxy)- naphthalene, 
isopropanol, sealed tube, 90 qC, 12 hr (25-31%), n=1 (a), n=2 (b), n=3 (c). 
Alkyne functional phthalamides were commercially available with literature procedures for the 
deprotection of these phthalamides to yield the amino-alkynes.142,143 Literature procedures for 
the deprotection were attempted but did not result in the required product. After aqueous 
workup, it was found that the resulting amine was extremely volatile. Attempts were made to 
make the hydrochloride salt but these were not successful. An alternative approach was 
developed to achieve the required linkers. The phthalamide-protected amines were deprotected 
in the presence of hydrazine monohydrate at 70 qC in a sealed tube for 2 hours, the vessel was 
cooled and the epoxide 27a added. The vessel was sealed and heated to 90 qC. An excess of 
starting phthalimide was needed over the hydrazide monohydrate to stop any excess hydrazine 
reacting with the epoxide. This resulted in yields of 25% to 31% after purification. The 
mechanism for the phthalimide deprotection is shown in figure 2.18. 
 
Figure 2.18. Phthalimide protecting group cleavage mechanism 
  ? ?
 
Scheme 2.14. i) DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW, 80 min, 80 °C, 40 W, (44-54%), 
 n=1 (a), n=2 (b), n=3 (c). 
Three novel alkyne functionalised orthosteric ligands 56a-c were synthesised and coupled to 
46. 
 
 
Figure 2.19. Structures of second-generation fluorescent adrenoceptor ligands (n=1 57a, n=2 57b, n=3 57c). 
Extending the linker between the triazole and the fluorophore was attempted. Two new 
fluorophores were synthesised, one with a straight six-carbon chain and the other contained an 
ether linkage.  
  ? ?
 
Scheme 2.15. i) K2CO3, DMF, 4-hydroxybenzaldehyde 12 hr (59%) ii) NaN3, DMF, reflux, 16 hr (89%). iii) DCM, 
2,4-Dimethylpyrrole, TFA, DDQ, Et3N,BF3.OEt2, 16 hr, (16%). 
 The synthesis for longer linker attached to the fluorophore starting with a Williamson ether 
synthesis of 1,5-dibromopetane (58) and 4-hydoxybenzaldehye in the presence of potassium 
carbonate. Slow addition and controlled stochiometry reduced disubstitution. The 
benzaldehyde 59 was heated under reflux with sodium azide to form the terminal azide. This 
was confirmed by IR spectroscopy with the characteristic peak at 2100 cm-1. The azide-
substituted benzaldehyde 60 was coupled to 2,4-dimethylpyrrole with the addition of boron 
trifluoride diethyl etherate and triethylamine to yield fluorophore 61 in 16% yield. NMR and 
IR confirmed the fluorophore had been synthesised and held azide functionality. 
 
Scheme 2.16. i) K2CO3, DMF, 4-hydroxybenzaldehyde 12 hr (67%) ii) NaN3, DMF, reflux, 16 hr (74%) iii) DCM, 2,4-
Dimethylpyrrole, TFA, DDQ, Et3N, BF3.OEt2, 16 hr, (39%). 
  ? ?
The second fluorophore to be synthesised included an ether linkage. Synthesis began with 1-
chloro-2-(2-chloroethoxy)ethane (62) and 4-hydroxybenzaldehyde in the presence of 
potassium carbonate to yield 4-(2-(2-chloroethoxy)ethoxy)benzaldehyde (63). Then 
benzaldehyde 63 was heated to 100 ºC with sodium azide to yield 64 which was confirmed 
with IR spectroscopy. The azide-functionalised benzaldehyde was finally reacted with 2,4-
dimethylpyrrole, and boron trifluoride diethyl etherate in the presence of TFA, DDQ and 
triethylamine to yield the ether-linked fluorphore 65 in 39% yield after column 
chromatography eluted in DCM. 
 
 
Scheme 2.17. i) 65, DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW 80min, 80 °C, 40 W (48%). ii) 61, DMF/H2O, 
CuSO4.5H2O, sodium ascorbate, MW 80min, 80 °C, 40 W (14%). 
The two new fluorophores 61 and 65 were conjugated to 53c to form two new fluorescent 
ligands 66a-b in yields ranging between 14% and 48% with microwave irritation after HPLC 
purification.   
2.4.2 Pharmacology of second-generation ligands 
The second-generation fluorescent ligands and pharmacophores were profiled with radioligand 
binding competition assays in the same format as the first-generation ligands.  
  
  ? ?
 
 
 
Figure 2.20. Fluorescent ligand displacement of [3H]-CGP 12177 specific binding at the human E-AR in whole CHO 
cells. Inhibition of [3H]-CGP 12177 specific binding to whole cells in a) E1 by compounds 56a, 56b and 56c and b) E2 
by compouds 56a, 56b and 56c. Inhibition of [3H]-CGP 12177 specific binding to whole cells in c) E1 by compounds 
57a, 57b and 57c and d) E2 by compounds by 57a, 57b and 57c. Inhibition of [3H]-CGP 12177 specific binding to 
whole cells in e) E1 by compounds 66a and 66b and f) E2 by compounds 66a and 66b in whole cells.  Nonspecific 
binding was determined by 10 µM propranolol. A concentration of 1 nM of [3H] CGP 12177 was used in each 
experiment. Data points are a mean ± s.e.m of triplicate determinations. These single experiments are  representative of 
a minimum of three different experiments 
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Compound E1 Log Ki (n) E2 Log Ki (n) 
56a -6.60 ± 0.01 (4) -7.60 ± 0.01 (4) 
56b -4.45 ± 0.20 (4) -5.36 ± 0.06 (4) 
56c - 5.30 ± 0.05 (4) -5.84 ± 0.20 (4) 
57a -5.77 ± 0.12 (4) -6.27 ± 0.10 (4) 
57b -5.00 ± 0.06 (4) -5.66 ± 0.16 (3) 
57c -6.77 ± 0.20 (8) -7.32 ± 0.05 (8) 
66a -4.61 ± 0.09 (8) -5.77 ± 0.10 (8) 
66b -4.65 ± 0.12 (4) -5.36 ± 0.09 (4) 
 
Table 2.4. Log Ki values were obtained from [
3H]-CGP12177 binding in whole cells expressing either the human E1 or 
E2-AR. Values are mean ± s.e.m from n number of experiments. Ki refers to the equilibrium dissociation constant and 
the values were calculated from the IC50 values. 
The results of the second-generation ligands and alkyne-linked pharmacophores, showed that 
no pharmacophore had an affinity close to that of propranolol. This result may suggest that a 
terminal alkyne is not tolerated to the level of an isopropyl group of propranolol.  
The binding affinities of the pharmacophores compared with their fluorescent counterparts do 
not show a signification change in binding affinity that would be expected. When tethering a 
large bulky fluorophore onto a known biologically active ligand, it would not be unreasonable 
to anticipate a decrease in the overall affinity. This result suggests that a triazole could be 
tolerated more than a terminal alkyne. This tolerance maybe due to more hydrogen bond 
donor/acceptors in a triazole compared with in the alkyne. The addition of a fluorophore does 
not seem to have affected the binding affinities relative to the terminal alkyne pharmacophores. 
This may be due to the fluorophore being positioned in an orientation that allows it to sit in the 
extracellular media and not interfere with binding.  
The fluorescent ligands have improved binding affinities compared with the previous best 
ligands. 52a had an affinity of -4.27 (± 0.10) at the E1 receptor while 51a had the best affinity 
at E2 with an affinity of -4.86 (± 0.01). The binding affinities have been improved with 57c 
having affinities of -6.77 (± 0.20) and -7.32 (±0.05) for E1 and E2 respectively. This 
  ? ?
improvement shows that moving the triazole away from the biologically active portion of the 
ligand improves the binding affinity. This was clearly observed across for second-generation 
ligands compared with the first-generation ligands. This ligand has binding affinities that are 
comparable to those of the weaker ligands synthesised by Baker et al.64  
Results from those compounds bearing an increased linker after the triazole did not show 
improved binding affinities. Affinities of the extended fluorophores dropped by 2 log units 
allowing the conclusion that this extention is not favoured.  
2.4.3 Confocal imaging studies 
Confocal imaging was used to study the fluorescent ligands. The use of confocal microscopy 
allowed the visualisation of ligands at the single cell level in order to determine whether they 
bind to the receptor, bind to the cell membrane, internalise or remain in the surrounding 
solution. A concentration of 100 nM was used initially for each ligand. All ligands were 
incubated with CHO cells expressing the human E2 receptor and the experiments were 
conducted at 37 °C (experimental section) The second-generation ligands had improved 
affinities to low micromolar and nanomolar. These ligands had affinities low enough to 
warrant confocal experiments to be carried out. Confocal imaging was used to investigate 
ligand-receptor interactions. Imaging was carried out in 8-well plates with cells being seeded 
24 hours before experiments. During each experiment for a separate antagonist, wells were 
washed with Hank’s buffered saline solution (HBSS) before antagonist addition. Individual 
antagonists were added to separate wells and confocal images were captured with the aim to 
visualise specific receptor binding.  
The results from the confocal microscopy experiments showed rapid intracellular accumulation 
which is the movement of a molecule into the cytoplasm of the cell. This is disappointing as 
the fluorescent antagonist should bind to receptors on the cell membrane and not enter the 
cytoplasm. Unfortunately it is not possible to distinguish between cytoplasmic ligand and 
receptor bound-ligand. Experiments reducing the concentration of antagonist were performed, 
but this did not stop the intracellular accumulation.  
As the antagonists contain a hydrocarbon linker and a bulky organic fluorophore, it was 
believed that the increased lipophilicity of the molecule caused the intracellular accumulation 
  ? ?
by allowing the drug to pass through the cell membrane’s lipid bilayer into the 
cytoplasm.
 
 
 
Figure 2.21. Confocal visualisation of fluorescent antagonists (100 nM) binding to CHO E2 cells. a) Transmitted light 
image taken at 0 min before the addition of 57a and b)  appearance of 57a 10 min after addition. c) Transmitted light 
image taken at 0 min before the addition of 57b and d) appearance of 57b 10 min after addition. e) Transmitted light 
image taken at 0 min before the addition of 57c and f) appearance of 57c 10 min after addition. Images of cells were 
undertaken in the continued presence of fluorescent the ligand. 
e) f) 
c) d) 
a) b) 
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2.4.4 Lipophilicity evaluation of fluorescent ligands 
The second-generation fluorescent ligands clearly accumulated inside the cells when viewed 
under a confocal microscope. This could be due to the increased lipophilicity of the ligands 
caused by the addition of the fluorescent moiety.  
The lipophilic nature of the ligands was assessed using HPLC techniques. One method that is 
becoming routinely used in drug discovery programmes, is the chromatographic 
hydrophobicity index (CHI).144 This HPLC method allows the characterisation of the 
interactions of drugs with an immobilised artificial membrane (IAM). With a set of standards, 
the gradient retention times at pH 7.4 can be converted to CHI values referring to IAM 
chromatography (CHIIAM 7.4) that approximates an acetonitrile concentration with which an 
equal distribution of compound can be achieved between the mobile phase and IAM. The 
longer the retention time the greater the interaction with the artificial membrane. 
Compound Retention time CHIIAM 7.4 
Propranolol N/A 55.50 
56a 6.39 49.30 
56b 6.48 50.41 
56c 6.50 50.65 
57a 7.71 66.17 
57b 7.71 66.17 
57c 5.14* 68.26 
66a 4.52* 55.44 
66b N/A N/A 
 
Table 2.5. Retention times and CHIIAM 7.4 values of second-generation ligands calculated from HPLC methods using a 
Regis IAM PC 12 Pm column (100 x 4.6mm), a flow rate of 1.00 mL/min and UV detection at 230 and 366 nm. Linear 
gradient 0 % - 100% solvent A over 7 min. Solvent A: 100% MeCN. Solvent B: water with 50 mM ammonium acetate. 
* Faster gradient used. 
The CHIIAM 7.4 values of all the second-generation ligands gave insight into the interaction of 
the molecule with an artificial immobilised column. Propranolol data were acquired through 
  ? ?
partnership with Novartis, which allowed comparison of propranolol to the second-generation 
ligands. The CHIIAM 7.4 data suggest that there is not a considerable difference between the 
fluorescent ligand congeners and propranolol, but when a fluorophore is attached the CHIIAM 7.4 
value changes dramatically. Clearly this will have an effect on how the molecule interacts with 
the receptor and the media. Modifications must be made to the ligands to try and mimic the 
properties of propranolol itself. Unfortunately it was not possible to obtain data for 66b due to 
low quantity of ligand available.  
Another HPLC method used to determine the lipophilic properties of the ligands was HPLC 
LogD analysis. This technique is described by Kerns et al.145  as a quick HPLC method for 
estimating the logarithm of the octanol-water partition coefficient at pH 7.4. A calibration 
graph is plotted with retention time vs LogD 7.4 (literature). In the publication this calibration 
graph was used to determine LogD 7.4 (HPLC) for 60 structurally diverse drugs and the 
correlation with LogD 7.4 (literature) was determined as r
2 = 0.89. 
Compound Retention time LogD 7.4 
Propranolol N/A 1.09 
56a 2.68 1.97 
56b 2.49 1.17 
56c 2.67 1.91 
57a 3.18 3.96 
57b 3.18 3.96 
57c 3.11 3.70 
66a 3.75 6.28 
66b 3.45 5.07 
 
Table 2.6. Second-generation ligand LogD 7.4 and retention times calculated by HPLC methods using a Polaris C18 5 
Pm HPLC column (50 x 4.6mm). A flow rate of 1.00 mL/min and UV detection at 230 and 366 nm. Linear gradient 
0 % - 95% solvent A over 4 min. Solvent A: 100% MeCN. Solvent B: water with 50 mM ammonium acetate. 
The logD 7.4 values confirm what was observed with the CHIIAM data. An increase of LogD 7.4 
values are observed in the pharmacophores with an acetylene moiety compared to that of 
  ? ?
propranolol. A large change was observed with the introduction of the fluorescent moiety and 
there was a noticeable increase when a longer linker was inserted after the triazole. Due to an 
increase in membrane interaction and LogD 7.4 values, modifications to the fluorescent ligands 
were important and reducing both values to a similar value of propranolol could be beneficial.  
 A new series of fluorescent antagonists required synthesis with a polar linker in order to 
investigate whether this would eliminate or reduce the intracellular accumulation of the 
antagonist and the lipophilic nature of the ligand. 
2.5. Amide linked ligands 
 To stop or reduce the intracellular accumulation of the fluorescent ligands, the insertion of an 
amide group into the linker may reduce the lipophilicity of the compound by increasing the 
amount of hydrogen bond donors and acceptors into the molecule. The linker would contain 
four atoms, the same as the most potent fluorescent ligand to allow comparison of affinity and 
membrane binding over the previous best ligand. It was acknowledged that such a small 
change in linker type may not reduce the lipophilicity of the molecule, but extensive change to 
the molecule may reduce the binding affinity to levels of the first generation ligands. Another 
approach to this would be to exchange to fluorophore for a smaller more polar fluorophore. 
This approach was not chosen due to the excellent properties that a BODIPY fluorophore has 
over the other possible fluorophores that could be used such as NBD, such as limited 
fluorescence in the aqueous media and high quantum yield when bound to the receptor.  
2.5.1 Amide linker synthesis 
 
Scheme 2.18. i) BocO2, 0 qC, H2O/dioxane, 12 hr. ii) DCM, HBTU, DIPEA, propargylamine, 5 hr. iii) TFA/DCM, 30 
min, (44%). 
The synthesis began with boc-protecting glycine (67) in water/dioxane. The protected amine 
68 was coupled to propargylamine (31) with O-(benzotriazol-1-yl)-N,N,Nƍ,Nƍ-
tetramethyluronium hexafluorophosphate (HBTU) as a coupling agent in the presence of 
  ? ?
DIPEA. The product was then deprotected in the presence of TFA/DCM to yield the TFA salt 
70 in 44% yield overall.  
 
Scheme 2.19. i) Isopropanol, DIPEA, reflux, 16hr (51%). 
The amide linker was reacted with the epoxide 27a to form the amide-linker pharmacophore 71. 
This was achieved by reflux in isopropanol in the presence of (DIPEA) in 51% yield after 
column chromatography.   
 
Scheme 2.20. i) 46 or 61 or 65, DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W. n= (CH2)2, a, 
n= (CH2)4 b, n= (CH2)2O(CH2)2 c. (24-90%). 
The alkyne-functionalised orthosteric ligand 71 was conjugated to the three previously used 
fluorophores 46, 61 and 65 with conditions used for other click reactions. 
2.5.2 Amide linker pharmacology 
The fluorescent ligands and the pharmacophore binding affinities were investigated using 
radio-ligand binding assay to determine the pharmacological properties of the ligands.  As 72b 
had solubility issues in media, data was obtained over a concentration range of 1×10-11 M to 
1×10-5 M. 
  ? ?
 
Figure 2.20. Fluorescent ligand displacement of [3H]-CGP 12177 specific binding at the human E-AR in whole CHO 
cells. Inhibition of [3H]-CGP 12177 specific binding to whole cells in a) E1 by compounds 72a, 72b and 72c and b) E2 
by compounds 72a, 72b and 72c. Nonspecific binding was determined by 10 µM propranolol. A concentration of 1 nM 
of [3H] CGP 12177 was used in each experiment. Data points are a mean ± s.e.m of triplicate determinations. These 
single experiments are a representative a minimum of three different experiments 
Compound E1 Log Ki (n) E2 Log Ki (n) 
72a -5.92 ± 0.07 (4) -6.36 ± 0.09 (4) 
72b -6.39 ± 0.09 (4) -6.58 ± 0.14 (4) 
72c -5.95 ± 0.07 (4) -6.11 ± 0.10 (4) 
 
Table 2.7. Log Ki values were obtained from [
3H]-CGP12177 binding in whole cells expressing either the human E1 or 
E2-AR. Values are mean ± s.e.m from n number of experiments. Ki refers to the equilibrium dissociation constant and 
the values were calculated from the IC50 values. 
The radioligand binding experiments for the amide-linked fluorescent ligands show low 
micromolar affinity to receptors. These affinities are comparable to those of previous ligands. 
Direct comparison between 57c and 72a shows that the amide-linker is not tolerated as well as 
the straight-carbon chained linker. The amide linked ligands lipophilic nature was examined 
with LogD 7.4 and CHIIAM 7.4 analysis to determine if the polar group did make and effect. If 
there was an effect the ligands would be forwarded for confocal imaging to investigate whether 
the polar linker would reduce intracellular uptake.  
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2.5.3 Lipophilic study of amide linker fluorescent ligands 
The amide linker pharmacophore and amide-linked fluorophores were analysed with regard to 
their membrane interaction and lipophilic properties using the previous HPLC methods. 
Compound CHIIAM 7.4 LogD 7.4 
Propranolol 55.50 1.09 
71 38.08 1.89 
72a 53.19 4.09 
72b 54.83 4.50 
72c 52.25 3.94 
 
Table 2.8. Retention times and CHIIAM 7.4 values of second generation ligands calculated from HPLC methods using a 
Regis IAM PC 12 Pm column (100 x 4.6mm), a flow rate of 1.00 mL/min and UV detection at 230 and 366 nm. Linear 
gradient 0 % - 100% solvent A over 7 min. Solvent A: 100% MeCN. Solvent B: water with 50 mM ammonium acetate. 
LogD 7.4 values calculated by HPLC methods using a Polaris C18 5 Pm HPLC column (50 x 4.6mm). A flow rate of 
1.00 mL/min and UV detection at 230 and 366 nm. Linear gradient 0 % - 95% solvent A over 4 min. Solvent A: 100% 
MeCN. Solvent B: water with 50 mM ammonium acetate 
CHIIAM 7.4 values of the amide linker pharmacophore show a reduced membrane interaction 
compared with propranolol. This is possibly due to the nature of the linker as there are 
additional polar groups attached. The amide must be reducing the interaction between the 
membrane and the pharmacophore. The LogD 7.4 is slightly elevated compared with that of 
propranolol. This possibly is the effect of the terminal alkyne. It could be assumed that the 
polar amide in the linker would reduce the LogD 7.4 value. Increased values of both LogD 7.4 
and CHIIAM 7.4 are observed with the attachment of the fluorophore which is comparable to 
previously synthesised ligands. CHIIAM 7.4 values are reduced compared with the previous 
fluorescent ligands 57a-c and 66a, with the largest reduction being 68.26 to 52.25. This is a 
very significant drop in LogD 7.4 values. The ether linkage in 72c clearly had an additional 
effect on the amide linker. Interestingly the short-chained fluorophore with amide linker 72a 
did not have a reduction of LogD 7.4.  
  ? ?
2.5.4 Amide linker confocal imaging 
With the slight loss of binding affinity, but improved LogD 7.4 and CHIIAM 7.4 values, the 
fluorescent ligands 72a-c were imaged by the confocal microscopy. Unfortunately the addition 
of the polar linker did not change the properties enough to stop intracellular accumulation. The 
insertion of a polar linker clearly did not reduce intracellular accumulation that was expected 
from the HPLC data. The large organic fluorophore clearly still has a major effect on the 
molecule even though there is a reduction in CHIIAM 7.4 and LogD 7.4 value. With the 
understanding of the fluorophore having such a major effect on the ligand, a different 
fluorescent tag would to be attached to the pharmacophore. From research within the group, it 
is known that longer wavelength fluorophores are less prone to intracellular accumulation but 
have the drawback that they are difficult to synthesise and give low yields. Investigation into 
clicking red-shifted fluorophores to the pharmacophores would allow this previous work to be 
confirmed. 
  
  ? ?
 
 
 
Figure 2.23. Visualisation of fluorescent antagonists (100 nM) on CHO E2 cells. a) Transmitted light image taken at 0 
min before the addition of 72a and b)  appearance of 72a 10 min after addition. c) Transmitted light image taken at 0 
min before the addition of 72b and d) appearance of 72b 10 min after addition, e) Transmitted light image taken at 0 
min before the addition of 72c, f) image taken 10 min after the addition of 72c. 
  
e) f) 
c) d) 
a) b) 
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2.6 Longer wavelength fluorophores 
Previous fluorophores that were synthesised have been of short excitation wavelength and 
there are some disadvantages of using shorter wavelength fluorophores, such as lower 
molecular brightness and a high incidence of background fluorescence,146 and less intracellular 
accumulation when confocaly imaged. Changing to a longer wavelength dye, i.e. a red-shifted 
dye, these disadvantages are overcome and cell and tissue auto-fluorescence are observed less. 
Another advantage of using a red-shifted dye is the reduction in background fluorescence that 
ultimately achieves improved sensitivity. Previous work within the group has also shown that 
red-shifted BODIPY fluorophores tethered to beta adrenoceptor ligands do not internalise like 
the short wavelength fluorophores.64 Utilising a longer wavelength fluorophore may improve 
the ligands behavior in the view of less internalisation and better confocal microscope imaging.  
Longer wavelengths BODIPY fluorophores usually contain an increased amount of 
conjugation within the structure. This increased amount of conjugation could give an increased 
amount of lipophilicity which contradicts the process that was tried with the amide linker, but 
as previously mentioned, previous work within the group shows that longer wavelength 
fluorophores achieve better results when imaged under the confocal microscope.  
2.6.1 Longer wavelength fluorescence ligand synthesis 
Long wavelength fluorophores are on occasions difficult to synthesis due to long synthetic 
procedures and low-yielding reactions but a commercially available red-shifted azide 
functionalised dye was available from Cambridge research biochemicals 73. As it was azide 
functionalised, it could be clicked to a chosen pharmacophore with no need for any synthetic 
modification. It has been noted that the commercially available fluorophore has a long linker 
between the azide and the fluorophore that has previously been shown to reduce binding 
affinity in the previously ligands synthesised.  
  ? ?
 
Scheme 2.21. i) 1-(naphthalen-8-yloxy)-3-(prop-2-ynylamino)propan-2-ol, DMF/H2O, CuSO4.5H2O, sodium 
ascorbate, MW 80 min, 80 °C, 40 W,(14%). ii) 1-(hex-5-ynylamino)-3-(naphthalen-1-yloxy)propan-2-ol, DMF/H2O, 
CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W, (22%). 
This reaction used previously described conditions in this chapter. Fluorophore 73 was clicked 
to pharmacophore 30a and pharmacophore 53c.  
2.6.2 Red-shifted fluorescent ligand pharmacology 
The two long wavelength fluorescent ligands were examined under radio-ligand competition 
assays. 
 
Figure 2.24. Fluorescent ligand displacement of [3H]-CGP 12177 specific binding at the human E-AR in whole CHO 
cells. Inhibition of [3H]-CGP 12177 specific binding to whole cells in a) E1 by compounds 74a, 74b and b) E2 by 
compouds 74a, 74b. Nonspecific binding was determined by 10 µM propranolol. A concentration of 1 nM of [3H] CGP 
12177 was used in each experiment. Data points are a mean ± s.e.m of triplicate determinations. These single 
experiments are a representative a minimum of three different experiments 
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Compound E1 Log Ki (n) E2 Log Ki (n) 
74a -5.02 ± 0.08 (4) -5.89 ± 0.15 (4) 
74b -4.27 ± 0.10 (4) -5.48 ± 0.12 (3) 
Table 2.9. Log Ki values were obtained from [
3H]-CGP12177 binding in whole cells expressing either the human E1 or 
E2-AR. Values are mean ± s.e.m from n number of experiments. Ki refers to the equilibrium dissociation constant and 
the values were calculated from the IC50 values. 
74a was based on the initial one carbon linked pharmacophore, in comparison there is an 
improvement in binding affinity. Compound 74b was based on the pharmacophore which 
when tethered to a fluorescent moiety had the greatest binding affinity 57c. Unfortunately there 
was no improvement in binding affinity, which could be due to the extended linker between the 
triazole and fluorophore. Extension of this linker has not been beneficial when linker extension 
was trialed with previous ligands 66a and 66b. The red shifted fluorophore is also bulkier, with 
side groups adjacent to the pyrrole rings.  
 Both ligands were taken forward for analysis with the HPLC methods to establish the LogD 7.4 
and CHIIAM 7.4 values to determine if the introduction of a red-shifted fluorophore has a 
reduction in membrane interaction and lower lipophilicity resulting in the overall desired effect 
of reduced intracellular accumulation. 
2.6.3 Lipophilic study of longer wavelength fluorescent ligands 
The red shifted fluorescent ligands were analysed with regard to their membrane interaction 
and lipophilic properties using the previous HPLC methods. 
Compound CHIIAM 7.4 LogD 7.4 
Propranolol 55.50 1.09 
74a 69.17 5.79 
74b 67.04 5.08 
Table 2.10 . CHIIAM 7.4 values of longer wavelength ligands calculated from HPLC methods using a Regis IAM PC 12 
Pm column (100 x 4.6mm), a flow rate of 1.00 mL/min and UV detection at 230 and 366 nm. Linear gradient 0 % - 
100% solvent A over 7 min. Solvent A: 100% MeCN. Solvent B: water with 50 mM ammonium acetate. LogD 7.4 
values calculated by HPLC methods using a Polaris C18 5 Pm HPLC column (50 x 4.6mm). A flow rate of 1.00 
mL/min and UV detection at 230 and 366 nm. Linear gradient 0 % - 95% solvent A over 4 min. Solvent A: 100% 
MeCN. Solvent B: water with 50 mM ammonium acetate. 
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The longer wavelength fluorescent ligands showed unfavorable properties when analytical 
LogD 7.4 and CHIIAM 7.4 values were determined. In comparison to Propranolol there is a 
noticeable change in both values. The LogD 7.4 of both red shifted fluorophores show that the 
ligands are highly lipophilic, the values are similar to the previous ligand 57c which showed 
unwanted characteristics when imaged. The CHIIAM 7.4 data shows high levels of membrane 
interaction and again is similar to 57c, which had a value of 68.26, compared to 74a that had a 
value of 69.18 and 74b of 67.04. The ligands were taken forward for confocal imaging, even in 
the light of poor CHIIAM 7.4 and LogD 7.4, as the previous work within the group showing red-
shifted ligands did not accumulate in the cytoplasm. 
2.6.4 Long wavelength fluorescent ligand confocal imaging  
Both ligands were imaged by confocal microscopy to see if the longer wavelength fluorophore 
would make a difference to intracellular accumulation but unfortunately intracellular 
accumulation was still present. The antagonists were used at a range of concentrations but this 
did not reduce the amount of intracellular accumulation. It was noted that this commercially 
available dye 73 did not react as successfully as the previous dyes 46, 61 and 65, the yields 
being much lower than those of the green shifted dye. Binding affinities were not improved 
and from the confocal imaging results showing intracellular accumulation, the fluorophore was 
discarded and the synthesis of a red-shifted dye was initiated. 
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Figure 2.25. Visualisation of fluorescent antagonists (100 nM) on CHO E2 cells. a) Transmitted light image taken at 0 
min before the addition of 74a and b) appearance of 74a 10 min after addition. c) Transmitted light image taken at 0 
min before the addition of 74b and d)  appearance of 74b 10 min after addition.  
 
2.7 Synthesis of longer wavelength fluorophore 
As the commercially available red fluorophore when coupled to the orthosteric ligand had poor 
binding affinity and the confocal imaging showed intracellular accumulation, synthesis of a 
longer wavelength fluorophore was necessary. Previous work within the group has suggested 
that fluorophores similar in structure to BODIPY 630/650 internalise to a lesser extent than 
other available fluorophores. This fluorophore needed azide functionality to allow an alkyne-
azide copper (I) catalysed cycloaddition with the alkyne-functionalised pharmacophore. This 
fluorophore would possibly be less lipophilic in comparison to the previous fluorophore 73, 
c) d) 
a) b) 
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with the benefit of the amide bond within the linker. With only one phenyl extension would 
also help to reduce the lipophilicity of the ligand and may stop the internalisation. Previous 
work by Baker et al.64 had success with an extremely similar fluorophore with an amide bond  
for tethering the fluorophore attached to an adrenergic ligand with brilliant confocal imaging 
and displacement of the fluorescent ligang was possible when the cells were pre-incubated 
with a known antagonist. 
2.7.1 Retrosynthesis of a long wavelength fluorophore 
 
 
Scheme 2.22. Retrosynthesis of BODIPY azide 
2.7.1.1 Synthesis of red shifted ligands 
Synthesis of the BODIPY azide would be separated into forming two pyrrole rings substituted 
differently then combining the two in the final step. 
 
Scheme 2.23. i) allylamine, pyridine, DCM, 4 hr (85%) ii) a- phosgene, DMF, 16 hr; b- KOtBu, 0 qC, 10min, (34%) 
iii) POCl3, DMF, DCE, 2 hr (45%). 
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The synthesis began with the acylation of allyamine with 2-thiophenecarbonyl chloride (75) to 
afford the amide 76 in 85% yield.147 Synthesis of 77 was achieved in a one-pot, two-step 
reaction. Starting with the amide 76 and a solution of phosgene in toluene to afford the iminoyl 
chloride. This was treated with potassium tert-butoxide without further purification. The 
resulting nitrogen ylide formed by the elimation of HCl undergoes a 1,5-dipolar ring closure 
and subsequent isomerisation to yield 77.  Formylation of pyrrole 77 was achieved using a 
Vilsmeier reagent formed from DMF and POCl3 in 1,2-dichloroethane. The mechanism for the 
Vilsmeier formylation is shown in figure 2.26. 
 
Figure 2.26. Mechanism for the Vilsmeier formylation of 77. 
 
Scheme 2.24. i) PPh3, benzene, reflux, 22 hr (85%) ii) 2-Pyrrole-carboxaldehyde NaH, toluene, reflux 16 hr, (5%). 
The second pyrrole to be coupled for the formation of the longer wavelength fluorophore 
requires a phenolic ring bonded to the pyrrole through a carbon-carbon double bond. This was 
achieved through a Wittig reaction. This required the synthesis of the ylid. 4-Methoxybenzyl 
chloride (79) was reacted with triphenylphosphine to afford the phosphoium salt (80) in 85% 
yield. The ylid was reacted with pyrrole-2-carboxaldehye to produce the desired product 81. 1H 
NMR confirmed that the product was of the E-isomer (J 16Hz). This reaction proceeded with a 
very low yield (5%) possibly due to the acidity of the amine of the pyrrole. Once deprotonated, 
  ? ?
the pyrrole nitrogen would be an extremely good nucleophile and could lead to possible side 
reactions.  
 
Scheme 2.25. i) Sodium ethanthiolate, reflux, 5 days ii) NaH, methyl bromoacetate, THF, 5 hr (48%). 
The next stage of synthesis required the demethylation of the methyl ether 81 and the addition 
of an acetate group. The initial synthesis, was a one-pot two-step synthesis with sodium 
ethanthiolate, reflux in DMF, then addition of methylbromoacetate. It was found that this 
reaction did not have a high yield. It was therefore decided to try a two-step, two-pot reaction 
forming the phenol first, then deprotonation with sodium hydride in THF and the addition of 
methyl bromoacetate. This resulted 83 in higher yield (48%).  
 
Scheme 2.26. i) 2-azidoethanamine, MeOH, reflux, 3 days (95%). 
The last step for the synthesis was the conjugation of 83 with the previously used linker 29, the 
reaction was heated at reflux for 3 days to yield the azido-amine motif 84. 
 
Scheme 2.27. i) a) POCl3, DCM:MeOH (1:1), 18 h b). Et3N, BF3.OEt2, DCM, 12 h, (34%). 
The final reaction was the coupling and subsequent mediated cyclicisation of pyrrole 78 and 
pyrrole 84 to generate the azide functionalised BODIPY dye 85. There are several one-pot 
  ? ?
reactions that have been reported.148,149 The reaction is a one-pot, two-step reaction which 
afforded the desired red-shifted dye in reasonable yield. The first step involved the coupling of 
the two components 78 and 84 in the presence of POCl3 followed by the introduction of the 
BF2 group through boron trifluoride diethyl etherate in the presence of triethylamine to yield 
85 in 34% yield. 
 
Scheme 2.28. i) DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W.  
The long wavelength fluorophore 85 was then conjugated to the previous best pharmacophore 
56c through the click reaction conditions used throughout. This yielded the desired product 86. 
Regrettably, the desired product had surprisingly poor solubility in all solvents including 
DMSO, DMF, methanol and water. Due to the insolubility of the ligand, binding affinities 
could not be calculated.  
As 86 was unusable, the amide-linked pharmacophore 71 was clicked to the in-house red 
shifted dye 85. Previous cycloaddition conditions were used to yield the fluorescent antagonist 
87. 
 
Scheme 2.29. i) DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W,(45%). 
 
  ? ?
2.7.1.2 Pharmacology of long wavelength fluorescent ligand 
 
Figure 2.27. Fluorescent ligand displacement of [3H]-CGP 12177 specific binding at the human E-AR in whole CHO 
cells. Inhibition of [3H]-CGP 12177 specific binding to whole cells in a) E1 by compounds 87 b) E2 by compound 87. 
Nonspecific binding was determined by 10 µM propranolol. A concentration of 1 nM of [3H] CGP 12177 was used in 
each experiment. Data points are a mean ± s.e.m of triplicate determinations. These single experiments are a 
representative a minimum of four different experiments 
Compound E1 Log Ki (n) E2 Log Ki (n) 
87  -5.16 ± 0.06 (4)  -5.96  ± 0.20 (4) 
 
Table 2.9. Log Ki values were obtained from [
3H]-CGP12177 binding in whole cells expressing either the human E1 or 
E2-AR. Values are mean ± s.e.m from n number of experiments. Ki refers to the equilibrium dissociation constant and 
the values were calculated from the IC50 values. 
Ligand 87 had improved binding affinities when compared with ligands 74a and 74b, the two 
previous red-shifted dyes. The binding affinities were lower than 57c, but had very comparable 
affinities to other amide linker ligands 72a-c. There is a slight loss of activity at the E1 receptor. 
This result shows interesting SARs. The fluorophore is orientated differently to the shorter 
wavelength fluorophore as the linker is conjugated to the pyrrole ring and not in the meso 
position of the core. This could possibly result in a slightly different orientation to that of the 
ligands 74a-b and the shorter wavelength ligands. The ligand was imaged by confocal imaging 
to gauge if this conjugate would not internalise like previously synthesised ligands. 
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2.7.2.1 Confocal imaging of red-shifted ligands 
The main area of interest with this ligand was the confocal imaging and with the previous 
knowledge of reduced intracellular accumulation diminished with a fluorophore of this type 
imaging was highly important. 
 
 
Figure 2.28. Visualisation of fluorescent antagonists (100 nM) on CHO E2 cells. a) Transmitted light image taken at 0 
min before the addition of 87 and b)  appearance of 87 10 min after addition. c) Transmitted light image taken at 0 min 
before the addition of 87 after preincubation with ICI 118551 (100 nM) and d) appearance of 87 10 min after addition. 
Confocal imaging of 87 clearly showed membrane binding of the fluorescent ligand and no 
internalisation of the ligand is shown. As membrane binding can be seen, experiments were 
carried out to determine if the ligand has receptor binding or non-specific binding. From the 
RLB experiments it could be assumed that it had receptor binding but to confirm, cells were 
pre-incubated with 1PM ICI 118551, a selective ȕ2 antagonist that would block all available 
binding sites. This occupation of the receptors does not allow the fluorescent ligand to bind to 
the receptor. Figure 2.28 shows no receptor binding and minimal non-specific binding. 
c) d) 
a) b) 
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Unfortunately the quantity of 87 synthesised and lack of time did not allow lipophilic 
characterisation to be carried out. This data would potentially have afforded excellent 
analytical data towards the understanding of internalisation of fluorescent molecules.   
2.8 Triazole bearing fluorophores and pharmacophores  
Attachment and incorporation of the triazole and fluorophore to a known orthosteric ligand has 
an effect on the binding affinities shown in the study. To quantify this, triazole bearing 
fluorophores and triazole-tethered pharmacophores were investigated to determine the extent 
of this, to whether the triazole-fluorophore had any specific binding or whether the triazole had 
a beneficial effect on binding when attached to the orthosteric ligand. This investigation 
required triazole bearing pharmacophore and triazole bearing fluorophores to be synthesised 
and tested assessed by radioligand binding competition assays.  
2.8.1 Capped molecule synthesis 
The fluorophores were conjugated with azide-functionalised amines to form simple 1,2,3-
triazoles that the azide would not interfere with binding. These molecules would mimic the 
fluorophore-triazole structure observed in the final ligand. 
 
Scheme 2.30. i), 4,4-Difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene, DMF/H2O, 
CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W (60%). ii) ,4-Difluoro-8-(4-(5-azidopentyl))phenyl-2,6-
dimethyl-4-bora-3a,4adiaza-s-indacene DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W. (76%). 
The fluorophores were capped with propargylamine to form the triazole with a terminal amine. 
Two capped fluorophores 88a-b were synthesised in reasonable yield.  
  ? ?
 
Scheme 2.31. i) 1,3-dibromopropane, K2CO3 12hr, (69%). ii) Sodium azide, DMF, 16hr, (80%). iii) 1-(hex-5-
ynylamino)-3-(naphthalen-1-yloxy)propan-2-ol, DMF/H2O, CuSO4.5H2O sodium ascorbate, MW 80 min, 80 °C, 40 W 
(62%). 
To get an understanding of the influence of the triazole on the pharmacophore 56c, a simple 
azide was coupled to the pharmacophore. This azide included the linker from the fluorophore 
resulting in a terminal phenol.  
The synthesis of the fluorophore linker began with 1,3 dibromopropane and phenol (89) 
stirrred at room temperature in the presence of K2CO3 to yield (3-azidopropoxy) benzene (90). 
This was clicked to the alkyne 56c to yield 92. 
2.8.2 Pharmacology of triazole pharmacophores and capped fluorophores 
Binding affinities of the capped molecules were calculated by radio ligands binding assays.  
  
Figure 2.27. Fluorescent ligand displacement of [3H]-CGP 12177 specific binding at the human E-AR in whole CHO 
cells. Inhibition of [3H]-CGP 12177 specific binding to whole cells in a) E1 by compound 92 and b) E2 by compounds 
92. Nonspecific binding was determined by 10 µM propranolol. A concentration of 1 nM of [3H] CGP 12177 was used 
in each experiment. Data points are a mean ± s.e.m of triplicate determinations. These single experiments are a 
representative a minimum of four different experiments. 
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Compound E1 Log Ki (n) E2 Log Ki (n) 
92 -7.21 ± 0.01 (4) -7.33 +0.09 (4) 
88a > -4.00* (4) > -4.00* (4) 
88b > -4.00* (4) > -4.00* (4) 
 
Table 2.10. Log Ki values were obtained from [
3H]-CGP12177 binding in whole cells expressing either the human E1 
or E2-AR. Values are mean ± s.e.m from n number of experiments. Ki refers to the equilibrium dissociation constant 
and the values were calculated from the IC50 values. *No displacement at the concentrations tested. 
The fluorophores do not displace the radioligand and they have no affinity to the receptor at the 
concentrations tested (binding curves not shown). 
Ligand 92 showed nano-molar affinity it has the best binding affinities of the non-fluorescent 
ligands tested. There is a large improvement on binding compared to alkyne-functionalised 
pharmacophores. This result again points towards the triazole being accommodated in the 
binding pocket. Comparison between the best fluorescent ligand 57c, which had log Ki values 
of -6.77 and -7.32 respectively at E1 and E2 and 92 there is no significant difference between 
the two at the E2 receptor. This shows addition of the fluorophore onto 92 is not having an 
effect on binding at the E2 receptor. Interestingly there is an effect on the E1 receptor. Activity 
drops from -7.21 to -6.77 Log Ki possibly showing receptor selectivity.  
2.8.3 Stability assays 
Stability assays were performed to determine whether the fluorescent ligands degraded in cell 
media. If the ligands decomposed in the media while incubating with the cells, this could result 
in a false positive or negative result. 
Antagonists were diluted from DMSO stock solution to 10-4 M concentration in serum free 
media and incubated for a maximum of six hours. The maximum incubation time was six hours 
as this would be beyond the time length for which the antagonists would be in solution. HPLC 
analytical traces were performed with 20 PL of antagonist/serum free media and were injected 
at 0, 0.5, 1, 2, 3, and 6 hours in order to observe if the media had caused any decomposition of 
the ligands. Results showed that there was no decomposition of any adrenoceptor antagonists.  
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2.9 Conclusions and future work 
A range of fluorescent E-adrenoceptor ligands were synthesised successfully using the alkyne-
azide copper (I) cycloaddition “click” reaction. 15 novel fluorescent beta adrenoceptor ligands 
were synthesised with a range of binding affinities, physicochemical propterties and confocal 
microscopy characteristics.  
The three main components of a fluorescent ligand are the pharmacophore, linker and 
fluorophore. Each component of the fluorescent conjugate can affect the ligand greatly. In this 
study a range of linkers and fluorophores were used in an attempt to synthesise a fluorescent 
ligand with high binding affinity and properties that were close to the parent ligand and could 
be used in a range of assays. Unfortunately not one fluorescent ligand had all these 
characteristics. 
 2.9.1. Effect of hydrocarbon linker length on binding affinity 
 Linker length was investigated in two separate ways, length between the pharmacophore and 
triazole and the linker between the fluorophore and the triazole. Non branched hydrocarbon 
linkers were investigated. 
 Generally, it appeared that the longer the linker between the pharmacophore and triazole the 
greater the binding affinity of the ligand. There was a difference of over two log units in 
difference between the shortest linker synthesised, a one carbon linker 52a (log Ki -4.27 ± 0.10 
ȕ1 and ȕ2 -5.13 ± 0.05) to the longest linker, a four carbon linker, 57c (log Ki -6.77 ± 0.20 ȕ1, 
and -7.32 ± 0.05 ȕ2). Interestingly the two carbon linker gave better affinity then the one 
carbon linker and three carbon linker but not as good as the four carbon linker.   
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Figure 2.28. Structures of ligands 52a and 57c. 
Increasing the linker between the triazole and the fluorophore had the opposite effect to 
binding affinity. Affinity reduced by over two log units when the most potent fluorescent 
ligand, a three carbon linker, 57c (log Ki -6.77 ± 0.20 ȕ1, and -7.32 ± 0.05 ȕ2 was altered to 
include a longer, five carbon linker between the triazole and fluorophore, 66a (log Ki -4.61 ± 
0.12 ȕ1, and -5.36 ± 0.09 ȕ2.)  
Figure 2.28 shows a representation of a fluorescent ligand. In general it was found that when 
linker A is longer, binding affinity increases while an increase in linker B causes a reduction in 
binding affinity. 
 
Figure 2.28. Representation of a fluorescent ligand. P = Pharmacophore, T = triazole, F = fluorophore, A is a linker 
and B is a linker. 
Effect of linker type on binding affinity 
 Fluorescent ligands were synthesised with an amide bond containing linker between the 
triazole and the pharmacophore, this was synthesised to reduce the lipophilicity of the 
fluorescent ligands to counter internalisation of the fluorescent ligands when imaged with a 
confocal microscope. This incorporation of an amide bond into the linker had an effect on the 
binding affinity of the ligand (72a) with roughly a 10-fold decrease in binding affinity at both 
receptors compared to the equivalent straight carbon linked fluorescent ligand (57c).  
An ethoxyethane linker between the triazole and fluorophore was synthesised and compared 
with longest triazole-fluorophore linker. This change in linker did not have a significant change 
in binding affinity over the equivalent straight hydrocarbon linker. 
Effect of the  fluorophore on binding affinity 
A range of fluorophores were attached to the pharmacophore, with each fluorophore having an 
effect on physiochemical properties and binding. One short wave fluorophore was used as well 
as two long wavelength fluorophores. The shorter wavelength fluorophore (46) when tethered 
  ? ?
to a pharmacophore gave better binding affinities than that of the longer wavelength 
fluorophores (73 and 85) with a minimum of a 10-fold reduction in binding affinity.  
Log D, CHI AIM and confocal microscopy 
Log D and CHI AIM values were calculated for all fluorescent ligands in an aim to assess the 
properties of the fluorescent ligand and allow comparison to the orthosteric ligand it was based 
on. The attachment of a fluorophore had a large impact on the physicochemical properties of 
the ligand, with a general large increase in both log D and CHI AIM values, signifying a large 
increase in lipophilicity. Amide bond linkers did improve these values. Longer wavelength 
ligands that were assessed had increased values than the shorter wavelength ligands.  
Confocal imaging of the ligands synthesised resulted in intracellular accumulation. When a 
polar linker was inserted into the ligand, no improvement was shown, and moving to a 
commercially available, azide functionalised longer wavelength fluorophore (73) intracellular 
accumulation still occurred. Only when the attachment of a BODIPY 630/650 fluorophore 
tethered to the amide linked pharmacophore, did intracellular accumulation stop and receptor 
binding was imaged. This binding could be stopped by pre-incubation with a known antagonist. 
Future work would include the synthesis of variations of both 57c and 87. As both of these 
ligands had excellent individual properties, merging the two together resulting in a ligand that 
has good affinity and images well would result in an excellent tool for fluorescent GPCR 
studies. One synthetic idea would be to incorporate the fluorophore (119 from chapter 3) onto 
the 4 carbon chained linker 56c. This may help reduce the lipophilicity of the ligand, which is 
shown in chapter 3 on a different ligand and receptor. Changes to improve 87 by coupling the 
dye to the three-carbon linker pharmacophore 56b could help improve affinity, as previous 
work with the four-carbon chained linker when clicked resulting in a non-soluble ligand. 
Investigation to longer linkers to determine if there is a more potent ligand available and 
whether there is a cut off to when a linker becomes too long and affinity is reduced.  
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3. Design and synthesis of fluorescent Muscarinic 
M3 antagonists 
3.1 Muscarinic receptors  
Another GPCR that is of interest for synthesising fluorescent ligands is the family of 
muscarinic receptors. There are three different muscarinic receptors expressed in the human 
airway, M1–M3.
150 It is known that acetylcholine is involved in airway smooth muscle 
contraction and narrowing, which can be targeted for COPD treatment.151-153 
There are five subtypes of muscarinic receptor, M1–M5, and they are members of the 
metabotropic GPCR family.1 Muscarinic M1 receptors are found primarily in the central 
nervous system (CNS), peripheral neurons and gastric parietal cells, and mediate excitatory 
postsynaptical potential.154  Muscarinic M2 receptors are predominately found within the heart. 
Activation of M2 receptors reduces the heart rate and reduces the contractile force of the 
atrium.1 Muscarinic M3 receptors are found in the lungs, smooth muscle, and endocrine and 
exocrine glands. Activation of M3 receptors results in the contraction of visceral muscle, an 
increase in exo- and endocrine secretion, and increases intracellular calcium in the vascular 
endothelium.155 The muscarinic M4 and M5 receptors are implicated in complex CNS responses, 
such as memory, arousal, attention and analgesia.1  
3.1.1 Muscarinic receptor structure 
The muscarinic receptor structure is similar to that of the adrenoceptors, with the orthosteric 
binding pocket being located in a similar position, namely in the middle of the TM helices.101 
Muscarinic receptors M1–M5 share a high degree of sequence homology and analysis of the 
sequences divides the receptors into two classes: Gi/o coupled and Gq/11 coupled.
156,157 It has 
been noted that the orthosteric binding pocket is formed by amino acids that are identical in all 
receptor subtypes.158 Recently, Kruse et al.159 published the crystal structure of an M3 receptor 
of Rattus norvegicus with a T4L lysozyme for stability and the ligand tiotropium bound, as 
shown in figure 3.1. Haga et al.158 published the crystal structure of the human M2 receptor, 
which also had a T4L lysozyme incorporated into the structure. The inverse agonist  
  ? ?
3-quinuclidinyl-benzilate (QNB) was bound to the receptor, as shown in figure 3.2. 
 
Figure 3.1. Crystal structure of the rattus norvegicus M3 receptor with Tiotropium bound. Source: Kruse et al, Nature 
2012, 482, 552-556.159 
 
Figure 3.2. Crystal structure of the human M2 receptor with ligand QNB bound. Source: Haga et al, Nature 2012, 
advance online publication 158   
3.1.2 Muscarinic M3 receptor 
Muscarinic M3 receptors, as previously stated, can be found in smooth muscle in numerous 
locations, including most glands, the stomach, iris and bronchi, with activation leading to iris 
  ? ?
muscular constriction, increased motility in the stomach, increased glandular secretion and 
constriction of the bronchi, respectively.1 
M3 receptors signal through the Gq/11 G-protein. On activation, the Įq-subunit causes activation 
of membrane-bound phospholipase C. This hydrolyses phosphatidylinositol 4,5-bisphosphate 
into 1,2-diacylgylcerol and inositol 1,4,5-triphosphate (IP3). IP3 promotes Ca
2+ release from 
specialised intracellular compartments43 and flux from voltage-dependent Ca2+ channels. 1,2-
diacylgylcerol promotes the activation of protein kinase C isoforms that phosphorylate 
numerous cellular enzymes involved in the regulation of diverse signaling events and cellular 
functions. 
3.2 Muscarinic M3 receptor as drug targets 
As the muscarinic M3 receptor is located in a range of cells throughout the human body, there 
is an assortment of uses for agonists and antagonists of the receptor. 
3.2.1 Glaucoma 
Glaucoma is a disorder of the eye in which the optic nerve suffers damage. This damage alters 
vision and if left untreated can lead to blindness. The damage to the nerve involves loss of 
ganglion cells.  There are two types of glaucoma, closed angle and open angle. Open-angle 
glaucoma has a slow onset glaucoma and vision deteriorates over time.1 Closed-angle 
glaucoma has a sudden onset and vision can be lost quickly; it is usually accompanied by 
sudden pain. Glaucoma is commonly caused by an increase in ocular pressure. It has been 
noted that glaucoma can be steroid induced or diabetic induced.160 Treatments for glaucoma 
include surgery, prostaglandin analogues, topical ȕ2AR agonists and M3 agonists, such as 
pilocarpine (93) and aceclidine (94).161 
 
 
Figure 3.3. Structures of pilocarpine and aceclidine. 
  ? ?
3.2.2 Urinary incontinence 
Urinary incontinence is a commonly reported problem caused by a range of factors. Causes 
include polyuria, enlarged prostate and caffeine/cola beverages that stimulate the bladder. 
There is a range of types of urinary incontinence relating to stress, urge, overflow structural, 
functional and transient. Treatment can range from behaviour management, dietary change, 
medication and surgery.162 Medications commonly used include solifenacin (95), tolterodine 
(96) and darifenacin (97), which target the M3 receptor in the bladder antagonistically. This 
reduces the contractions within the bladder and therefore reduces the urgency to urinate.163 
 
Figure 3.4. Structures of solifenacin, tolterodine and darifenacin 
3.2.3 Chronic obstructive pulmonary disease 
An area of growing research is the use of the M3 receptor as a target in COPD 
treatment.85,123,164-167 The World Health Organisation predicts that COPD will become the 
fourth most common cause of death by 2030 and the third most common cause of chronic 
disability by 2030.168,169 COPD is the co-occurrence of chronic bronchitis and emphysema, 
which results in the narrowing of the airways in the lung. Chronic bronchitis is the 
inflammation of the bronchi and bronchioles. Emphysema is distention and damage of the lung 
beyond the respiratory bronchioles, and it supervenes after years of coughing. This 
combination results in limited airflow to the lungs, causing shortness of breath.1 Causes of 
COPD include smoking, occupational exposure, air pollution and genetics.121,122 There is 
currently no cure for COPD; however, COPD is a preventable and treatable disease. 
Anticholinergics that have been recently developed for COPD include ipratropium bromide 
(98) (a short-term agent) and tiotropium bromide (99) (a long-term agent).165  
  ? ?
 
Figure 3.5. Structure of ipratropium bromide and tiotropium bromide. 
3.2.4 Aim  
This chapter describes the design, synthesis and pharmacological evaluation of fluorescent 
ligands active at the muscarinic M3 receptor. The main aims of this chapter are to use the 
knowledge gained in the previous chapter and incorporate this into the design and synthesis of 
synthons for the synthesis of novel fluorescent M3 ligands utilising click chemistry. Once this 
has been achieved, investigation into the physiochemical properties, ligand interaction by 
receptor binding assays, confocal microscopy and receptor kinetics will allow full 
characterisation and profiling of the novel fluorescent ligands.  
3.3 Design and synthesis of fluorescent M3 Ligands 
With the previous success of using the alkyne-azide copper (I) cycloaddition to conjugate a 
fluorophore to a known pharmacologically active orthosteric ligand, this methodology was 
revisited in order to synthesise novel fluorescent muscarinic receptor ligands, initially targeting 
the M3 subtype. The pharmacophore chosen for the M3 antagonist was a tiotropium bromide 
analogue (100) recently exemplified by Prat et al.165 Tiotropium bromide (99) is a long-acting 
24-hour bronchodilator used for the treatment of COPD.164 
 
Figure 3.6. Structures of pharmacophore and tiotropium bromide. 
It is known that some functional groups are key for interaction with the receptor. The nitrogen 
species is essential for binding and binding is improved when it is positively charged. The 
nitrogen has a strong interaction with the anionic side group of an aspartic acid residue. The 
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Scheme 3.1. Retrosynthetic scheme for muscarinic M3 antagonists. 
3.3.2 Synthesis of pharmacophore and linker 
 
 
Scheme 3.2. i) Oxalyl chloride, DMF, CHCl3, 90 min. ii) (3R)- quinuclidinol, K2CO3, CHCl3, 4 hr (96%). 
Synthesis of the pharmacophore started from phenylglyoxylic acid (101), which was converted 
into the acid chloride 102 by treatment with oxalyl chloride and DMF. The acid chloride was 
then reacted with (3R)-quinuclidinol to form the ester 103 in a yield of 96%.  
The final step required was a nucleophilic addition to the carbonyl. 103 was treated with 
phenyllithium at í 42°C to produce the diphenyl. This was achieved in 66% yield. 1H NMR 
confirmed that addition of a second phenyl group and the formation of an alcohol with a broad 
peak at 5.19 ppm. 
 
Scheme 3.3. PhLi (1.8M in dibutyl ether), THF, - 42 qC to RT, 2 hr, (66%). 
 
  ? ?
The next step was to attach a linker by alkylation of the tertiary amine. The same strategy was 
applied to linker length from chapter 2 (section 2.3). Linkers ranged from a single-atom linker 
to a four-carbon linker. An amide linker was also synthesised similar to pharmacophore 71. 
The straight carbon-chained linkers were commercially available, but the amide linker required 
synthesis.  
 
Scheme 3.4. i) Oxalyl chloride, DMF, CHCl3, 2 hr. ii) progargylamine, CHCl3, K2CO3, 4 hr, (52%). 
Synthesis began with the conversion of bromoacetic acid (105) to its corresponding acid 
chloride 106 using oxalyl chloride. The product 106 was reacted in situ with progargylamine to 
generate 2-bromo-N-(prop-2-ynyl)acetamide (107) in 52% yield.  
The second linker synthesised was a phenolic derivative. The literature suggests that inclusion 
of a phenoxypropyl moiety bound to the nitrogen increases activity;165 therefore, this linker 
was incorporated with the starting material 3-ethynylphenol (109), allowing a terminal alkyne 
to be attached. 
 
scheme 3.5. i) Acetone, K2CO3, 12 hr, (46%). 
 
This linker was synthesised by a Williamson ether synthesis between 1,3-dibromopropane 
(108) and phenol (109) to produce the alkynyl ether (110) in 46% yield.   
 
Scheme 3.6. Propargyl bromide, MeCN:CHCl3 (6:4), reflux, 12 hr, (45%). 
  ? ?
Attachment of the linker to the orthosteric head-group was achieved via alkylation of the 
tertiary amine. The ester 104 was refluxed with six separate linkers in acetonitrile:chloroform 
(6:4) to afford six different alkyne-functionalised congeners 111af. One example is shown in 
scheme 3.6. 
 
Figure 3.2. Structures of M3 alkyne functionalised pharmacophores. 
3.3.3 Synthesis of fluorescent ligands 
Conjugation of the orthosteric ligand to the fluorophore was achieved by click chemistry. The 
congeners were coupled to four different fluorophores utilising the optimised conditions 
previously described in chapter 2, to synthesis a range of novel fluorescent M3 antagonists. An 
example of this reaction is illustrated in scheme 3.7. The structures of the fluorescent ligands 
are show in figure 3.2 and table 3.1. 
 
Scheme 3.7. i) DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W, (50%). 
  ? ?
 
Figure 3.2. General structure of 517 nm emitting ligands. 
 
 
(m) 
 
(CH2)3 
 (n) 
(CH2)5 
 
(CH2)2O(CH2)2 
Counter-ion 
(X) 
CH2 112a 112b 112c Br 
(CH2)2 113a 113b 113c Br 
(CH2)3 114a 114b NS Cl 
(CH2)4 115a 115b 115c Cl 
CH2CONHCH2 116a 116b 116c Br 
p-(CH2)3O-Ph 117a 117b 117c Br 
 
Table 3.1. Structures of different M3 fluorescent antagonists synthesised. NS = not synthesised. 
Two red-shifted ligands were synthesised using pharmacophores 111b and 111f and coupled to 
the previous long-wavelength fluorophore 85.  
 
Scheme 3.8.i) DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W, (35%). 
Two fluorescent ligands with 650 nm emission were synthesised and are list in table 3.2.  
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Figure 3.3. General structure of 650 nm emitting ligands 
 
(m) Compound number 
(CH2)2 118a 
p-(CH2)3OPh 118b 
Table 3.2. Structures of 650 nm emitting fluorescent M3 antagonists 
3.4 Muscarinic antagonist pharmacology 
3.4.1 Antagonist confirmation and initial screen 
The pharmacology of the M3 ligands was assessed by intracellular calcium mobilisation assays. 
When M3 agonists activate their respective receptor, one series of downstream signaling 
processes results in a release of Ca2+ from specialised intracellular compartments. This calcium 
can be monitored by an intracellular fluorescent dye, 2-[5-[bis[(acetoxymethoxy-
oxomethyl)methyl]amino]-4-[2-[2-[bis[(acetoxymethoxy-oxo-methyl)methyl]amino]-5-
methylphenoxy]ethoxy]benzofuran-2-yl]oxazole-5-carboxylate (fura-2). When this fluorescent 
dye detects calcium, a change in the fluorescence was detected by the change of spectral 
properties when calcium is bound to the fluorescent calcium detector and the signal can be 
monitored. The fluorescence excitation wavelegnth is dependent on the amount of calcium 
within the cell as the ratio between the excitation is calculated. The more calcium bound to 
fura-2, the greater the lower excitation (330 nm) is over the base-level excitation (380 nm). If 
there is no activation of receptor, there will be no change or increase in the fluorescent 
properties. This allows competitive binding experiments to calculate the IC50 and Ki values. 
The affinities are determined by competitive displacement of carbachol from CHO cells 
expressing M3 receptors. Three separate experiments were performed in triplicate. Each ligand 
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response. The increase in fluorescent activity was above the expected threshold for calcium 
production and must be due to the fluorescent ligands. While figure 3.9 shows antagonist 
addition following pre-incubation with brilliant black, this clearly showed no fluorescent 
activity either due to extracellular ligand or calcium production.  
An initial investigation was carried out to determine if the fluorescent ligands had agonist 
activity. The experimental conditions were repeated with brilliant black and all ligands that 
were tested showed no agonist activity in three separate experiments in triplicate. Responses 
were identical to that shown in figure 3.5, when the fluorescent ligand was preincubated and 
carbachol was added at 20 seconds. 
3.4.2 Percentage inhibition assay 
After this initial antagonist screening process, a competition assay was conducted on all 
fluorescent ligands and congeners within a calcium assay to assess which ligands had the 
greatest activity. This assay was a single-point concentration experiment using 1 PM 
fluorescent antagonist and 0.1 PM carbachol. This assay allowed the measurement of the 
percentage inhibition. 
  ? ?
 
Figure 3.10. Histograms showing relative calcium production, when antagonist a) pharmacophores 111a-f and b) 
fluorescent ligands 112a-c, 113a-c, 114a-b, 115a-c, 116a-c, 117a-c and 118a-b at 1 PM concentration in competition 
against carbachol at 0.1 PM concentration on CHO cells expressing the human M3 receptor. Experiments were 
repeated three times and all compounds were tested in triplicate in each experiment. 
The results of this initial assay clearly show that all pharmacophores (111af) completely 
inhibit carbachol at this concentration. There is a range of inhibition profiles from the 
fluorescently tagged antagonists, ranging from minimal inhibition to complete inhibition.  
The initial assay showed that four fluorescent ligands (114a, 114b, 117a and 117b) greatly 
inhibited carbachol. All four of these fluorescent ligands had major similarities, one being the 
type of linker attached to the pharmacophore and the second being the linker attached to the 
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fluorophore. The fluorophore was the short wavelength fluorophore in all fluorescent ligands 
and the linkers attached to the pharmacophore were of two types; either a three carbon linker or 
the phenyl derived linker. The short linkers were not favoured with one carbon and two carbon 
linkers giving little inhibition. This was also the case for the longer wavelength fluorophore 
and the four carbon linkers gave a varying inhibition response dependent to which fluorophore 
was attached. 
 
 
Figure 3.11.  Structures of most potent fluorescent ligands. 
3.4.3 Dose response competition assays 
From the initial screening assay, the most promising ligands 114ab and 117ab were taken 
forward for further study. An intracellular calcium assay was again used, with a range of 
concentrations of antagonist and one concentration of agonist per experiment. The varying 
response of the antagonist would allow a dose–response curve to be produced, giving an IC50 
value that then could be used to produce a Kb value by using the Schild equation:
171 
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where DR (dose ratio) is the ratio of the concentrations of agonist required to produce an 
identical response in the presence and absence of antagonist, [A] is the concentration of 
antagonist and Kb is the antagonist inhibitory constant.  
This assay used concentrations of carbachol ranging from 0.1 ȝM.  The range of antagonist 
concentration was from 1×10í10 to 1×10í5 M. An example curve from each fluorescent ligand 
and non-fluorescent ligand is shown in figure 3.12. 
 
Figure 3.12. Inhibition of Carbachol binding to whole CHO expressing the human M3 cells by a) pharmacophores 
111a-f and b) fluorescent antagonists 114a-b and 117a-b. Data points are mean ± s.e.m (triplicate determinations) from 
a single experiment which is representative of 3 separate experiments for each ligand. A concentration of 0.1 ȝM of 
Carbachol was used in each experiment. 
  
Compound Log IC50 (n=) Log Kb (n=) 
111a -7.16 ± 0.02 (3) -9.44 ± 0.23 (3) 
111b -7.85 ± 0.03 (3) -10.00 ± 0.13 (3) 
111c -9.02 ± 0.18 (3) -10.29 ± 0.10 (3) 
111d -7.96 ± 0.20 (3) -6.68 ± 0.19 (3) 
111e -8.85 ± 0.11 (3) -10.15 ± 0.01 (3) 
111f -8.58 ± 0.15 (3) -9.72 ± 0.19 (3) 
114a -7.62 ± 0.20 (3) -8.89 ± 0.11 (3) 
114b -6.73 ± 0.20 (3) -8.02 ± 0.09 (3) 
117a -7.16 ± 0.24 (3) -8.42 ± 0.16 (3) 
117b -6.69 ± 0.16 (3) -7.97 ± 0.07 (3) 
 
Table 3.3. Inhibition of carbachol binding to CHO cells expressing the human M3 receptor induced by antagonists 
111a-f, 114a-b and 117a-b. Ki refers to the equilibrium dissociation constant and the values were calculated from the 
IC50 values. All values are expressed as mean value ± s.e.m of different experiments (n). 
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The binding data from competition assays gave very promising information. First, the 
pharmacophores were of a similar standard to the compounds published in the literature.165 The 
non-quaternised pharmacophore (104, figure 3.1) had a Log IC50 of í9.05 in radioligand 
binding studies and the phenoxypropyl-functionalised ligand had a Log IC50 of í9.21. The 
synthesised congeners had a similar IC50 to these ligands, with the best ligand having a Log 
IC50 of í9.02 with a binding affinity of í10.29 (Log Kb). It is noteworthy that the congener 
111f based upon the best compound in the literature did not give the highest affinity.165 The 
best congener was 111c, which contained a three-carbon linker. This congener also afforded 
the best fluorescent ligand, 114a, with a binding affinity of í8.89 ± 0.11 (Log Kb). Of the 
fluorescent ligands, those with greater binding affinity possessed the shorter linker after the 
triazole to the fluorophore and not the extended six-atom linker. These data also agree with 
those from earlier studies whereby the extended linker was not tolerated to the same extent as 
the shorter linker. All ligands had low nanomolar affinity, which was a relative improvement 
of binding affinity for the desired receptor in comparison to the ȕ-adrenoceptor ligands 
synthesised in chapter 2. 
3.4.4 Confocal imaging 
The ligands were assessed by confocal microscopy for visualisation at the single-cell level. A 
concentration of 100 nM was used initially for each ligand as this was greater than the Kb and 
would allow for good imaging. All ligands were incubated with CHO cells expressing the 
human M3 receptor. All experiments were conducted at 37°C (experimental section). Imaging 
was carried out in 8-well plates, with cells being seeded 24 hours before experimentation. The 
wells were washed and HBSS added before antagonist addition. The antagonists were added to 
the wells and confocal images were produced with the aim to see specific receptor binding.   
The initial confocal imaging of the fluorescent ligands did not produce the anticipated results. 
The images suggested that the ligand was binding to the glass and not to the membrane. After 
two separate washes the fluorescent ligand was not removed and was still bound to the glass. 
This binding to the glass is likely to be due to the positive charge of the ligand while the glass 
has a slight negative charge, which is common to silica and silicate glassware. To combat this 
  ? ?
problem, the cover slips were pre-treated with poly-L-lysine. This changes the contact charge 
of the glass from negative to positive and minimise binding to the glass and allow receptor-
binding visualisation. 
 
 
 
Figure 3.13. Visualisation of fluorescent antagonists (100 nM) on CHO M3 cells. a) Transmitted light image taken at 
0mins before the addition of 114a and b) appearance of 114a 10 min after addition. c) Transmitted light image taken at 
0 min before the addition of 114a and d) appearance after well washed with HBSS. e) Transmitted light image taken at 
0min before the addition of 114a and f) appearance after multiple washings. 
e) f) 
c) d) 
a) b) 
  ? ?
 
 
 
 
 
Figure 3.14. Visualisation of fluorescent antagonists (100 nM) on CHO M3 cells and wells preincubated with poly-L-
lysine. a) Transmitted light image taken at 0 min before the addition of 117a and b)  appearance of 117a 10 min after 
addition. c) Transmitted light image taken at 0 min before the addition of 114b and d) appearance of 114b 10 min after 
addition. e) Transmitted light image taken at 0 min before the addition of 117b and f) appearance of 117b 10 min after 
addition. g) Transmitted light image taken at 0 min before the a addition of 114a and h) appearance of 114a 10 min 
after addition. 
g) h) 
e) f) 
c) d) 
a) b) 
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With wells being pre-incubated with poly-L-lysine, the ligand binding to the glass has 
dramatically reduced allowing the ligand membrane binding to be captured. Figure 3.14b. 
displays cell membrane binding of all fluorescent ligands. 117a still showed binding of ligand 
to the glass but it is still possible to see membrane binding. Ligands were then administered 
with cells being pre-incubated with atropine, an known antagonist to the muscarinic 
acetylcholine receptor.172 Pre-treatment with atropine will help distinguish between specific 
and non-specific receptor binding. The pre-incubation of atropine would saturate the receptor 
not allowing the fluorescent ligand to bind. 
  
  ? ?
 
 
 
 
Figure 3.15. Visualisation of fluorescent antagonists (100 nM) on CHO M3 cells and wells preincubated with poly-L-
lysine and atropine (100 nM). a) Transmitted light image taken at 0 min before the addition of 114a and b) appearance 
of 114a 10 min after addition. c) Transmitted light image taken at 0 min before the addition of 114b and d) appearance 
of 114b 10 min after addition. e) Transmitted light image taken at 0 min before the addition of 117a and f) appearance 
of 117a 10 min after addition. g) Transmitted light image taken at 0 min before the addition of 117b and h) appearance 
of 117b 10 min after addition. 
g) h) 
e) f) 
c) d) 
a) b) 
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The confocal images in figure 3.15 show no fluorescent ligand binding when atropine is 
administered to the cells. Thus showing specific receptor binding by all fluorescent ligands and 
no internalisation is present either.  These ligands show specific membrane binding with low 
nanomolar affinity.  
3.4.5. Lipophilicity evaluation of fluorescent ligands 
The fluorescent ligands are clearly binding to the receptors when viewed using confocal 
microscopy. Previous ligands 57ac with shorter wavelength fluorophores showed 
cytoplasmic accumulation when imaged. One possible reason for this was the lipophilic nature 
of the ligand. Investigation into the lipophilic nature of the M3 ligands was conducted using 
CHIIAM 7.4 and LogD 7.4 HPLC methods, as used in chapter 2.
144,145 This would allow 
comparisons to be made with regard to the possible intracellular accumulation and lipophilicity 
of the ligands synthesised in chapter 2. 
Compound CHIIAM 7.4 LogD 7.4 
111a 45.72 1.16 
111b 46.16 1.48 
111c 46.92 1.67 
111d 48.22 1.89 
111e 48.42 1.37 
111f 53.94 2.55 
114a 60.11 3.59 
114b 61.76 3.92 
117a 61.65 4.06 
117b 62.87 4.55 
 
Table 3.4. CHIIAM 7.4 values of M3 ligands wavelength ligands calculated from HPLC methods using a Regis IAM PC 
12 Pm column (100 x 4.6mm), a flow rate of 1.00 mL/min and UV detection at 230 and 366 nm. Linear gradient 0 % - 
100% solvent A over 7 min. Solvent A: 100% MeCN. Solvent B: Water with 50 mM ammonium acetate. LogD 7.4 
values calculated by HPLC methods using a Polaris C18 5 Pm HPLC column (50 x 4.6mm). A flow rate of 1.00 
mL/min and UV detection at 230 and 366 nm. Linear gradient 0 % - 95% solvent A over 4 min. Solvent A: 100% 
MeCN. Solvent B: Water with 50 mM ammonium acetate. 
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The CHIIAM 7.4 and LogD 7.4 values are consistent with those observed for previously 
synthesised ligands, e.g. ligand 57c had a CHIIAM 7.4 of 68.26 and a LogD 7.4 of 3.70. The 
addition of a fluorophore greatly increases the LogD 7.4 and CHIIAM 7.4 values compared with 
those of the pharmacophore alone. The CHIIAM 7.4 values are lower than those for the shorter 
wavelength ligands for the ȕ-adrenoceptors, possibly due to the quaternised nitrogen, but the 
LogD 7.4 values are larger than those for the majority of the previously tested ligands. This 
result showed that the ligands have a reduced interaction with the membrane but are more 
lipophilic. Once again, the attachment of the fluorophore is impacting on the molecule overall 
with regard to the physicochemical properties. Investigation to whether a more polar 
fluorophore would improve the lipophilic nature of the fluorescent ligands. 
3.5. Polar fluorophore synthesis 
The pattern of lipophilicity and the incorporation of a fluorophore into a muscarinic fluorescent 
ligand followed the same observations to that of ligands synthesised in chapter two. 
Incorporation of a fluorophore dramatically increases the lipophilicity. This increase changes 
the physicochemical properties of the fluorescent ligand from the parent ligand that it was 
based on. The possible incorporation of a more polar fluorophore into a ligand may imbue 
properties similar to that of the parent drug. This could be achieved by the addition of a 
sulfonic acid group onto the fluorophore, as this would introduce a charged group. Sulfonation 
of BODIPY dyes has been previously described173 and this route was followed for the 
synthesis of a novel azide-functionalised fluorophore. Another route to more polar dyes would 
be to insert a polar side chain within the linker between the triazole and fluorophore. This side 
chain with a terminal carboxylic acid could be coupled to a number of amines or amino acids 
to allow fine adjustment to the fluorophore. One major benefit of both concepts is that the 
spectral properties of the fluorophores would be extremely similar to those of previously 
synthesised fluorophores. 
3.5.1 Synthesis of polar fluorophores 
Synthesis of the sulfonated dye (119) started with the previously synthesised fluorophore 46. 
This fluorophore was treated with chlorosulfonic acid for 10 minutes at í40 °C and then 
warmed to room temperature for 30 minutes and purified by HPLC in 62% yield. This was 
  ? ?
confirmed by mass spectroscopy and NMR spectroscopy. The 1H NMR spectra showed that 
the molecule did not have symmetry and the terminal methyl groups were not equivalent. The 
starting material showed two singlet peaks, integrating for six protons each, while fluorophore 
46 showed four singlets all integrating to three protons each. Mass spectroscopy also 
confirmed monosulfonation.   
 
Scheme 3.9.i) Chlorosulfonic acid, DCM, -40 °C to RT, 30 min, (62%). 
 
 
Scheme 3.10.i) NaN3, DMF, reflux, 3 hr, (91%). ii) 4-Hydroxybenzaldehyde, K2CO3, 60 °C, 3 hr, (58%). iii) 2,4-
Dimethylpyrrole, TFA, DCM, DDQ, BF3.OEt2, Et3N, 36 hr, (23%). iv) LiOH, MeOH/H2O, 3 hr,(98%). 
Synthesis of the polar side-chained fluorophore began with an azide substitution of methyl 2,4-
dibromobutanoate (120) in DMF. Methyl 2-azido-4-bromobutanoate (121) was then coupled to 
4-hydroxybenzaldehyde with a Williamson ether synthesis in the presence of potassium 
carbonate in 58% yield. Benzaldehyde 122 was then coupled to 2,4-dimethylpyrrole and then 
boron trifluoride diethyl etherate to yield the methyl ester-protected fluorophore 123. The final 
step was to deprotect the methyl ester in the presence of LiOH to yield the free carboxylic acid 
124, primed for further modification.  
  ? ? ?
 
Scheme 3.11. i) DCM, HBTU, DIPEA, 3 hr. ii) LiOH, MeOH/H2O, 12hr (95%). 
The synthesis of a fluorophore with a terminal glycine residue began with the coupling of 
glycine methyl ester (125) to the fluorophore 124 in the presence of HBTU and DIPEA and 
then deprotected by aqueous LiOH in methanol to yield the carboxylic acid 127. 
 
Scheme 3.12. i) 4,4-difluoro-8-(4-(2-azido-4-(4-formyl)phenoxy))phenyl-2,6-dimethyl-4-bora-3a,4-adiaza-s-indacene 
DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW 80 min, 80 °C, 40 W, (57%). ii) 4,4-difluoro-8-(4-(2-(2-azido-4-(4-
formyl)phenoxy)butanamido))phenyl-2,6-dimethyl-4-bora-3a,4-adiaza-s-indacene, DMF/H2O, CuSO4.5H2O, sodium 
ascorbate, MW, 80 min, 80 °C, 40 W, (47%). 
The three polar fluorophores were coupled to 111c to yield three novel fluorescent ligands. 
 
  ? ? ?
 
Scheme 3.13. i) DMF/H2O, CuSO4.5H2O, sodium ascorbate, MW, 80 min, 80 °C, 40 W, (42%). 
3.5.2 Pharmacology of polar ligands 
The binding affinities of the three ligands with polar fluorophores were investigated to 
determine whether changes in the fluorophore’s properties affects the receptor interaction.  
 
Figure 3.16. Inhibition of carbachol binding to whole CHO cells expressing the human M3 cells by antagonists 128a-b 
and 129. Data points are mean ± s.e.m (triplicate determinations) from a single experiment which is representative of 3 
separate experiments for each ligand. A concentration of 0.1 ȝM of carbachol was used in each experiment. 
 
Compound Log Kb (n=) 
128a -7.36 ± 0.12 (3) 
128b -7.04 ± 0.14 (3) 
129 -7.26 ± 0.03 (3) 
 
Table 3.5. Inhibition of carbachol binding to whole CHO cells expressing the human M3 receptor induced by 
antagonists 128a-b and 129. Ki refers to the equilibrium dissociation constant and the values were calculated from the 
IC50 values. All values are expressed as mean value ± s.e.m of different experiments (n). 
The introduction of a sulfonic acid group onto the fluorophore, making the compound neutral 
overall, resulted in some loss of activity. A reduction from í8.89 to í7.26 (Log Kb) suggests 
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that the overall positive charge of the compound is important for receptor interaction. With the 
insertion of a polar side chain, affinity is also reduced compared with the equivalent non-polar 
side chain ligand 108a. These affinities are respectable for fluorescent ligands. 
3.5.3. Confocal imaging of polar ligands 
Ligands 128a-b and 129 were evaluated by confocal microscopy. As ligand 129 has an overall 
neutral charge, pre-incubation with poly-L-lysine was not required. 
Confocal images of 129 without the addition of poly-L-lysine show membrane specific binding. 
Figure 3.17 also shows that the binding is receptor specific as there is no fluorescence present 
when atropine is administered prior to antagonist addition.  
 
 
 
Figure 3.17. Visualisation of fluorescent antagonists (100 nM) on CHO M3 cells. a) Transmitted light image taken at 0 
min before the addition of 129 and b) appearance of 129 10 min after addition. c) CHO cells Preincubated  with 
atropine (100 nM). Transmitted light image taken at 0 min before the addition of 129 and d) appearance of 129 10 min 
after addition with CHO cells preincubated with atropine (100 nM). 
c) d) 
a) b) 
  ? ? ?
 
 
Figure 3.18. Visualisation of fluorescent antagonists (100 nM) on CHO M3 cells preincubated with poly-L-lysine. a) 
Transmitted light image taken at 0 min before the addition of 128a and b) appearance of 128a 10 min after addition. c) 
Transmitted light image taken at 0 min before the addition of 128b and d) appearance of 128b 10 min after addition. 
  
c) d) 
a) b) 
  ? ? ?
 
 
 
Figure 3.19. Visualization of fluorescent antagonists (100 nM) on CHO M3 cells preincubated with poly-L-lysine and 
atropine (100 nM). a) Transmitted light image taken at 0 min before the addition of 128a and b) appearance of 128a 10 
min after addition. c) Transmitted light image taken at 0 min before the addition of 128b and d) appearance of 128b 10 
min after addition. 
The polar-tailed ligands show good membrane binding in figure 3.18. Ligand 128b showed 
minor background fluorescence, which is due to poor treatment of the glass with poly-L-lysine. 
Both ligands cannot be seen at the receptor when atropine has been administered prior to 
antagonist addition. Thus clearly showing that ligands 128a and 128b are receptor specific and 
not non-specific binding, identical to the ligands 114ab and 117ab. 
3.5.4 Physicochemical properties of Polar ligands 
The addition of a sulfonic acid, glycine residue or just a terminal carboxylic acid to the ligand 
will have an effect on the physicochemical properties of the ligand. All three ligands, 128ab 
and 123, were investigated for changes in CHIIAM 7.4 values.  
c) d) 
a) b) 
  ? ? ?
Compound CHIIAM 7.4 
111c 46.92 
114a 60.11 
128a 46.76 
128b 47.09 
129 44.04 
 
Table 3.6. CHIIAM 7.4 values of polar M3 ligands, 111c, 114c, 128a-b and 129 calculated from HPLC methods using a 
Regis IAM PC 12 Pm column (100 x 4.6mm), a flow rate of 1.00 mL/min and UV detection at 230 and 366 nm. Linear 
gradient 0 % - 100% solvent A over 7 min. Solvent A: 100% MeCN. Solvent B: Water with 50 mM ammonium 
acetate. LogD 7.4 values calculated by HPLC methods using a Polaris C18 5 Pm HPLC column (50 x 4.6mm). A flow 
rate of 1.00 mL/min and UV detection at 230 and 366 nm. Linear gradient 0 % - 95% solvent A over 4 min. Solvent A: 
100% MeCN. Solvent B: Water with 50 mM ammonium acetate. 
It is clear that with the addition of polar and charged groups to the fluorophore, CHIIAM 7.4 
values are improved and closer to the value of the parent ligand. With the charged sulfonic acid 
group attached to the ligand, the CHIIAM 7.4 is reduced to below the value of the parent ligand, 
indicating less interaction with the membrane relative to the parent ligand. This result showed 
that it is possible to modify a ligand to have characteristics similar to the parent ligand, but 
unfortunately reduces the binding affinity of the ligand.  
3.6 Receptor kinetics 
With a range of novel high-affinity fluorescent M3 ligands successfully synthesised, imaged 
and investigated at the physicochemical level, further investigation into the receptor kinetics 
could determine if association and dissociation rates are comparable to those of the parent 
ligand. This would give a greater profile of the fluorescent ligands synthesised to give a greater 
understanding of the introduction of a fluorophore and linker. Receptor association and 
disassociation rates are usually determined by either direct radiolabelling of the specific ligand 
of interest or in a competition-style assay with a radioligand specific for that receptor. Slow 
receptor dissociation kinetics have been implicated in the long clinical duration of action of 
some drugs.166,167 Therefore, calculating the kinetic parameters of new ligands early in the drug 
discovery process may be beneficial to improved SAR information and drug action. 
  ? ? ?
Investigation into whether the fluorescent ligands retain the kinetic properties of the parent 
ligand would be of interest in the development of fluorescent ligands.  
3.6.1 Binding affinities for M3 membranes 
First, new IC50 and binding affinity values were calculated, as the binding kinetic studies are 
carried out on cell membranes and not whole cells. The affinities were determined by 
competitive displacement of the radioligand [3H]-N-methyl scopolamine ([3H]-NMS) from 
CHO membranes expressing the human M3 receptor. Radioligand binding was performed as 
previously described by Dowling et al.166 and cell membrane preparation was performed as 
previously described by Skyes et al.37 At least three different experiments were conducted for 
each ligand in triplicate. The assays were run with a range of concentrations from 1 × 10í5 to 1 
× 10í10 M for the fluorescent ligands and from 1 × 10í8 to 1× 10í12 M for the parent ligand 104, 
to produce dose–response curves. Each ligand was diluted to 10í2 M using DMSO and the 
stock solution was stored at í20qC until the ligand was tested.  
 
Figure 3.20. Inhibition of [3H]-NMS binding to CHO membranes expressing the human M3 receptor by antagonists 
104, 114a-b, 117a-b, 128a-b and 129. Data points are mean ± s.e.m (triplicate determinations) from a single 
experiment which is representative of 3 separate experiments for each ligand. [3H]-NMS was used at a concentration of 
1 nM. 
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Compound  Log Ki (n=) 
104 -11.36 ± 0.13 (3) 
114a -8.36 ± 0.04 (3) 
114b -8.32 ± 0 .04 (3) 
117a -8.12 ± 0.05 (3) 
117b -8.34 ± 0.06 (3) 
128a -7.26 ± 0.11 (3) 
128b -7.58 ± 0.08 (3) 
129 -7.20 ± 0.18 (3) 
  
Table 3.7. Inhibition of [3H]-NMS binding to CHO membranes expressing M3 receptors induced by antagonists 104, 
114a-b, 117a-b, 128a-b and 129. Ki refers to the equilibrium dissociation constant and the values were calculated from 
the IC50 values. All values are expressed as mean value ± s.e.m of different experiments (n). [
3H]-NMS was used at a 
concentration of 1 nM. 
Data from radioligand binding assays were used to calculate the IC50 values of the 
pharmacophores. These values were then used to calculate the binding affinities, Ki, using the 
Cheng–Prushoff equation:141  
D?H?ൌ D?D?H?H?  ? ൅ሾD?D?D?D?D?D?D?D?D?D?D?ሿD?H?  
where [radioligand] is the concentration of the free radioligand used in the assay and KD is the 
dissociation constant of the radioligand for the receptor. IC50 is the concentration of the ligand 
that displaces 50% of the specific binding of the radioligand. 
The binding affinities calculated from the radioligand binding experiments on cell membranes 
are similar to those calculated on whole cells by the intracellular calcium. The radioligand 
binding experiments are more accurate due to the longer incubation time of the antagonist, 
membrane and radioligand (3 hours). In the intracellular calcium assay, the antagonist was 
incubated with the cells and the agonist was added with a reading straight away not allowing 
for equilibrium to be reached.   
 
  ? ? ?
Compound Membrane Log Ki (n=) Whole cell  LogKb (n=) 
104 -11.36 ± 0.13(3) Not tested 
114a -8.36 ± 0.04 (3) 8.89 ± 0.09 (3) 
114b -8.32 ± 0 .04 (3) -8.02 ± 0.09 (3) 
117a -8.12 ± 0.05 (3) -8.42 + 0.16 (3) 
117b -8.34 ± 0.06 (3) -7.97 ± 0.07 (3) 
128a -7.26 ± 0.11 (3) -7.36 ± 0.12 (3) 
128b -7.58 ± 0.08 (3) -7.04 ± 0.14 (3) 
129 -7.20 ± 0.18 (3) -7.26 ± 0.03 (3) 
 
Table 3.8. Comparision of binding affinities of antagonists 104, 114a-b, 117a-b, 128a-b and 129. All values are 
expressed as mean value ± s.e.m of different experiments (n). 
3.5.2 Receptor Kinetic experiments  
With the IC50 values calculated, it was possible to calculate the association and disassociation 
rates. First, the observed dissociation rate (koff) of radioligand [
3H]-NMS was required and then 
the association rate (kon) of the radioligand [
3H]-NMS was calculated. Finally, the kinetics of 
the unlabelled antagonist were investigated. Kinetic experiments were carried out on seven 
fluorescent ligands and the parent ligand in table 3.14. Kinetic experiments of unlabelled 
antagonists and radiolabelled [3H]-NMS were performed as previously described by Dowling 
et al.166 Approximately 1 nM [3H]-NMS was added with fluorescent ligand (at t = 0) to CHO 
M3 membranes in 500 mL of assay buffer and then membrane was added at each time point in 
separate wells. The degree of [3H]-NMS bound to the receptor was assessed at multiple time 
points by filtration harvesting and liquid scintillation counting. Three different concentrations 
of fluorescent ligand were tested to ensure the rate parameters calculated were independent of 
ligand concentration. All compounds were tested at 3-, 10- and 30-fold of the Ki. Data were 
interpreted according to Sykes et al.37 
 
First, the t½ was calculated for [
3H]-NMS. In one half-life, half of the radioligand will have 
dissociated from the receptor, whereas in two half-lives, three-quarters of the radioligand will 
have dissociated, etc. Dissociation data were fitted to a single-phase exponential decay 
function and the t½ value obtained was transformed into a koff rate using the following 
  ? ? ?
equation: 
 D?H?H?H?ൌ  ?Ǥ ? ? ?D?H?H?  
 
It was found that [3H]-NMS had a koff equal to 0.015 ± 0.0004 min
í1. It was possible to 
calculate the kon as the observed association rate of a ligand is dependent upon its concentration, 
kon and koff values. This was possible by constructing a family of association curves using a 
range of radioligand concentrations. [3H]-NMS association data were fitted to a single-phase 
exponential association function to calculate an observed rate constant, kob. The association 
rate constant, kon, was calculated using the following equation, as described originally by 
Hill:174 
 D?H?H?ൌ ሺD?H?H?െ D ?H?H?H?ሻሾD?D?D?D?D?D?D?D?D?D?D?ሿ 
 
where the koff value used was predetermined from dissociation rate experiments. 
Ki could be calculated by the following equation: 
 D?H?ൌD?H?H?H?D?H?H? 
 
The association (k3) and disassociation rate (k4) for the fluorescent ligands were calculated in 
line with Sykes et al.37 
 
 
  ? ? ?
 
Figure 3.21. [3H]-NMS Competition kinetics curves in the presence of 104 (a), 117a (b), 114a (c), 128a (d), 114b (e), 
128b (f), 117a (g) and 129 (h). CHO-M3 cell membranes were incubated with ~1 nM [
3H]-NMS and either 0, 3-fold Ki, 
10-fold Ki or 30-fold Ki. Plates were incubated at room temperature for the indicated time points and non specific 
binding levels determined in the presence of 5 ȝM atropine from a single experiment, which is representative of 3 
separate experiments for each ligand. 
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can be directly compared are 114a, 114b, 128a, 128b and 129. These ligands contain the same 
pharmacophore and different fluorophores based on a similar BODIPY core. Comparison of 
the two types of fluorophore, fluorophores with the polar tailed fluorophore and non-polar 
tailed fluorophore. Between these two types there is a shift of one log unit in association rates. 
The ligands containing a polar-tailed dye have a lower CHI AIM7.4 in comparison to the 
ligands without the polar tail and the reduced association rate is believed to be dependent on 
local concentration modulation. Ligands with larger CHI AIM7.4 values will be located around 
the membrane, causing a higher concentration around the receptor, which will result in a faster 
association rate.  
The dissociation rates of the ligands are similar throughout the antagonists tested, including the 
parent ligand. This result could be because the fluorescent ligand has the same binding 
interaction to the receptor and that the fluorescent group is not interacting with the binding site 
or interfering with binding. If this is the case, it could be expected that the dissociation rates 
would be faster than for the parent ligand, due to weaker interactions.  Comparison of the novel 
fluorescent ligand association and dissociation rates to known and therapeutically used M3 
antagonists, the fluorescent ligands dissociate much slower than atropine (0.27 miní1), N-
methyl scopolamine (0.017 miní1) and ipratropium (0.07 miní1).166  Tiotropium is a long-
duration, slow-dissociation muscarinic M3 antagonist
167 with a k4 value of 0.0015 min
í1, which 
is very similar to the fluorescent ligands shown in figure 3.21.166 The association rates of the 
fluorescent ligands in figure 3.15 are slower than those of atropine (1.5 × 10í9 Mí1miní1), 
tiotropium (1.58 × 10í8 Mí1miní1) and the parent ligand.  
3.7 Conclusions 
A range of novel fluorescent M3 antagonists have been successfully synthesised utilising the 
alkyne-azide copper (I) cycloaddition “click” reaction. 19 fluorescent were assessed with a 
single point concentration inhibition study. From this result four fluorescent ligands were 
deemed to be of interest after an initial screening process and these ligands were studied 
pharmacologically.   
From the initial screen, there was a wide variety of inhibition from the fluorescent ligands. It 
was apparent that the longer wavelength fluorophores did not result in high affinity ligands. 
  ? ? ?
Small chained linkers were not favoured, both one carbon and two carbon linkers gave poor 
inhibition responses, the best one carbon chain fluorescent ligand gave 20% inhibition while 
the best two carbon chain linker gave 60%.  The amide linker was not favoured with an 
average inhibition of 40% and four carbon linkers were reasonable with an average of 50% 
inhibiton. The most favoured linkers to use were the non branched three carbon linker and the 
para-phenyl linkers with over 90% inhibition in four of the ligands, two with each linker.  
Four ligands had IC50 values and binding affinities calculated giving a range of log Kb values 
from -7.97 ±0.16 to -8.89 ± 0.11 calculated by the functional calcium assay.   
During this investigation, three ligands based on the highest affinity ligand (114a, log Kb -8.89) 
were synthesised to include either a polar side chain or a sulfonic acid group on the 
fluorohpore for investigation into lipophilicity. The binding affinity values decreased by at 
least 10-fold to give a range of log Kb values from -7.04 ± 0.14 to -7.36 ± 0.12. 
The physicochemical properties of all the ligands synthesised were assessed by log D and CHI 
AIM HPLC analysis.  Attachement of the fluorophore to the pharmacophore had the same effect 
that was shown in chatper 2. An increase in both CHI AIM values and log D values were 
significant. A change from 46.92 to 60.11 in CHI AIM for the most potent fluorescent ligand 
and its alkyne functionalised pharmacophore. A change in log D from 1.67 to 3.59 was also 
observed and all fluorescet ligands followed this trend with similar values. The insertion of a 
sulfonate group to the fluorophore (ligand 129) or a polar side chain in the fluorophore linker 
(ligands 128a and 128b) did reduce the CHI AIM values back to the original pharmacophore 
profile (46.92) with values of 44.04 for 129, and 47.09 and 46.76 for the polar side chain 
fluorophores. Thus showing it is possible to have a fluorescent ligand with the similar 
physicochemical properties of the parent ligand.  
The seven ligands with binding affinity values and physicochemical properties profiled were 
imaged confocally. The confocal images showed membrane specific binding that could be 
inhibited by pre-incubation with atropine.  
The association and dissociation rates of the ligands were investigated. It was shown that the 
fluorescent ligands had a slower association rate in comparison to the parent ligand. Within the 
  ? ? ?
fluorescent ligands, the polar-tailed ligands had a lower association rate, which is believed to 
be due to modulation of the local concentration due to lipophilicity of the ligands. The 
dissociation rates of the ligands were comparable to that of the parent ligand and tiotropium, 
which is a long-duration, slow-dissociation muscarinic M3 antagonist. With dissocation rate of 
the fluorescent ligands similar to that of the parent ligand, this shows that the fluorescent 
ligand has similar binding interactions of that parent pharmacophore and the properties of the 
fluorescent molecules are comparable to that of congener. 
This chapter has shown that it is possible to synthesise fluorescent ligands that have properties 
highly comparable to those of the parent ligand without a major effect on the binding and 
receptor interaction. 
3.7.1 Future Work 
With several fluorescent antagonists for the M3 receptor being synthesised and highly 
characterised, future work could consist of developing fluorescent-based assays using the 
ligands. Assays that could be developed would include fluorescent polarisation, fluorescent 
competition binding assays and kinetic assays using fluorescent ligands instead of radioligands.  
Other future work could consist of developing ligands for another GPCR receptor type. 
Utilising the results from the two chapters to build ligands and use them in protocols that could 
eventually be used in a medium-throughput environment.  
Since this research has been carried out, a crystal structure of the muscarinic M3 receptor from 
rattus norvegicus. has been published.159 This receptor has the known antagonist tiotropium 
bound and gives insight into the binding position of this ligand, and could result in a better 
fluorescent ligand to be synthesised. Comparisons could be made with between the bound 
ligand and the fluorescent ligands evaluated in this chapter. 
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This pocket could allow the fluorescent moiety and linker to sit out of the active site and 
improve binding interaction of the fluorescent ligand. Future work could include molecular 
modeling to assess this hypothesis of the binding interactions of the fluorescent ligand. Further 
synthesis of a new fluorescent ligand, such as ligand 130, would give experimental data to 
whether a different orientation of the fluorophore and linker is favoured. 
 
Figure 3.28. Structure of a possible fluorescent ligand with an alternative fluorophore orientation. 
 
  
  ? ? ?
4. Conclusion and Future work 
This chapter is not intended to replace the individual conclusions within each chapter, but to 
complement them by pulling findings together from each chapter. It will also set out plans for 
future work. 
4.1. Click Chemistry 
Fluorescently tagging a biologically active molecule through alkyne-azide copper (I) 
cycloaddition click reaction was successful at both receptor types. It is widely accepted that 
click reactions require the reaction to have certain properties: give very high yields, isolation 
by non-chromatographic methods and use a solvent that is easily removed for example.88 
Clearly these properties are not shown in this work but in the context of this thesis, properties 
of this reaction were exploited to yield a final step reaction that was quick, reproducible and 
direct. The alkyne-azide copper (I) cycloaddition has yielded a range of fluorescent ligands 
with fluorophores that can be connected to other alkyne or azide functionalised molecules 
which do not need protecting groups being removed or added for tethering.  
4.2 Linker Length 
 At both receptor types linker length before and after the triazole had a large impact on the 
binding affinities of the ligand, primarily due to steric interactions. At both receptor types a 
short linker between the pharmacophore and triazole were not tolerated and longer linkers 
between the fluorophore and triazole not well tolerated either. Combining both gives a narrow 
region for incorporating the triazole in between the fluorophore and pharmacophore. A range 
of 11 to 13 atoms between the pharmacophore and fluorophore has given the best ligands with 
the triazole situation in the middle containing atoms 5-7 for both receptor types.  
4.3 Fluorophore Selection 
 A range of fluorophores (46, 48, 61, 65, 85, 119, 124 and 127) were synthesised and coupled 
to the pharmacophores. These fluorophores had different influences on each ligand on a whole 
with a range of effect on receptor interaction and physicochemical properties. With the beta-
adrenoceptors the shorter wavelength fluorophores (46, 48, 61 and 65) gave ligands with good 
  ? ? ?
affinity but when examined under confocal microscopy intracellular accumulation was 
detected. Beta-adrenoceptors with the longer wavelength fluorophore (85) resulted in reduced 
affinity and no intracellular accumulation when examined with confocal microscopy. On the 
other hand the M3 ligands with the shorter wavelength fluorophores were well tolerated in 
confocal microscopy with no internalisation and producing the greater binding affinities while 
the red shifted dye had poor interaction with the receptor with no investigation with confocal 
microscopy. 
The fluorophore clearly has an effect on the physicochemical properties of the ligand and 
selection of a fluorophore is extremely important when designing a fluorescent ligand. Using 
software that predicts ClogP values could be beneficial when designing a fluorescent ligand to 
reduce the lipophilic nature of the ligand. The benefit of azide or alkyne functionalised 
fluorophores, incorporating them onto a drug is a simple one step reaction while other 
fluorophores use amide bonds for tethering, protecting groups would be needed if coupling the 
polar tailed fluorophores.  
4.4 Future Work 
Firstly future work would include the development of the beta-adrenoceptor fluorescent 
ligands with the coupling of pharmacophore 56c with the polar tailed fluorophores 124 and 127 
and the sulfonic acid fluorophore 119 to investigate whether this would stop intracellular 
accumulation.  An improved synthetic scheme for the red shifted fluorophore 85 would be 
addresses as this synthesis was capricious. Some steps would be poor yielding or would not 
yield product. Once this is addressed physicochemical analysis could be carried out and help 
determine how the red shifed dye 85 does not become internalised unlike all the other beta 
adrenoceptor ligands. 
Assay development using the M3 fluorescent ligands synthesised in chapter 3 as they have 
shown great potential to be used in a range of assays that could include competition binding 
assays and FP assays. Utilising these ligands in a routine drug discovery programme would 
highlight the benefits to fluorescent ligands in replacement of radioligands. 
  ? ? ?
Finally developing the technique used through this work to develop a range of fluorescent 
ligands at another GPCR to validate the method and to provide a basic protocol for 
synthesising fluorescent ligands for GPCRs on a whole. Such protocols could give a basic 
linker length and fluorophore as a starting point for fluorescent ligand synthesis with only 
small modifications need to get a usable fluorescent ligand.  
  
  ? ? ?
5. Experimental 
All chemicals and solvents were obtained from commercial suppliers and used without further 
purification. Thin-layer chromatography (TLC) was done using precoated aluminium backed 
plates (Silica gel 60F 254 plates) purchased from Merck. Flash Chromatography was 
performed using E. Merck Kieselgel silica gel 60 (230-440 mesh, 0.040-0.063 mm). TLC plate 
visualisations were examined under UV light (256 & 366 nm). General staining carried out 
with ninhydrin and potassium permanganate. All organic extracts after aqueous work-up 
procedures were dried with Na2SO4 before gravity filtering and evaporation to dryness. 
Organic solvents were evaporated under reduced pressure at  40°C (water bath temperature). 
Melting point was recorded on a Reichert 7905 apparatus. Mass spectra (TOF ES +/-) were 
recorded on a waters 2795 separation module/micromass LCT platform. Avatar 360 Nicolet 
FT-IR spectrometer was used to record FT-IR spectra on KBr discs and NaCl plates in the 
range of 4000-500 cm-1. 1H-NMR spectra were recorded on a Bruker-AV 400 at 400.13 MHz 
and 13C-NMR was recorded at 101.62 MHz. Chemical shifts (į) were obtained in ppm with 
reference to the chemical shift of the deuterated solvent. Coupling constants (J) are recorded in 
Hz and the significant multiplicities described by singlet (s), doublet (d), triplet (t), quartet (q), 
multiplet (m), doublet of doublets (dd), and broad (br). Unless otherwise stated all spectra were 
recorded in CDCl3.  
Analytical HPLC was performed using system 1 and system 2 to confirm purity. All retention 
times (Rt) are quoted inminutes.  
System 1: YMC reverse phase C8 column (150 x 4.6mm), a flow rate of 1.00 mL/min and UV 
detection at 254 and 366 nm. Linear gradient 5% - 95% solvent B over 16 min. Solvent A: 
0.06% TFA in water; solvent B: 0.06% TFA in MeCN. 
System 2: Kromasil reverse phase C18 column (250 x 4.6 mm), a flow rate of 1.00 mL/min 
and UV detection at 254 and 366 nm. Linear gradient 5% - 95% solvent B over 16 min. 
Solvent A: 0.06% TFA in water; solvent B: 0.06% TFA in MeCN. 
System 3: YMC reverse phase C8 column (150 x 4.6mm), a flow rate of 1.00 mL/min and UV 
detection at 254 nm and 366 nm. Samples were run in isocratic 40% solvent A - 60% solvent B 
over 16 min. Solvent A: 0.06% TFA in water; solvent B: 0.06% TFA in MeCN. 
  ? ? ?
System 4: YMC reverse phase C8 column (150 x 4.6mm), a flow rate of 1.00 mL/min and UV 
detection at 254 nm and 366 nm. Samples were run Linear gradient 20% - 95% solvent B over 
25 min. Solvent A: 0.06% TFA in water; solvent B: 0.06% TFA in MeCN. 
 
Preparative HPLC was performed using system 5 and 6. All retention times (Rt) are quoted in 
minutes.  
System 5: Luma reverse phase C8 column (150 x 30 mm), a flow rate of 20.00 mL/min and 
UV detection at 254 nm and 366 nm. Samples were run in 5% - 95% solvent B over 16 min. 
Solvent A: 0.06% TFA in water; solvent B: 0.06% TFA in MeCN. 
System 6: YMC reverse phase C8 column (150 x 10 mm), a flow rate of 3.00 mL/min and UV 
detection at 254 nm and 366 nm. Samples were ran in 40% solvent A 60% solvent B isocratic 
over 20 min. Solvent A: 0.06% TFA in water; solvent B: 0.06% TFA in MeCN. 
 
CHI IAM 7.4 HPLC method: Regis IAM PC 12 Pm column (100 x 4.6mm), a flow rate of 1.00 
mL/min and UV detection at 230 and 366nm. Linear gradient 0 % - 100% solvent A over 7 
min. Solvent A: 100% MeCN. Solvent B: Water with 50 mM ammonium acetate. 
 
Log D 7.4 HPLC method: Polaris C18 5 Pm HPLC column (50 x 4.6mm). A flow rate of 1.00 
mL/min and UV detection at 230 and 366nm. Linear gradient 0 % - 95% solvent A over 4 min. 
Solvent A: 100% MeCN. Solvent B: Water with 50 mM ammonium acetate. 
 
General procedure 1, alkyne-azide copper (I) catalysed cycloaddition  
Azide functionalised compound (1 equiv) and alkyne functionalised compound (1eq) were 
dissolved in DMF (2 mL). Sodium ascorbate (0.1 eq) dissolved in water (1 mL) and copper 
sulfate pentahydrate (0.05 eq) dissolved in water (1 mL) was added to the DMF. The resulting 
mixture was microwaved for 80 minutes at 80 °C and 40 watts. When the reaction was 
complete, the solvents were evaporated under vacuum and the residue was dissolved in DCM. 
This was washed with water, filtered, dried and concentrated. The product was purified using 
reverse phase HPLC using either system 3 or 4. 
  ? ? ?
General procedure 2, alkylation of (3R)-1-azabicyclo[2.2.2]oct-3-yl 
hydroxy(diphenyl)acetate 
(3R)-1-azabicyclo[2.2.2]oct-3-yl hydroxy(diphenyl)acetate was dissolved in 
acetonitrile:chloroform (4:6). Linkers were added in 10 equivalents and refluxed overnight. 
When the reaction was complete the solvents were evaporated. The residue was suspended in 
ether (20 mL) and extracted with water (3 × 10 mL). The aqueous layer was evaporated to 
yield the alkyne-linked pharmacophores. 
  ? ? ?
Synthesis of 1-(2,3-epoxypropoxy)- naphthalene
64
 27a 
 
Sodium hydride (60% dispersion in mineral oil) (308 mg 12.7 mmol) was suspended in 
anhydrous DMF (7 mL) and stirred under an environment of nitrogen for five minutes. A 
solution of 1-naphthol  (1.0 g, 6.9 mmol) and anhydrous DMF (7mL) was added to the sodium 
hydride drop wise in an ice bath and stirred for 20minutes. Epichlorohydrin 26 (1.8 mL, 23.3 
mmol) was added dropwise into the solution and was stirred overnight at ambient temperature.  
The solution was quenched cautiously with methanol and partitioned between a large excess of 
water (60 mL) and was extracted with diethyl ether (3 × 30 mL). The organic layer was washed 
with 2M sodium hydroxide, dried and concentrated. 
 A silica plug was performed with ethyl acetate: petroleum ether (1:9) for purification to yield 
the product as a clear oil (760 mg, 83%). 
 
1H NMR: į 2.86 (1H, dd, J 2.5, 5.0, epoxide CH2), 2.97 (1H dd, J 4.0, 4.5, epoxide CH2), 3.50 
(1H, m, Epoxide CH), 4.16 (1H, dd, J 5.5, 11.0, OCH2), 4.40 (1H, dd, J 3.0, 11.0, OCH2), 6.82 
(1H, d, J 7.5, ArH), į 7.36 (1H, t, J 7.5, ArH), į 7.44-7.52 (3H, m, ArH), į 7.8 (1H, m, ArH), į 
8.31 (1H, m, ArH). 
13C NMR: 44.78 (Epoxide CH2), 50.30 (Epoxide CH), 69.05 (ArOCH2), 105.11 (naphthyl C), 
120.93 (naphthyl C), 122.10 (naphthyl C), 125.39 (naphthyl C), 125.39 (naphthyl C), 125.58 
(naphthyl C) 126.57 (naphthyl C), 127.52 (naphthyl C), 134.61 (naphthyl C), 154.58 (naphthyl 
C). 
FT-IR: (NaCl) 3053 (Epoxide CH), 2925, 2871, 1594, 1509 (aryl str), 1240 (epoxide C-O, str) 
1099 (C-O-C). 
 
 
 
  ? ? ?
Synthesis of 2-((4-(2-methoxyethyl)phenoxy)methyl)oxirane
175
 27b 
 
Sodium hydride (60% dispersion in mineral oil) (693 mg, 28.7 mmol) in anhydrous DMF (25 
mL) was stirred under nitrogen for five minutes. To this solution 4-(2-methoxyethyl)phenol 
(3.5 g, 21 mmol) in anhydrous DMF (20 mL) was added. This was left to stir in an ice bath for 
20minutes. Epichlorohydrin 26, (18 mL, 233.1 mmol) was added dropwise and the solution 
was left to stir overnight at ambient temperature.  The solution was the quenched with 
methanol. Water (50 mL) and diethyl ether (50 mL) was added to and the organic layer was 
separated and extracted three times with diethyl ether (50 mL). The organic layer was washed 
with 2M sodium hydroxide, dried and concentrated. The product was then washed through a 
silica plug in DCM:MeOH (9:1) yielding a yellow oil  (2.81 g, 64%). 
 
1H NMR: į 2.74 (1H, dd, J 2.5, 5.0, Epoxide CH2), 2.82 (2H, t, J 7.0, OCH2CH2), 2.89 ( 1H, 
dd, J 4.5, 5.0, Epoxide CH2), 3.31 ( 3H, s, OCH3), 3.34 ( 1H, m, epoxide CH), 3.63 (2H, t, J 
7.0, OCH2), 3.94 ( 1H, dd, J 5.5, 10.5,  OCH2), 4.21 (1H, dd, J 3.0, 10.5, OCH2) 6.85 (2H, d, J 
8.5, ArH), 7.13 ( 2H, d, J 9.01, ArH). 
13C NMR: į 35.33 (CH2CH2O), 44.71 (Epoxide CH2), 50.24 (OCH), 58.74 (OCH3), 68.80 
(OCH2CH), 73.86 (CH2OCH3), 114.62 (ArCH), 129.82 (ArCH), 131.70 (ArC), 157.03 (ArCO). 
FT-IR: (NaCl) (Epoxide CH), 2597, 1722, 1512 (aryl str), 1242 (epoxide C-O, str) 1112 (C-O-
C). 
Synthesis of 2-azidoethanamine 29 
176
  
 
2-Bromoethylamine hydrobromide 28, (2.5 g,12.3 mmol) and sodium azide (2.38 g, 36.6 
mmol) were dissolved in water (10 mL), the reaction mixture was stirred at reflux for 21 hours. 
  ? ? ?
The solution was cooled to 0 °C and diethyl ether (10 mL) and potassium hydroxide (4 g, 71.1 
mmol) was added. The organic phase was separated with diethyl ether (3 × 20 mL), dried and 
concentrated to yield a clear oil (0.97 g, 94%). The product was used without further 
purification. 
 
1H NMR: į 1.38 (2H, s, Br, NH2), 2.82, (2H, t, J 5.5, CH2N3), 3.36 (2H, t, J 5.5, CH3NH2). 
13C NMR: į 41.41 (CH2NH2), 54.73 (CH2N3). 
FT-IR: (NaCl) 3476 (br NH stretch), 2077 (N3) 1599, 1446 1282. 
Synthesis of 1-(2-azidoethylamino)-3-(naphthalen-5-yloxy)propan-2-ol 30a  
 
1-(2,3-Epoxypropoxy)- naphthalene 27a (200 mg, 1 mmol) and 2-azidoethanamine 29 (516 mg, 
6 mmol) were dissolved in isopropanol (10 mL) and refluxed for 12 hours at 60 °C. The 
reaction mixture was cooled to room temperature and concentrated.  The residue was purified 
by column chromatography with MeOH: DCM (5:95) to yield a yellow solid (92 mg, 32%). 
 
1H NMR: į 2.28 (1H, Br S, NH), 2.88-3.0 (4H, m, CH2NHCH2CH2N3), 3.45 (2H, t, J 5.5 
CH2NHCH2), 4.19 (3H, m, OCH2CHOH), 6.84 (1H, d, J 7.5, ArH), 7.36 (1H, t, J 7.5, ArH), 
7.44-7.52 (3H, m, ArH), 7.80 (1H, m, ArH), 8.30 (1H, m, ArH). 
13C: NMR į 48.68 (CH2N3), 51.44 (CH2NH), 51.79 (NHCH2), 68.6 (CHOH), 70.51 (OCH2), 
104.99 (Naphthyl C2), 120.75 (naphthyl C), 121.75 (naphthyl C), 125.31 (naphthyl C) 125.54 
(naphthyl C), 125.82 (naphthyl C), 126.47 (naphthyl C), 127.57 (naphthyl C), 134.53 (naphthyl 
C), 154.25 (naphthyl C). 
Mpt: 135-136 qC. 
FT-IR: (KBr) 3067(NH str), 2926 (OCH2 sym str), 2127 (N3), 1580, 1397. 
  ? ? ?
ES-MS MH+ calc. For C15H19N402 287.1503 found 287.0657. 
Synthesis of 1-(2-azidoethylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol 30b 
 
2-Azidoethanamine (992 mg, 11.52 mmol) 29 and 2-((4-(2-methoxyethyl) phenoxy ) methyl) 
oxirane 27b (400 mg, 1.92 mmol) were dissolved in isopropanol (20 mL). This reaction 
mixture was refluxed overnight. When reaction was complete, the product was concentrated 
and purified by column chromatography eluted with MeOH:DCM (1:9) to yield a clear oil (233 
mg, 41%). 
 
1H NMR: į 2.80 (6H, m, CH2N3, CH2CH2O, CHOHCH2), 3.30 (3H, s, OCH3), 4.05 (1H, m, 
CHOH), 3.56 (2H, t, J 7.0, OCH2), 3.42 (2H, t, J 5.8, NHCH2), 3.94 ( 2H, d, J 5.16, 
OCH2CHOH), 6.84 (2H, d, J 8.6, ArH), 7.13 ( 2H, d, J 8.7, ArH). 
13C NMR: į 35.22 (CH2CH2O), 48.5 (CH2N3), 51.2 (CHOHCH2), 51.6 (NHCH2), 58.7 (OCH3), 
68.7 (CHOH), 70.5 (OCH2CHOH), 73.8 (CH2CH2O), 114.6 (ArC), 129.8 (ArH), 131.4 (ArCq), 
157.1 (ArCq). 
Mpt: 138-140 qC. 
ES-MS MH+ calc. For C14H23N403 295.1765 found 295.0803. 
FT-IR: (KBr) 3031 (NH str), 2934 (O-CH2 str), 2100 (N3), 1612, 1515, 1245. 
 
 
 
  ? ? ?
Synthesis of 1-(naphthalen-8-yloxy)-3-(prop-2-ynylamino)propan-2-ol 32a 
 
 
1-(2,3-Epoxypropoxy)- naphthalene 27a (400 mg, 2 mmol) and propargylamine 31 (0.68 mL, 
12 mmol) were dissolved in isopropanol (20 mL) and refluxed overnight. The reaction mixture 
was cooled to room temperature and concentrated.  The residue was purified by column 
chromatography with NH4OH:MeOH: DCM (1:9:90) to yield a yellow solid (391 mg, 77%). 
 
1H NMR: į 2.25 (1H, t, J 2.4, CCH), 2.97 (1H, dd, J 7.30, 5.0, COH2CH2NH), 3.11 (1H, dd, J 
3.6, 8.5, COH2CH2NH), 3.51 (2H, d, 2.3, NHCH2), 4.22 (3H, m, CH2CHOH), 6.83 (1H, d, J 
7.5, ArH), 7.36 (1H, t, J 7.5, ArH), 7.44-7.51 (3H, m, ArH), 7.80(1H, m, ArH), 8.24 (1H, m, 
ArH). 
13C NMR: į 38.27 (CH2CCH), 51.03 (CH2NH), 68.60 (CHOH), 70.60 (OCH2), 71.8 (CCH), 
81.77(CCH) 105.11 (naphthyl C), į 120.93 (naphthyl C), į 122.10 (naphthyl C), į 125.39 
(naphthyl C), į 125.39 (naphthyl C), 125.58 (naphthyl C), į 126.57 (naphthyl C), į 127.52 
(naphthyl C), į 134.61 (naphthyl C), į 154.58 (naphthyl C). 
Mpt: 134-135 qC. 
FT-IR: (KBr) 3301 (OH str), 3050 (NH str), 1593, 1508, 1269. 
ES-MS MH+ calc. For C16H18N02 256.1332 found 256.0943. 
  
  ? ? ?
Synthesis of 1-(4-(2-methoxyethyl)phenoxy)-3-(prop-2-ynylamino)propan-2-ol 32b 
 
Propargylamine 31 (476 mg, 5.76 mmol) and 2-((4-(2-methoxyethyl)phenoxy)methyl)oxirane 
27b (200 mg, 0.96 mmol) were dissolved in isopropanol (10 mL). This reaction mixture was 
refluxed overnight. When reaction was complete, the product was concentrated and purified by 
flash column chromatography eluted with  MeOH: DCM (5:95) to yield a yellow solid (86 mg, 
39%). 
 
1H NMR: į 2.23 (1H, t, J 2.40 CH), 2.83 (3H, m, CH2CH2O and CH2NH), 2.97 (1H, dd, J 3.8, 
8.2, CH2NH), 3.34 (3H, s, OCH3), 3.48 (2H, d, J 2.4, CH2CCH)3.56 (2H, t, J 7.08, CH2CH2O), 
3.98 (2H, m, OCH2CHOH), 4.06 (1H, m, CHOH), 6.84, (2H, d, J 8.8, ArH), 7.13 ( 2H, d, J 
8.50, ArH). 
13C NMR: į 35.43 (CH2CH2O), 38.38 (CH2CCH), 50.87 (CHOHCH2), 58.79 (OCH3), 68.74 
(CHOH), 70.59 (OCH2CHOH), 71.81 (CCH), 73.97 (CH2CH2O), 81.97 (CH2CCH), 114.68 
(ArC), 129.95 (ArH), į131.71 (ArCq), 157.26 (ArCq). 
Mpt:137-140q C. 
FT-IR: (KBr) 3278 (OH str), 3031 (NH str), 1612, 1515, 1245. 
ES-MS MH+ calc. For C14H19NO3 264.3395 found 264.1117. 
  
  ? ? ?
Synthesis of 4-azidobutyric acid ethyl ester 38 
177
  
 
4-Bromobutyric acid ethyl ester 37 (2.21 mL, 15.4 mmol) was dissolved in acetone/water (22.5 
mL/ 7.5 mL). Sodium azide (2.0 g, 30.8 mmol) was added to the reaction mixture which was 
refluxed for seven hours. The acetone was removed and the water was partitioned with DCM 
(10 mL). The organic layer was removed and the aqueous layer was washed with DCM (3 x 10 
mL). The product was dried and concentrated to yield a yellow oil (2.05 g, 85%). The product 
was used without further purification. 
 
1H NMR: į 1.26 (3H, t, J 7.1, CH3), 1.88-1.96 (2H, m, N3CH2CH2), 2.40 (2H,t, J 7.0, COCH2), 
3.35 (2H, t, J 7.1, CH2N3), 4.15( 2H, q, J 7.0, 7.4, CH3CH2O). 
13C NMR: į 14.20 (CH3), 24.27 (CH2CH2CH2), 31.19 (COCH2), 50.66 (CH2N3), 60.56 
(CH2CH3), 172.50 (C=O). 
FT-IR: (NaCl) 3546 ( CO stretch), 2980 ( O-CH2 str), 2098 (N3), 1731, 1447. 
Synthesis of 4-azidobutyric acid 39 
177
  
 
4-Azidobutyric acid ethyl ester 38 (11.2 g, 73.0 mmol) was dissolved in MeOH/water (174/ 
141 mL). Potassium hydroxide (20.44 g, 365 mmol) was added to the reaction mixture while in 
an ice bath. The reaction mixture was stirred overnight at room temperature. The solvent was 
evaporated and the residue was partioned between DCM and water. The aqueous layer was 
extracted and acidified to pH 1 with 1M HCl. The product was then extracted several times in 
diethyl ether, dried and concentrated to afford the product as a yellow oil. (7.55 g, 80%). 
 
  ? ? ?
1H NMR: į 1.89-1.96 (2H, m, CH2CH2N3), 2.48 (2H, t, J 7.2, CH2CO), 3.38 (2H, t, J 6.7, 
CH2N3), 8.86 (1H, s, OH). 
13C NMR: į 178.67 (CO), 50.59 (CH2N3), 30.95 (COCH2), 23.96 (CH2CH2CH2). 
FT-IR: (NaCl) 2939 (COOH), 2100 (N3), 1710 (C=O stretch), 1413.  
Synthesis of 4-(3-bromopropoxy) Benzaldehyde 44 
178 
 
A solution of bromopropanol (1.32 mL, 14.4 mmol), 4-hydroxybenzaldehyde 43 (1.46 mg, 12 
mmol), triphenyphosphine (3.76 g, 14.4 mmol) and THF (60 mL) were stirred for fiveminutes, 
to which DIAD (2.84 mL in 15 mL DCM) was added drop wise to the solution over an ice bath. 
The solution was stirred overnight at room temperature. The reaction mixture was concentrated 
to residue and dissolved in diethyl ether (60 mL) and the mixture was sonicated. Petroleum 
ether (30 mL) was added and sonicated further. The precipitate was filtered and the filtrate was 
washed with sodium hydroxide (2M), and brine. The organic layer was dried and concentrated. 
 The residue was purified by column chromatography eluted with ethyl acetate: petroleum 
ether (10:90) to yield a pale yellow oil (1.79 mg, 62%). 
 
1H NMR: į 2.32- 2.38 (2H, m, CH2CH2CH2), 3.60 (2H, t, J 6.5, CH2Br), 4.19 (2H, t, J 5.8, 
OCH2), 7.01 (2H, d, J 9.0 ArH), 7.83 (2H, d, J 8.5, ArH), 9.88 (1H, s, OH).  
13C NMR: į 28.71 (BrCH2), į 48.15 (OCH2CH2), 65.01 (OCH2), 114.86 (ArCH), 132.11 
(ArCH), 63.79 (ArCO), 190.88 (COOH). 
FT-IR: (NaCl) 2936, 2827 (C=O str), 2739, 1691, 1577, 1508. 
  ? ? ?
Synthesis of 4-(3-azidopropoxy) Benzaldehyde 45 
98 
 
 A solution of 4-(3-bromopropoxy)benzaldehyde 44 (410 mg, 1.7 mmol) and sodium azide 
(276 mg, 4.25 mmol) in DMF (6 mL) was refluxed over night at 100 °C. The reaction mixture 
was cooled and added to a large excess of water. The product was extracted several times into 
chloroform, dried and concentrated to yield the azido-benzaldehyde as a dark yellow oil. (150 
mg, 44%). This product was used without further purification. 
 
1H NMR: į 2.08 (2H,m, CH2CH2CH2), 3.52 (2H, t, J 6.5, CH2N3), 4.13 (2H, t, J 6.0 OCH2), 
6.98 (2H, d, J 9.0 ArH), 7.83 (2H, d, J 8.5, ArH), 9.88 (1H, s, OH). 
13C NMR į 28.73 (CH2CH2N3), 48.17 (CH2N3), 65.02 (OCH2), 114.88 (ArC), 130.27 (ArC), 
132.13 (ArC), 163.79 (ArCO), 190.89 (C=O). 
FT-IR: (NaCl) 3492, 2929 (C=O str), 2098 (N3), 1678, 1600, 1505, 1256. 
 
 
Synthesis of 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene 46  
 
 2,4-Dimethylpyrrole (0.2 mL, 1.47 mmol) and 4-(3-azidopropoxy)benzaldehyde 45 (150 mg, 
0.73 mmol) were dissolved in anhydrous DCM (200 mL) and was stirred under an atmosphere 
of nitrogen. TFA (one drop) was added and the reaction mixture was stirred for 4 hours. DDQ 
  ? ? ?
(180 mg, 0.73 mmol) was added and the reaction mixture was stirred further for 30 minutes. 
Triethylamine (1 mL, 0.73 mmol) and boron trifluoride diethyl etherate, (1 mL, 0.94 mmol) 
were added to the reaction mixture and it was stirred overnight. 
The reaction mixture was then washed with water (3 × 100 mL), dried and concentrated. The 
residue was purified by column chromatography eluted in chloroform to yield a red solid (51 
mg, 17% yield). 
 
1H NMR: į 1.42 (6H, s, CH3), 2.09-2.12 (2H, m, CH2CH2CH2N3), 2.53 (6H, s, CH3), 3.55 (2H, 
t, J 6.5, CH2CH2CH2N3), 4.09 (2H, t, J 6.0, CH2CH2CH2N3), 5.96 (2H, s, CH), 7.00 (2H, d, J 
8.5, ArH), 7.15 (2H, d, J 8.45, ArH). 
13C NMR: į 14.72 (CH3), 28.94 (CH2CH2N3), 48.36 (CH2N3), 64.79 (OCH2), 115.21 (phenyl 
CH), 121.27 (pyrrole CH), 127.51 (Phenyl C), 129.44 (NCCCH3), 131.98 (Phenyl CH), 141.88 
(CH3CC), 143.28 (PhenylC-C), 155.46 (NCCH3), 159.40 (Phenyl CO). 
FT-IR: 3431 (br, pyrrole ring), 2933, 2737, 2676, 2092 (N3), 1607(conjugated C=N).  
Mpt: 141-143 qC. 
 
 
Synthesis of 4,4-difluoro-8-(1-acetylene)phenyl-2,6-dimethyl-4-bora-3a,4a-diaza-s-
indacene 48 
134
  
 
2,4-Dimethylpyrrole (182mg, 0.2mL, 1.47mmol) and 4-ethynylbenzaldehyde 47 (100 mg, 0.74 
mmol) were dissolved in anhydrous DCM (200 mL) under a nitrogen environment. TFA (one 
drop) was added and the reaction mixture was stirred for four hours. DDQ (180 mg, 0.74 
  ? ? ?
mmol) was added in DCM (15 mL) and was stirred for 30minutes. Triethylamine (1 mL, 0.73 
mmol) and Boron trifluoride diethyl etherate (1 mL, 0.94 mmol) were added and the reaction 
mixture was left to stir overnight.  
The reaction mixture was washed several times with water, dried and concentrated. The residue 
was purified by column chromatography eluted in ethyl acetate: petroleum ether (2:8) to yield 
a pink solid (72 mg, 28%). 
 
1H NMR: į 1.39 (6H, s, CH3), į 2.55 (6H, s, CH3), į 3.17 (1H, s, CCH), į 5.98 (2H, s, 
CCH3CH), į 7.26 (2H, d, J 7.7, ArH), į 7.62 (2H, d, J 8.3, ArH).  
13C: NMR į 14.71 (CH3), 76.69 (CCH alkyene), 83.02 (CCH), 121.54 (Pyrrole CH), 123.10 
(Phenyl C-C), 128.37 (phenyl CH), 133.01 (Phenyl CH), 135.74 (Pyrrole C-CH3), 140.70 
(NCCCH3), 143.12 (Phenyl C-C), 155.99 (NCCH3). 
Mpt: 251-253 qC. 
FT-IR: (KBr) 3444 (br, pyrrole ring), 2912, 2747, 2676, 1607(conjugated C=N). 
 
 
Synthesis of 1-(((4,4-difluoro-8-(4-propoxy)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)methyl)amino)-3-(naphthalen-1-yloxy)propan-2-ol 51a  
 
  ? ? ?
Using general procedure 1 starting with 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-
dimethyl-4-bora-3a,4adiaza-s-indacene 46 and 1-(naphthalen-8-yloxy)-3-(prop-2-
ynylamino)propan-2-ol 32a yielded a red solid (1.2mg, 46%). 
 
HPLC Rt: 8.73 (System 3). 
ES-MS MH+ calc. For C38H42BF2N603 679.3374 found 679.1365. 
Synthesis of 1-((2-(4,4-difluoro-8-(4-propoxy)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-1-yl)ethyl)amino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol 
51b 
 
Using general procedure 1 starting with 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-
dimethyl-4-bora-3a,4adiaza-s-indacene  46 and 1-(naphthalen-8-yloxy)-3-(prop-2-
ynylamino)propan-2-ol 32b yielded a red solid (1.8 mg, 70%). 
 
HPLC Rt: 5.80 (System 3). 
ES-MS MH+ calc. For C38H42BF2N603 687.3636 found 687.1597. 
 
Synthesis of 1-((2-(4,4-difluoro-8-phenyl-2,6-dimethyl-4-bora-3a,4a-diaza-s-indacene -1H-
1,2,3-triazol-1-yl)ethyl)amino)-3-(naphthalen-1-yloxy)propan-2-ol (52a) 
  ? ? ?
 
Using general procedure 1 starting with 4,4-difluoro-8-(1-acetylene)phenyl-2,6-dimethyl-4-
bora-3a,4a-diaza-s-indacene 48 and 1-(2-azidoethylamino)-3-(naphthalen-5-yloxy)propan-2-ol 
30a yielded a red solid (1.9 mg, 24%). 
 
HPLC Rt: 9.35 (System 3). 
ES-MS MH+ calc. For C36H38BF2N602 635.3112 found 635.1654. 
 
  
  ? ? ?
Synthesis 1-((2-(4,4-difluoro-8-phenyl-2,6-dimethyl-4-bora-3a,4a-diaza-s-indacene -1H-
1,2,3-triazol-1-yl)ethyl)amino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol 52b 
 
Using general procedure 1 starting 4,4-difluoro-8-(1-acetylene)phenyl-2,6-dimethyl-4-bora-
3a,4a-diaza-s-indacene 46 and 1-(2-azidoethylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-
2-ol 30b to yield a red solid (3.4 mg, 56%). 
 
HPLC Rt: 7.65 (System 3). 
ES-MS MH+ calc. For C35H41BF2N603 643.3374 found 643.1825. 
Synthesis of but-3-yn-1-yl[2-hydroxy-3-(naphthalen-1-yloxy)propyl]amine 56a 
 
 N-(3-butynyl)-phthalimide 54a (2.5 g, 12.5 mmol) and hydrazine monohydrate (0.57 mL, 
11.87 mmol) were dissolved in isopropanol (60 mL) and heated in a sealed tube at 70 °C for 
two hours. Once reaction was complete (formation of precipitate), the reaction mixture was 
cooled to room temperature. To the mixture 1-(2,3-epoxypropoxy)- naphthalene 27a (778 mg, 
3.88 mmol) was added. The vessel was sealed and heated to 90 °C overnight. Reaction was 
then cooled to room temperature and the reaction mixture was concentrated. The residue was 
redissolved in DCM (20 mL). The organic later was washed with water (3 × 20 mL), dried and 
  ? ? ?
evaporated. The residue was purified by column chromatography eluted in MeOH:DCM (5:95) 
to yield a brown oil (26 3mg, 25%). 
 
1H NMR: į 2.06 (1H, t, J 2.68, CCH) 2.42- 2.46 (2H, m, CH2CCH) 2.82 – 2.91 (3H, m, 
CH2NHCH2), 2.95 - 2.99, (1H, m, COHCH2) 4.10-4.20 (2H, m, OCH2), 4.24 - 4.28 (1H, m, 
CHOH), 6.83 (1H, d, J 7.5, ArH), į 7.36 (1H, t, J 7.5, ArH), į 7.44-7.51 (3H, m, ArH), į 7.82 
– 7.85(1H, m, ArH), į 8.30-8.34 (1H, m, ArH). 
13C NMR: į 19.43 (NHCH2CH2), 47.77 (NHCH2), 51.87 (CH2NH), 68.30 (OCH2CHOH), 
69.95 (CCH), 70.57 (OCH2), 82.12 (CCH), 105.11 (naphthyl C), 120.93 (naphthyl C), 122.10 
(naphthyl C), 125.39 (naphthyl C), 125.39 (naphthyl C), 125.58 (naphthyl C), 126.57 (naphthyl 
C), 127.52 (naphthyl C), 134.61 (naphthyl C), 154.58 (naphthyl C). 
Mpt: 141-143°C 
FT-IR (KBr) 3301 (OH str), 3050 (NH str), 1593, 1508, 1269. 
ES-MS MH+ calc. For C17H19N02 270.1488 found 270.1250. 
Synthesis of 1-(naphthalen-1-yloxy)-3-(pent-4-ynylamino)propan-2-ol 56b 
 
N-(4-pentynyl)-phthalimide 54b (2.5 g, 11.0 mmol) and hydrazine monohydrate (0.55 mL, 
10.0 mmol) were dissolved in isopropanol (40 mL) and heated in a sealed tube at 70 °C for two 
hours. Once reaction was complete (formation of precipitate), the reaction mixture was cooled 
to room temperature. To the mixture 1-(2,3-epoxypropoxy)- naphthalene 27a (205 mg, 3.14 
mmol) was added. The vessel was sealed and heated to 90 °C overnight. Reaction was then 
cooled to room temperature and concentrated. The residue was redissolved in DCM (20 mL). 
The organic later was washed with water (3 × 20 mL), dried and evaporated. The crude was 
purified by column chromatography eluted in MeOH:DCM (1:9) to yield a brown/yellow solid 
(500 mg, 31%). 
  ? ? ?
1H NMR: į 1.95 (1H, t, J 2.6, CCH), 2.19-2.23 (2H, m, CH2CCH), 2.69-2.72 (3H, m, 
CH2NCH2), 2.86-3.1 (3H, m, CH2NCH2), 4.10-4.27 (3H, m, OCH2CHOH), 6.82 (1H, d, J 7.5, 
ArH), į 7.37 (1H, t, J 7.5, ArH), į 7.42-7.49 (3H, m, ArH), į 7.80(1H, m, ArH), į 8.24 (1H, m, 
ArH). 
13C NMR: į 18.20 (CH2CCH), 26.05 (CH2CH2CCH), 28.91 (CH2), 49.91 (NHCH2), 50.71 
(CH2NH), 68.22 (OCH2CHOH), 69.81 (CCH), 70.65 (OCH2), 84.20 (CCH), 105.11 (naphthyl 
C2), į 120.66 (naphthyl C), į 121.80 (naphthyl C), į 125.28 (naphthyl C), į 125.39 (naphthyl 
C), 125.58 (naphthyl C), į 126.57 (naphthyl C), į 127.52 (naphthyl C), į 134.61 (naphthyl C), 
į 154.58 (naphthyl C). 
Mpt: 140-142 °C. 
FT-IR: (KBr) 3319 (OH str), 3049 (NH str), 1592, 1508, 1279. 
ES-MS MH+ calc. For C18H22N02 284.1645 found 284.1364 
Synthesis of 1-(hex-5-ynylamino)-3-(naphthalen-1-yloxy)propan-2-ol 56c 
 
N-(5-hexynyl)-phthalimide 54c (1.5 g, 6.6 mmol) and hydrazine monohydrate (0.3 mL, 6.27 
mmol) were dissolved in isopropanol (60 mL) and heated in a sealed tube at 70 °C for two 
hours. Once reaction was complete (formation of precipitate), the reaction mixture was cooled 
to room temperature. To the mixture 1-(2,3-epoxypropoxy)- naphthalene 27a (1.1 g, 5.7 mmol) 
was added. The vessel was sealed and heated to 90 °C overnight. Reaction was then cooled to 
room temperature and concentrated. The residue was redissolved in DCM (20 mL). The 
organic later was washed with water (3 × 20 mL), dried and evaporated. The crude was 
purified by column chromatography eluted in MeOH:DCM (1:9) to yield a brown solid (289 
mg, 31%). 
 
  ? ? ?
1H NMR: į 1.93 (1H, t, J 2.6, 5.2, CCH), 2.19-2.23 (2H, m), 2.68-2.74 (3H, m), 2.90-2.97 (3H, 
m), 4.12-4.20 (4H, m), 6.82 (1H, d, J 7.5, ArH), į 7.33 (1H, t, J 7.5, ArH), į 7.42-7.49 (3H, m, 
ArH), į 7.78-7.80(1H, m, ArH), į 8.22-8.25 (1H, m, ArH). 
13C NMR: 18.29 (CH2CCH), 26.08 (CH2CH2CCH), 28.99 (CH2), 49.28 (NHCH2), 50.74 
(CH2NH), 52.04 (CH2), 68.28 (OCH2CHOH), 68.58 (CCH), 70.62 (OCH2), 84.20 (CCH), 
104.93 (naphthyl C2), į 120.66 (naphthyl C), į 121.80 (naphthyl C), į 125.23 (naphthyl C), į 
125.83 (naphthyl C), 126.45 (naphthyl C), į 127.55 (naphthyl C), į 143.50 (naphthyl C), į 
138.59 (naphthyl C), į 154.29 (naphthyl C). 
Mpt: 141-143 °C.  
FT-IR: (KBr) 3300 (OH str), 3050 (NH str), 1560, 1512, 1269 
ES-MS MH+ calc For C19H24NO2 298.1802 found 298.1308. 
Synthesis of 1-((2-(4,4-difluoro-8-(4-propoxy)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)ethyl)amino)-3-(naphthalen-1-yloxy)propan-2-ol 57a 
 
 
Using general procedure 1 starting with but-3-yn-1-yl[2-hydroxy-3-(naphthalen-1-
yloxy)propyl]amine 56a and 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene 46 yielded a red solid (2 mg, 52%). 
 
HPLC Rt: 12.42 (System 1), 14.55 (System 2). 
ES-MS MH+ Calc. for C39H44BF2N6O3 693.3531 found 693.3589. 
  ? ? ?
Synthesis of 1-((3-(4,4-difluoro-8-(4-propoxy)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene 
-1H-1,2,3-triazol-4-yl)propyl)amino)-3-(naphthalen-1-yloxy)propan-2-ol 57b 
 
Using general procedure 1 starting with 1-(naphthalen-1-yloxy)-3-(pent-4-ynylamino)propan-
2-ol 56b and 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene 46 yielded a red solid (2 mg, 54%).  
 
HPLC Rt: 12.42 (System 1), 14.53 (System 2). 
ES-MS MH+ Calc. for C40H46BF2N6O3 707.3687 found 707.3749. 
Synthesis of 1-((4-(4,4-difluoro-8-(4-propoxy)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)butyl)amino)-3-(naphthalen-1-yloxy)propan-2-ol 57c 
 
Using general procedure 1 starting with 1-(hex-5-ynylamino)-3-(naphthalen-1-yloxy)propan-2-
ol 56c and 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene 46 yielded a red solid (1.7 mg, 44%).  
 
  ? ? ?
HPLC Rt: 12.47 (System 1), 14.55 (System 2). 
ES-MS MH+ Calc. for C41H48BF2N6O3 721.3844 found 721.3900. 
 
Synthesis of 4-(5-bromopentyloxy)Benzaldehyde
179
 59 
 
1,5-Dibromopentane 58 (2.08 mL, 15.2 mmol) and K2CO3 (3.8 g, 27.6 mmol) was dissolved in 
DMF (50 mL). 4-Hydroxybenzaldehyde (1.69 g, 13.84 mmol) dissolved in DMF (50 mL) was 
added dropwise and stirred for 15 hours. The reaction mixture was poured into toluene and 
washed with water. The organics were extracted in toluene (3 × 25 mL), dried and 
concentrated. The residue was purified by column chromatography eluted in chloroform to 
yield a clear oil (1.7 g, 54%). 
 
1H NMR: į 1.66-1.76 (2H, m, CH2), 1.81-1.95 (4H, m, CH2’s), 3.38-3.46 (2H, m, CH2), 4.02-
4.08 (2H, m, CH2), 6.95-6.99 (2H, m, ArCH), 7.79-7.83 (2H, m, ArCH), 9.86 (1H, s, COH). 
13C NMR: į 24.74 (CH2), 28.25 (CH2), 31.86 (CH2), 33.32 (CH2), 67.98 (OCH2), 114.74 
(phenyl CH), 129.87 (Phenyl C), 131.99 (Phenyl C), 164.40 (phenyl C), 190.77 (CO). 
FT-IR: (NaCl) 2945, 2882, 2832, 1679 (C=O str), 1602, 1463 (C-O str), 1162. 
 
Synthesis of 4-(5-azidopentyloxy)benzaldehyde  60 
 
4-(5-Bromopentyloxy)benzaldehyde 59 (3 g, 11.1 mmol) and sodium azide (1.8 g, 27.75 
mmol) were refluxed in DMF (75 mL) at 100 qC for five hours. Once complete the reaction 
mixture was poured into water and extracted with ethyl acetate and evaporated to yield a clear 
oil (2.32 g, 89%).  
  ? ? ?
The product was used without further purification  
 
1H NMR: į 1.47-1.63 (4H, m, CH2CH2CH2N3), 1.74-1.88 (2H, m, CH2CH2CH2N3) 3.19-3.26 
(2H, m, CH2N3), 3.96-4.06 (2H, m, OCH2), 6.90 (2H, dd, J 2.2, 8.8 ArCH), 7.75 (2H, dd, J 2.2, 
8.8, ArCHCO), 9.79 (1H, s, COH) 
13C NMR: į 23.25 (CH2), 28.53 (CH2), 28.71 (CH2), 51.22 (CH2N3), 67.94 (OCH2), 114.60 
(phenyl CH), 129.80 (Phenyl C), 131.90 (Phenyl C), 162.44 (phenyl C), 190.77 (CO)  
FT-IR: (NaCl) 2940, 2880, 2828, 2110 (N3), 1688 (C=O str), 1600, 1468 (C-O str), 1159.  
 
Synthesis of 4,4-difluoro-8-(4-(5-azidopentyl))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene 61 
 
4-(5-Azidopentyloxy)benzaldehyde 60 (1 g, 4.28 mmol) and 2,4-dimethylpyrrole (0.814 g, 
0.88 mL, 8.56 mmol) with TFA (5 drops) were dissolved in anhydrous DCM (300 mL) and 
stirred under N2 for 12 hours at room temperature. DDQ (1.94 g, 8.56 mmol) was added as a 
single portion and left to stir for one hour. Then DIPEA (8.5 mL, 48.79 mmol) and BF3OEt2 
(8.6 mL, 68.48 mmol) were added and the solution stirred for six hours. 
The solution was washed with water and extracted in chloroform and concentrated to residue. 
The residue was purifed with column chromatography eluted in chloroform to yield a red solid 
(304mg, 16%). 
 
  ? ? ?
1H NMR: į 1.42 (6H, s, CH3), 1.60 (4H, m, CH2CH2CH2N3), 1.80 (2H, m, CH2CH2CH2N3) 
2.54 (6H, s, CH3), 3.31 (2H, m, CH2N3), 4.01 (2H, m, OCH2), 5.9 (2H, s, CH), 6.97 (2H, d, J  
8.3 ArCH), 7.15 (2H, d, J 8.3, ArCH) 
13C NMR: į 14.59 (CH3), 23.45 (CH2), 28.70 (CH2), 28.82 (CH2), 51.4 (CH2N3), 67.70 
(OCH2), 115.04 (phenyl CH), 121.10 (pyrrole CH), 126.98 (Phenyl C), 129.20 (NCCCH3), 
131.85 (Phenyl CH), 141.90 (CH3CC), 143.16 (PhenylC-C), 155.23 (NCCH3), 159.55 (Phenyl 
CO) 
Mpt: 148-150 qC. 
FT-IR (KBr) 2919, 2086 (N3), 1609, 1544. 
ES-MS MH+ Calc. for C24H27BF2N5O 452.2428 found 452.2464.  
Synthesis of 4-(2-(2-chloroethoxy)ethoxy)benzaldehyde 63 
 
4-Hydroxybenzaldehyde (5.0 g, 40.96 mmol) and K2CO3 (11.25 g, 81.69 mmol) were 
dissolved in DMF (300 mL). Bis-(2-chloroethyl) ether 62 (14.38 mL, 122.9 mmol) and 
refluxed for 20 hours. the reaction mixture was filter, poured into water (500 mL) and 
extracted into ethyl acetate (3 x 60 mL). The organic layer was washed with water, dried and 
evaporated. The residue was precipitated from diethyl ether/water to yield a white solid (6.28 g, 
67%). 
 
1H NMR: į 3.65 (2H, t, J 5.8, CH2), 3.83 (2H, t, J 5.5, CH2), 3.91 (2H, t, J 4.7, CH2), 4.22 (2H, 
t, J 4.7, CH2), 7.02 (2H, d, J 8.6, ArH), 7.83 (2H, d, J 8.6, ArH), 9.88 (1H, s, COH). 
13C NMR: į 42.81, 67.80, 69.63, 71.75 (CH2), 115.00 (ArCH), 130.33 (ArCH), 132.12 (ArC), 
163.83 (ArCO), 190.10 (COH).  
Mpt: 65-66 qC. 
  ? ? ?
FT-IR: (KBr) 2930, 2780 (C=O str), 2628, 1588, 1500, 1468,1259 (C-O-C str). 
Synthesis of 4-(2-(2-azidoethoxy)ethoxy)Benzaldehyde 64 
 
4-(2-(2-Chloroethoxy)ethoxy)benzaldehyde  63 (500 mg, 2.19 mmol) and sodium azide (691 
mg, 10.95 mmol) was heated in DMF (50 mL) at 100 qC for 20 hours. The reaction mixture 
was cooled to room temperature and poured into water (100 mL) and extracted into ethyl 
acetate (3 × 60 mL). The organics were washed with water (2× 50 mL), dried and evaporated. 
to yield a clear oil (377mg, 74% yield). The product was used without further purification.  
 
1H NMR: į 3.40 (2H, t, J 5.1, CH2), 3.74 (2H, t, J 4.8, CH2), 3.88 (2H, t, J 4.8, CH2), 4.21 (2H, 
t, J 4.6, CH2), 7.02 (2H, d, J 8.7, ArH), 7.82 (2H, d, J 8.8, ArH), 9.86 (1H, s, CHO). 
13C NMR: į 50.72, 67.81, 69.54, 70.42 (CH2), 114.96 (ArCH), 130.42 (ArCH), 132.03 (ArC), 
163.80 (ArCO), 190.81 (COH).  
Mpt: 60-62 qC. 
FT-IR: (KBr) 2929, 2789, 2632, 2097 (N3), 1570, 1512, 1488,1239. 
Synthesis of 4,4-difluoro-8-(4-(2-azidoethoxy)ethoxy))phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene 65 
 
4-(2-(2-Azidoethoxy)ethoxy)benzaldehyde 64 (200 mg, 0.85 mmol) and 2,4-dimethylpyrrole 
(162 mg, 1.70 mmol) were dissolved in anhydrous DCM (80 mL) with TFA (4 drops) and 
stirred under a nitrogen environment for 12 hours. DDQ (193 mg, 0.85 mmol) was added in a 
  ? ? ?
single portion and the reaction was stirred for one hour. Triethylamine (0.674 mL, 4.84 mmol) 
and boron trifluoride diethyl etherate (1.67 mL, 13.6 mmol) was added to the reaction mixture 
and stirred under a nitrogen environment for 10 hours. The reaction mixture was washed with 
water (3 × 100 mL) and brine (3 × 50 mL), dried and concentrated. The residue was purified by 
column chromatography eluted with DCM to yield a red solid (150 mg, 39%).  
 
1H NMR: į 1.42 (6H, s, CH3), 2.54 (6H, s, CH3), 3.39-3.48 (2H, m, CH2), 3.76-3.82 (2h, m, 
CH2), 3.89-3.94 (2H, m, CH2), 4.18-4.22 (2H, m, CH2), 5.97 (2H, s, CH), 7.02-7.03 (2H, m, 
ArCH), 7.15-7.17 (2H, m, ArCH). 
13C NMR: į 14.72 (CH3), 47.3 (CH3), 50.80 (CH2), 67.60 (CH2), 69.81 (CH2), 70.44 (CH2), 
115.23 (phenyl CH), 121.24 (pyrrole CH), 127.44 (Phenyl C), 129.30 (NCCCH3), 131.91 
(Phenyl CH), 141.90 (CH3CC), 143.35 (PhenylC-C), 155.31 (NCCH3), 159.40 (Phenyl CO). 
Mpt: 138-140 qC. 
FT-IR: (KBr) 3445, 2801, 2490, 2114 (N3), 1612 (conjugated C=N). 
ES-MS MH+ calc. For C23H26BF2N502 454.2222 found 454.2230. 
Synthesis of 1-((4-(4,4-difluoro-8-(4-pentyl)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)butyl)amino)-3-(naphthalen-1-yloxy)propan-2-ol 66a 
 
Using general procedure 1 starting with 4,4-difluoro-8-(4-(5-azidopentoxy))phenyl-2,6-
dimethyl-4-bora-3a,4adiaza-s-indacene 61 and 1-(hex-5-ynylamino)-3-(naphthalen-1-
yloxy)propan-2-ol 53c yielded a red solid (2.6 mg, 14%). 
 
  ? ? ?
HPLC Rt: 12.42 (System 1), 14.53 (System 2). 
ES-MS MH+ Calc. for C43H52BF2N6O3 749.4157 found 749.3139 
Synthesis of 1-((4-(4,4-difluoro-8-(4-(2-ethoxy)ethoxy)phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)butyl)amino)-3-(naphthalen-1-yloxy)propan-
2-ol 66b 
 
Using general procedure 1 and starting with 1-(hex-5-ynylamino)-3-(naphthalen-1-
yloxy)propan-2-ol 53c and 4,4-difluoro-8-(4-(2-azidoethoxy)ethoxy))phenyl-2,6-dimethyl-4-
bora-3a,4adiaza-s-indacene 65 yielded a red solid (2.4 mg, 48%). 
 
HPLC Rt: 19.85 (System 4). 
ES-MS MH+ calc. for C42H50BF2N6O4 751.3949 found 751.3956 
Synthesis of 2-amino-N-(prop-2-ynyl)acetamide180 (TFA salt) 70 
 
Glycine 67 (4.4 g, 59.2 mmol) was dissolved in water/dioxane (1:1, 80 mL). Sodium hydroxide 
(2.36 g, 0.06 mmol), was added and cooled to 0 qC BOC anhydride (14.12 g, 64.8 mmmol) 
was added in three portions to the reaction. The Reaction mixture was stirred at 0 qC for 
30minutes then room temperature for 12 hours. The solvent was removed in vacuo and the 
residue was dissolved in water (200 mL) and washed with ether (3 × 100 mL). The aqueous 
layer was washed with citric acid to pH 4 and the product was extracted with ether (3 × 75 mL). 
  ? ? ?
The organics were dried and concentrated to yield a white solid (2.9 g) the product was used 
without further purification. 
The product  68 (1.93 g, 13.12 mmol) was dissolved in DCM (15 mL) to which HBTU (4.8 g, 
13.12 mmol) was added with DIPEA (2.27 mL, 13.13 mmol). The reaction was stirred for 30 
seconds and then propargylamine (662 mg, 12.04 mmol) was added and the reaction mixture 
was stirred for five hours. The solvent was evaporated and redissolved in ethyl acetate (20 mL) 
and washed with 1M HCl  (10 mL) and 1M NaOH (10 mL) followed by a brine wash (10 mL), 
dried and concentrated. 
The product 69 was dissolved in DCM (10 mL) treated with trifluoroacetic acid (10 mL) and 
stirred for 30 minutes. The reaction mixture was concentrated, and co-evapourated with 
petroleum ether (3 x 10 mL) and triturated with diethyl ether. The product was dissolved in 
water and lyophilised to yield a brown oil (687 mg, 44%). 
 
1H NMR: (DMSO-d6) į 3.18-3.19 (1H, t, J 2.5, CCH), 3.56 (2H, s, CH2NH3), 3.93-3.95 (2H, 
dd, J 2.5, 5.5, CH2CCH), 8.07 (3H, br s, NH3), 8.81 (s, NH). 
13C NMR: (DMSO-d6) į 28.5 (CH2CCH), 40.52 (CH2NH3), 74.0 (CCH), 80.8 (CCH), 166.2 
(C=O).  
FT-IR: (NaCl) 2954, 2732, 1672 (C=O str), 1549 (NH Bend), 742. 
ES-MS M+ calc for C5H9N2O+ 113.070 found 113.0625. 
Synthesis of 2-(2-hydroxy-3-(naphthalen-1-yloxy)propylamino)-N-(prop-2-
ynyl)acetamide 71 
 
2-Amino-N-(prop-2-ynyl)acetamide 70 (687 mg, 3.03 mmol) and 1-(2,3-epoxypropoxy)- 
naphthalene 27a (150 mg, 0.75 mmol) were dissolved in isopropanol (10 mL) and DIPEA 
  ? ? ?
(0.527 mL, 3.03 mmol) was added and refluxed for 16 hours.  The reaction mixture was 
evaporated and washed with water. The organic layer was dried and concentrated. The redisue 
was purified by column chromatography eluted in MeOH:DCM (1:9) to yield a white solid 
(120 mg, 51% yield). 
 
1H NMR: į 2.18-2.19 (1H, t, J 2.5, CCH), 2.93-2.95 (2H, m, COH2CH2NH), 3.39 (2H, d, J 6.5, 
COCH2), 4.05-4.07 (2H, dd, J 2.5,5.5, CH2CCH), 4.15- 4.23 (2H, m, NHCH2CO), 4.26-4.30 
(1H, m, COHH), 6.83 (1H, d, J 7.5, ArH), į 7.36 (1H, t, J 7.5, ArH), į 7.44-7.51 (3H, m, ArH), 
į 7.80 (1H, m, ArH), į 8.21 (1H, m, ArH). 
13C NMR: į 28.71, 52.42, 52.51, 69.39 (CH2), 70.47 (CCH), 71.46 (CCH), 75.70 (CHOH), 
105.11 (naphthyl C), 121.02 (naphthyl C), 121.50 (naphthyl C), 125.51 (naphthyl C), 125.73 
(naphthyl C), 125.58 (naphthyl C), 126.57 (naphthyl C), 127.52 (naphthyl C), 134.61 (naphthyl 
C), 154.58 (naphthyl C), 161.1 (C=O). 
Mpt: 141-143 qC. 
FT-IR (KBr) 3301 (OH str), 3050 (NH str), 1671 (C=C Ar str), 1593, 1508, 1269. 
ES-MS M-TFA+ calc. For C18H19N2O3+ Calc 313.1547 found 313.1449. 
Synthesis of N-((4,4-difluoro-8-(4-(3-propoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)methyl)-2-((2-hydroxy-3-(naphthalen-1-
yloxy)propyl)amino) acetamide 72a 
 
Using general procedure 1 starting with 2-(2-hydroxy-3-(naphthalen-1-yloxy)propylamino)-N-
(prop-2-ynyl)acetamide 71 and 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-dimethyl-4-
bora-3a,4adiaza-s-indacene 46 to yield an orange solid (3.4 mg, 90% yield). 
  ? ? ?
 
HPLC Rt: 16.55 (System 4). 
ES-MS M-F+ calc. For C40H43BFN7O4 Calc 715.3443 found 715.3568. 
 
Synthesis of N-((4,4-difluoro-8-(4-(pentyl))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)methyl)-2-((2-hydroxy-3-(naphthalen-1-
yloxy)propyl)amino)acetamide 72b 
 
Using general procedure 1 and starting with 2-(2-hydroxy-3-(naphthalen-1-
yloxy)propylamino)-N-(prop-2-ynyl)acetamide 71 and 4,4-difluoro-8-(4-(5-
azidopentyl))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 61 yielded a red solid (3.4 mg, 
24%). 
  
HPLC Rt: 17.70 (System 4). 
ES-MS M+ calc. For C42H49BF2N7O4 764.3902 found 764.3896. 
 
 
 
 
  ? ? ?
Synthesis of N-((4,4-difluoro-8-(2-ethoxy)ethoxy)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-
s-indacene -1H-1,2,3-triazol-4-yl)methyl)-2-((2-hydroxy-3-(naphthalen-1-
yloxy)propyl)amino) acetamide 72c 
 
Using general procedure 1 starting with 2-(2-hydroxy-3-(naphthalen-1-yloxy)propylamino)-N-
(prop-2-ynyl)acetamide 71 and 4,4-difluoro-8-(4-(2-azidoethoxy)ethoxy))phenyl-2,6-dimethyl-
4-bora-3a,4adiaza-s-indacene 65 yielded a red solid (1.9 mg, 58%). 
 
HPLC Rt: 19.97 (System 4). 
ES-MS M+ calc. For C41H47BF2N7O5 Calc 766.3694 found 766.3694. 
Synthesis of 1-((2-(4-2-chromis 630 N L5H -1H-1,2,3-triazol-1-yl)ethyl)amino)-3-(4-(2-
methoxyethyl)phenoxy)propan-2-ol 74a 
 
Using general procedure 1 and starting with chromis 630 N L5H azide 73 and 1-(naphthalen-8-
yloxy)-3-(prop-2-ynylamino)propan-2-ol 30a yielded a blue solid (1.4 mg, 14%).  
 
  ? ? ?
HPLC Rt: 14.64 (System 2). 
ES-MS MH+ Calc. for C50H54BF2N6O4 851.4262 found 851.4284. 
Synthesis of 1-(2-(1-(2-chromis 630 N L5H -1H-1,2,3-triazol-4-yl)butyl)amino)-3-
(naphthalen-1-yloxy)propan-2-ol 74b  
 
Using general procedure 1 starting with chromis 630 N L5H azide 73 and 1-(hex-5-
ynylamino)-3-(naphthalen-1-yloxy)propan-2-ol 53c yielded a blue solid (2.2 mg, 22%). 
HPLC Rt: 23.35 (System 4). 
ES-MS MH+ Calc. for C53H60BF2N6O4 893.4732 found 893.4713. 
 
Synthesis of N-2-propenyl-2-thiophenecarboxamide 76 147  
 
2-Thiophene carbonyl chloride 75 (2.58 mL, 24 mmol) in anhydrous DCM (10 mL) was added 
drop wise to a mixture of allylamine (1.84 mL, 25 mmol) and pyridine (3.9 mL, 48.4 mmol) in 
anhydrous DCM (40 mL). The reaction was stirred for four hours under nitrogen. The reaction 
was diluted with water (25 mL) and the two layers were separated. The organic layer was 
washed with 2M hydrochloric acid (2 x 10 mL), Brine (2 × 10 mL) and dried. The product was 
  ? ? ?
concentrated to afford a pale yellow solid (3.54 g, 85%). The product was used without further 
purification. 
 
1H NMR: į 4.04-4.08 (2H, m, CH2), 5.18 (1H, dd, J 1.5, 10.0, Hb), 5.25- 5.30 (1H, dd, J 1.5, 
17.0, Ha), 5.89-5.97 (1H, m, Hc), 6.11 (1H, br s, NH), 7.09 (1H, dd, J 3.5, 5.0, ArH), 7.47 (1H, 
dd, J 1.1, 5.0, ArH), 7.52 (1H, dd, J 1.0, 3.5, ArH). 
13C NMR: į 42.35 (CH2), 116.78 (=CH2), 127.61, 128.13, 129.90, 134.01 (3 x ArCH, CH=), 
138.81 (4°), 161.78 (C=O). 
Mpt: 57-59 °C (Lit 65°C140). 
FT-IR: (KBr) 3302 (NH str), 1621 (C=O), 1502, 1306, 708.  
ES-MS MH+ calc for C8H10NOS  168.0478 found 168.1099. 
Synthesis of 2-(2-thienyl)pyrrole
181
 77 
 
N-2-propenyl-2-thiophenecarboxamide 76 (850 mg, 5.1 mmol) was dissolved in phosgene 
(20% in toluene) (10 mL) with anhydrous DMF (1 drop). The reaction was stirred at room 
temperature for 16 hours. Then the solvent was evaporated and the residue was redissolved in 
anhydrous THF (5 mL). Potassium tert-butoxide (1.78 g, 15.8 mmol) was dissolved in 
anhydrous DMF (10 mL). The THF solution was added dropwise to the DMF solution slowly 
over an ice bath and stirred for 10minutes. The mixture was poured into ice water (25 mL) and 
the product was extracted in ether (3 x 15 mL), dried and concentrated. The product was 
purified by column chromatography eluted in petroleum ether: DCM (1:2) and recrystalised 
from petroleum ether to yield a yellow solid (262 mg, 34%).  
 
  ? ? ?
1H NMR: (DMSO-d6) į 6.05-6.07 (1H, m, ArH of pyrrole), 6.25-6.27 (1H, m, ArH of pyrrole), 
6.78-6.80 (1H, m, ArH of pyrrole), 7.01 (1H, dd, J 3.5, 5, ArH of thienyl), 7.18, (1H, dd, J 1.2, 
3.5, ArH of thienyl), 7.28 (1H, dd J 1.2, 5.0, ArH of thienyl), 11.27 (1H, br, s, NH).  
13C NMR: (DMSO-d6) į 106.34 (ArCH of pyrrole), 109.36 (ArCH of pyrrole), 119.38 (ArCH 
of pyrrole), 120.92 (ArCH of thienyl), 122.77 (ArCH of thienyl), 126.37 (4 °), 128.17 (ArCH 
of thienyl), 137.00 (4 °). 
Mpt: 73-74 °C (Lit 78°C172). 
FT-IR: (KBr) 3362 (NH str), 3111 (Ar-H), 726, 686. 
Synthesis of 2-formyl-5-(2-thienyl)pyyrole 
182
 78 
 
Phosphorus oxychloride (1.34 mL, 14.8 mmol) was added dropwise to anhydrous DMF (1.1 
mL, 14.8 mmol) and cooled to 0 qC. The solution was warmed to room temperature and stirred 
for 15minutes under a N2 atmosphere. The reaction was cooled to 0 qC and anhydrous 1,2-
dichloroethane (25 mL) was added. 2-(2-thienyl) pyrrole 77 (2.0 g, 13.4 mmol) was dissolved 
in anhydrous 1,2-dichloroethane (66 mL) and added dropwise to the phosphorus oxychloride 
and refluxed for 90minutes. The reaction was then cooled to room temperature and a solution 
of sodium acetate (10 g, 27.36 mmol) in water (26 mL) was added and the solution was 
refluxed for one hour. The solution was cooled to room temperature, the organic layer was 
collected and the aqueous layer was washed with chloroform (3 × 50 mL). The organic phase 
was washed with saturated sodium bicarbonate solution (2 × 25 mL), waster (3 × 25 mL) and 
dried. The organics were concentrated and the residue was purified by column chromatography 
eluted with petroleum ether: ethyl acetate (3:1) and recrystalised from chloroform and hexane 
to yield off white crystals (1.07 g, 45%). 
 
  ? ? ?
1H NMR: į 6.53 (1H, dd, J 1.5, 3.9, ArH of pyrrole), 6.99 (1H, dd, J1.2, 3.8, ArH of pyrrole), 
7.09 (1H, dd, J 3.6,5.0, ArH of thienyl), 7.31 (1H, dd, J 1.1, 5.0, ArH of thienyl), 7.39 (1H, dd, 
J 1.1, 3.6, ArH of thienyl), 9.98 1H, br s, NH). 
13C NMR: į 109.56 (ArCH of pyrrole), 123.10 (ArCH of pyrrole), 124.58, 125.94, 128.33 
(ArCH of thienyl), 132.99, 133.86, 134.89 (4  ), 178.76 (CHO). 
Mpt: 166-167 qC (Lit 167-168173). 
FT-IR: (KBr) -3170 (NH str), 1646 (C=O), 1481, 1283. 
ES-MS MH+ Calc. for C9H7NOS 178.0327 found 178.0291. 
Synthesis of 4-methoxybenzyl triphenylphosphonium chloride
183,184
 80 
 
4-Methoxybenzyl chloride 79 (10 g, 63.8 mmol) and triphenylphosphine (16.5 g, 63.8 mmol) 
were dissolved in anhydrous benzene (30 mL) and refluxed for 22 hours. The solid was then 
filtered and washed several times with benzene and the product was dried to afford the salt as a 
white solid (22.8 g, 85%). The product was used without further purification. 
 
1H NMR: (DMSO-d6) į 3.69 (3H, s, OMe), 5.08 (2H, m, CH2), 6.78 (2H, d, J 8.5, 2 x ArH), 
6.96 (2H, dd, J 2.5, 9.0 Hz, 2 x ArH), 7.60-7.76 (15H, m, PPh3).  
13C NMR: (DMSO-d6) į 29.88 (CH2), 55.37 (CH3), 114.34, 114.37(ArCH), 117.92, 118.77 
(4°), 
 130.14, 130.27, 132.87, 132.92, 134.53, 134.63, 134.91, 134.94, (ArCH). 
Mpt: 239-241 °C (Lit 238-240174).  
FT-IR: (KBr) 2779 (OMe), 1605, 1505, 1438, 1246, 1111. 
  ? ? ?
ES-MS MH+ calc for C26H24OP: 383.155 found 383.8857. 
Synthesis of 2[(E)-methoxyphenyl)ethen-1-yl] pyrrole  149,185 81 
 
4-Methoxybenzyl triphenyl phosphonium chloride 80 (13.15 g, 31.156 mmol) and sodium 
hydride (60% dispersion in oil) (1.26 g, 31.56 mmol) were stirred in anhydrous benzene (45 
mL) for 30minutes. After this time pyrrole-2-carboxaldehyde (2.5 g, 26.03 mmol) in anhydrous 
toluene (25 mL) was added by canulla and the reaction was stirred at refluxed for 16 hours. 
The reaction mixture was then cooled to room temperature and concentrated. The residue was 
purified by column chromatography eluted with petroleum ether: ethyl acetate (6:4) and then 
recrystalised from toluene: petroleum ether to yield a grey solid (260 mg, 5%). 
 
1H NMR: į 3.82 (1H, s, OCH3), 6.22-6.24 (1H, m, Pyrrole H), 6.30-6.39 (1H, m, Pyrrole H), 
6.60-6.64 (1H, d, J 16.5, CH=), 6.79-6.80 (1H, m, Pyrrole H), 6.82-6.86 (1H, d, J 16.5, CH=), 
6.86-6.88 (2H, d, J 8.8, ArH), 7.35-7.37 (2H, d, J 8.8, ArH). 
13C NMR: į 55.46 (OCH3), 108.54 (Pyrrole CH), 110.06 (pyrrole CH), 114.29 (Phenyl CH), 
117.26 (Pyrrole CH), 118.78 (alkenyl CH), 123.26 (alkenyl CH), 127.12 (Phenyl CH), 
159.89(Phenyl C-O), 130.46 (Pyrrole C), 131.21 (phenyl C). 
Mpt: 176-177 °C (169-170°C142). 
FT-IR: (KBr) 3403 (NH), 1250 (ArC-O), 1602, 1510, 1031, 816.  
ES-MS MH+ calc. For C13H14NO 200.1070 found 200.1068. 
 
 
 
  ? ? ?
Synthesis of 2-[(E)-2[(4-methoxycarbonylmethoxy)phenyl]ethen-1-yl]pyrrole 83 
 
 Sodium ethanethiolate (90%, 932 mg, 9.92 mmol), was dissolved in anhydrous DMF (35 mL) 
at 0 qC. 2-[(E)-methoxyphenyl)ethen-1-yl] pyrrole 81 (1 g, 4.96 mmol) was added and refluxed 
for 3 days under a N2 environment. The reaction mixture was cooled to room temperature, and 
washed with water extracted with chloroform. The organics were dried and concentrated. The 
residue 82 was dissolved in anhydrous THF (20 mL) and treated with Sodium hydride 
dispersion inmineral oil (60%) (396 mg, 9.92 mmol) and stirred for 5minutes. Methyl 
bromoacetate (1 mL, 10 mmol) was added to the reaction mixture and stirred for 4 hours under 
a N2 environment. The reaction mixture was poured into water (250 mL) and extracted with 
chloroform (3 x 100 mL). The organics were dried and concentrated. The residue was purified 
by column chromatography eluted in chloroform to yield a grey solid (610 mg, 48%).  
 
1H NMR: į 3.81 (3H, s, OMe), 4.64 (2H, s, CH2), 6.23-6.24 (1H, m, ArH of pyrrole), 6.30-6.32 
(1H, m, ArH of pyrrole), 6.59 (1H, dd, J 16.4, CH=), 6.78-6.79 (1H, m, ArH of pyrrole), 6.88 
(1H, d, J 16.4, CH=), 6.9 (2H, 8.7, Phenyl CH), 7.33 (2H, J, 8.7, Phenyl CH), 8.3(1H, br s, 
NH). 
13C NMR: į 52.30 (OMe), 65.41 (CH2), 108.63, 109.93 (ArCH of pyrrole), 114.90 (Phenyl 
ArCH), 117.73 (CH=), 118.86 (ArCH of pyrrole), 122.75 (CH=), 127.06 (ArCH of Phenyl) 
130.92, 131.50, 156.91 (4°), 169.39 (C=O). 
Mpt: 130-132 qC. 
FT-IR: (KBr) 3330 (NH), 1748 (C=O), 1222 (ArC-O), 1511, 1178, 731. 
ES-MS MH+ calc. For C15H15N03 258.1125 found 258.1144. 
 
  ? ? ?
Synthesis of N-(2-azidoethyl)-2-{4-[(E)-2  (1H-pyrrol-2-yl)ethenyl]phenoxy}acetamide 84 
 
2-[(E)-2[(4-Methoxycarbonylmethoxy)phenyl]ethen-1-yl]pyrrole 83 (100 mg, 0.38 mmol) and 
2-azidoethanamine (160 mg, 1.9 mmol) were dissolved in methanol (10 mL) and refluxed for 5 
days. Reaction was cooled to room temperature and concentrated. The residue was purified by 
column chromatography eluted in ethyl acetate: hexane (1:1) to yield a grey solid (114 mg, 
95%).  
 
1H NMR: į 3.48-3.56 (4H, m, CH2CH2N3), 4.51 (2H, s, CH2), 6.23-6.25 (1H, m, ArH of 
pyrrole), 6.32-6.34 (1H, m, ArH of pyrrole), 6.59 (1H, dd, J 16.4, CH=), 6.80-6.81 (1H, m, 
ArH of pyrrole), 6.87 (1H, d, J 16.4, CH=), 6.9 (2H, 8.7, Phenyl CH), 7.39 (2H, J, 8.7, Phenyl 
CH), 8.30 (1H, br s, NH). 
13C NMR; į 38.40 (CH2NH), 50.73 (CH2N3), 67.42 (CH2), 108.81, 110.01 (ArCH of pyrrole), 
114.93 (Phenyl ArCH), 118.04 (CH=), 118.96 (ArCH of pyrrole), 122.43 (CH=), 127.22 
(ArCH of Phenyl) , 130.80, 131.90, 156.11 (4°), 168.52 (C=O). 
Mpt: 144-146 qC. 
FT-IR: (KBr) 3330 (NH), 1748 (C=O), 1222 (ArC-O), 1432, 1288, 631 
 ES-MS MH+ calc. For C16H17N502 312.1455 found 312.1494. 
 
 
  
  ? ? ?
Synthesis of N-(((2  azidoethyl)-2-(4,4-difluoro-4,4a-dihydro-5-(thiophenyl)-4-bora-3a,4a-
 diaza-s  indacene 3-yl)vinyl)phenoxy)acetamide 85 
 
N-(2-azidoethyl)-2-{4-[(E)-2 (1H-pyrrol-2-yl)ethenyl]phenoxy}acetamide  84 (50 mg, 0.16 
mmol) and 2-formyl-5-(2-thienyl)pyrrole 78 (28 mg, 0.16 mmol) were dissolved in 
MeOH:DCM (1:10, 11 mL). POCl3 (14.8 PL, 0.2 mmol) was added and stirred for 18 hours 
under a N2 environment. The reaction mixture was evaporated and the residue was redissolved 
in DCM (50 mL) Triethylamine (0.1 mL, 0.7 mmol) and BF3.OEt2 (0.19 mL, 1.5 mmol) added 
and stirred for 12 hours under a N2 environment. The mixture was poured into water (150 mL) 
and washed with brine (3 × 50 mL), dried and concentrated. The residue was purified by 
preparative layer chromatography eluted in MeOH:DCM (1:9) to yield a blue solid (28 mg, 
34%). 
 
1H NMR: į 3.48-3.56 (4H, m, CH2CH2N3), 4.53 (1H, s, OCH2), 6.78 (1H, d, J 4.1, ArH), 6.84-
7.09 (5H, m, ArH), 7.21 (1H, dd, J 3.9,5.0, ArH of thienyl), 7.30 (1H, m, CH=), 7.47 (1H, dd, 
J 0.9, 5.0,ArH of thienyl), 7.58-7.63 (3H, m, CH= and 2 × phenyl ArH), 8.20 (1H, dd, J 0.9, 
3.8, ArH of thienyl) 
13C NMR: į 38.40 (NHCH2), 50.75 (CH2N3), 67.22 (CH2), 115.00, 117.21, 117.74, 119.95, 
124.04, 128.23, 128.81, 129.02, 129.55, 129.83, 130.16, (11 × ArCH), 230.6 (ArCH of 
Thienyl), 134.44, 136.54, 136.82 (3 × 4°) 137.01 (ArCH), 149.34 (4°), 156.33 (4°), 157.95 (4°), 
168.21 (C=O). 
Mpt: 157-158 °C. 
ES-MS MNa+ calc. For C25H21BF2N602S 541.1400 found 541.1448. 
 
  ? ? ?
Synthesis of N-(( N-((ethyl-2-(4,4-difluoro-4,4a-dihydro-5-(thiophenyl)-4-bora-3a,4a-
 diaza-s  indacene 3-yl)vinyl)phenoxy)acetamide -1H-1,2,3-triazol-4-yl)methyl)-2-((2-
hydroxy-3-(naphthalen-1-yloxy)propyl)amino)acetamide 87 
 
Using general procedure 1 starting with N-(2  azidoethyl)-2-(4,4-difluoro-4,4a-dihydro-5-
(thiophenyl)-4-bora-3a,4a- diaza-s indacene 3-yl)vinyl)phenoxy)acetamide 85 and 2-(2-
hydroxy-3-(naphthalen-1-yloxy)propylamino)-N-(prop-2-ynyl)acetamide 71 yielded a blue 
solid (2 mg, 45%). 
 
HPLC Rt: 23.32 (System 4). 
ES-MS MH+ calc. For C43H42BF2N805 831.3055 found 831.2963. 
Synthesis of capped fluorophores 
Synthesis of 4,4-difluoro-8-(4-((1-(2-phenoxypropyl)-1H-1,2,3-triazol-4-
yl)methanamine))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 88a 
 
Using general procedure 1 starting with propargylamine and 4,4-difluoro-8-(4-(3-
azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 46 yielded red solid. (6 mg, 
60%). 
 
  ? ? ?
HPLC Rt: 12.37 (System 1), 15.55 (System 2). 
ES-MS MH+ calc. For C25H30BF2N602 479.2537 found 479.2273. 
Synthesis of 4,4-difluoro-8-(4-((1-(2-phenoxypentyl)-1H-1,2,3-triazol-4-
yl)methanamine))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 88b 
Using general procedure 1 starting with progargylamine and 4,4-difluoro-8-(4-(5-
azidopentyl))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 61 yielded a red solid (3.5 mg, 
76%). 
 
HPLC Rt: 15.02 (System 1), 16.85 (System 2). 
ES-MS M-FH+ calc. For C27H33BFN6O 486.2523 found 486.2526. 
Synthesis of (3-bromopropoxy) benzene
186
 90 
 
1,5-Dibromopentane (2.08 mL, 15.2 mmol) K2CO3 (3.8 g, 27.6 mmol) were stirred in DMF 
(100 mL). to this, phenol 89 (1.69 g, 13.84 mmol) dissolved in DMF (10 mL) was added 
dropwise and stirred at room temperature for 15 hours. The reaction mixture was poured into 
water and extracted with toluene. The organic phase was washed with brine, dried and 
concentrated. The residue was purifed by column chromatography eluted in MeOH:DCM (1:9) 
to yield a clear oil (3.7 g, 99% yield). 
 
1H NMR: į 2.26-2.32 (2H, m, CH2CH2Br), 3.58 (2H, t, J 6.4, CH2Br), 4.08 (2H, t, J 5.8 OCH2) 
6.92 (2H, d, J 8.8, ArCHCO), 6.90-6.97 (1H, m, ArCH), 7.26-7.30, (2H, m, ArCHCO). 
13C NMR: į 30.09 (CH2CH2Br), 32.43 (CH2Br), 65.19 (OCH2), 114.53 (ArCH-p), 120.94 
(ArCH-m), 129.52 (ArCH-o), 158.69 (ArCO) 
FT-IR: (NaCl) 3039, 2928 (C=O str(, 1600, 1498, 1387 (C-O str). 
  ? ? ?
Synthesis of (3-azidopropoxy)benzene 91 
 
(3-Bromopropoxy) benzene 90 (3 g, 13.9 mmol) and sodium azide (2.26 g, 34.75 mmol) were 
refluxed in DMF (50 mL) at 100 qC for six hours. The reaction mixture was poured into water 
and extracted with ethyl acetate, dried and concentrated to yield a clear oil (2.47 g, 80%). This 
product was used without further purification. 
 
1H NMR: į 2.02-2.08 (2H, m, CH2CH2N3), 3.51 (2H, t, J 6.5, CH2N3), 4.04 (2H, t, J 5.9 OCH2) 
6.91 (2H, d, J 7.8, ArCHCO), 6.94-6.98 (1H, m, ArCH), 7.25-7.31, (2H, m, ArCHCO). 
13C NMR: į 28.79 (CH2CH2N3), 48.26 (CH2N3), 64.36 (OCH2), 114.46 (ArCH-p), 120.90 
(ArCH-m), 129.42 (ArCH-o), 158.64 (ArCO). 
FT-IR: (NaCl) 3042, 2916, 2103, 1599, 1492, 1374. 
Synthesis of 1-(naphthalen-1-yloxy)-3-((4-(1-(3-phenoxypropyl)-1H-1,2,3-triazol-4-
yl)butyl)amino)propan-2-ol 92 
 
Using general procedure 1 starting with (3-azidopropoxy)benzene 91 and 1-(hex-5-
ynylamino)-3-(naphthalen-1-yloxy)propan-2-ol 56c yielded a brown solid (1.3 mg, 62%). 
 
HPLC Rt: 15.55 (System 1). 
ES-MS MH+ calc. For C28H35N403 475.2704 found 475.2794. 
  ? ? ?
Synthesis of (3R)-1-azabicyclo[2.2.2]oct-3-yl oxo(phenyl)acetate165 103 
 
Phenylglyoxylic acid 101 (1 g, 6.6 mmol) dissolved in anhydrous chloroform (22 mL) and 
cooled to 0 qC. Oxalyl chloride (1 mL, 11.5 mmol) was added with DMF (2 drops). The 
reaction mixture was warmed to room temperature and stirred for 90minutes.  
The solvent was evaporated and co-evaporated with chloroform (2 x 10 mL) and petroleum 
ether (1 x 15 mL). The residue was redissolved in anhydrous chloroform (10 mL) and added to 
a solution of (3R)- quinuclidinol (1 g, 7.86 mmol, dissolved in chloroform 15 mL). The 
reaction was stirred for 4 hours and a solution of K2CO3 (10%) was added. The product was 
extracted with chloroform (3 x 25 mL), dried and concerntrated to yield an off white solid 
(1.64 g, 96%). 
 
1H NMR: į 1.40-1.49 (1H, m, CH), 1.59-1.68 (1H, m, CH2), 1.73-1.76 (1H, m, CH2), 1.84-1.91 
(1H, m,CH2 ), 2.72-2.93 (5H, m, CH2 ), 3.32-3.39 (1H, m, CH2 ), 5.12-5.16 (1H, m, OCH), 
7.50-7.45 (m, 2H, ArCH), 7.64-7.69 (1H, m, ArCH), 7.98-8.01 (2H, m, ArCH).  
13C NMR: į 19.29 (CH2), 24.49 (CH2), 25.26 (CH), 46.47 (CH2), 47.32 (CH2), 55.09 (CH2), 
74.00 (OCH), 128.97 (ArCH), 129.96 (ArCH), 132.43 (ArC), 134.97 (ArCH), 163.87 
(ArCCO), 186.36 (COOCH). 
Mpt: 187-188 °C. 
FT-IR (KBr) 2784, 1820, 1726 (ester), 1449, 1020. 
ES-MS MH+ calc. For C15H17N03 260.1281 found 260.1281. 
 
 
  ? ? ?
Synthesis of (3R)-1-azabicyclo[2.2.2]oct-3-yl hydroxy(diphenyl)acetate165 104 
 
A solution of (3R)-1-Azabicyclo[2.2.2]oct-3-yl oxo(phenyl)acetate 103 (1 g, 3.85 mmol) 
dissolved in anhydrous THF (10 mL) was cooled to -42 qC. Phenyllithium (1.8 M in dibutyl 
ether, 2.5 mL, 4.24 mmol) was added slowly and the reaction mixture was stirred for 
10minutes. The reaction mixture was then warmed to room temperature and stirred for a 
further 90minutes.  
The reaction mixture was then poured into a saturated solution of ammonium chloride and the 
product was extracted with diethyl ether (3 x 50 mL). The organics were combined, dried and 
concentrated. The residue was treated with diisopropyl ether and the product was filtered to 
yield a yellow solid (862 mg, 66%). 
1H NMR: į 1.16 (1H, m, CH), 1.20-1.25 (1H, m, CH2), 1.29-1.35 (1H, m, CH2), 1.44-1.54 (1H, 
m, CH2), 1.56-1.68 (1H, m, CH2), 1.96-2.01 (1H, m, CH2), 2.43-2.51 (2H, m, CH2), 2.59-2.69 
(3H, m, CH2), 3.08-3.14 (1H, m, CH2), 4.93-4.95 (1H, m, OCH), 5.19 (s, br, 1H, OH), 7.29-
7.39 (6H, m, ArCH), 7.42-7.46 (4H, m, ArCH).  
13C NMR: į 19.16 (CH2), 24.05 (CH2), 25.01 (CH), 46.00 (CH2), 46.84 (CH2), 54.64 (CH2), 
73.81 (OCH), 77.29 (COH), 127.03 (ArC), 127.45(ArC), 127.80(ArC), 127.95(ArC), 
128.00(ArC), 128.06(ArC), 128.24(ArC), 142.33(ArC), 174.16 (CO). 
Mpt: 189-191 qC. 
FT-IR: (KBr) 3051(OH str), 2784, 1726 (ester), 1449. 
HPLC Rt: 12.37 (System 1), 15.55 (System 2). 
ES-MS MH+ calc. For C21H24N03 338.1751 found 338.1876. 
 
  ? ? ?
Synthesis of 2-bromo N-(prop-2-ynyl) acetamide187 107 
 
Bromoacetic acid 105 (1 g, 7.2 mmol) was dissolved in anhydrous chloroform (10 mL) and 
cooled to 0 qC. Oxalyl chloride (0.81 mL, 9.44 mmol) was added to the solution followed by 
DMF (2 drops). The reaction mixture was warmed to room temperature and stirred for 
90minutes. The solvent was evaporated and co-evaporated with chloroform (2 × 10 mL) and 
petroleum ether (1 × 10 mL). The residue was redissolved in anhydrous chloroform (10 mL) 
and added to a solution of propargylamine (0.51 mL, 79 mmol) dissolved in anhydrous 
chloroform (10 mL). The reaction was stirred for 4 hours and a solution of 10% K2CO3 was 
added. The aqueous layer was washed with chloroform. The organics were combined and wash 
with 1M HCl. The organic phase was washed with brine, dried and concentrated to yield a 
yellow solid (660 mg, 52%). The product was used without further purification. 
 
1H NMR: į 2.27 (1H, t, J 2.5, CCH), 3.89 (2H, s, NHCH2), 4.07-4.09 (2H, m, BrCH2CO), 6.70 
(1H, s, br, NH). 
13C NMR: į 28.6 (NHCH2), 29.96 (BrCH2CO), 72.2 (CCH), 78.5 (CCH) 
Mpt: 144-145 qC. 
FT-IR: (KBr) 3330 (NH str), 2956, 1672 , 1544. 
Synthesis of 1-(3-bromopropoxy)-3-ethynylbenzene 110 
 
1,3-Dibromopropane 108 (1.88 mL, 18.6 mmol) was dissolved in acetone (100 mL). K2CO3 
(1.17 g, 8.46 mmol) was added and stirred for 15minutes. 3-Hydroxyphenol acetylene 109 
(0.46 mL, 4.23 mmol) was dissolved in acetone (50 mL) and was added dropwise to the 
reaction mixture over 3 hours and then stirred overnight.The solvent was evaporated and the 
  ? ? ?
residue was redisolved in DCM. The organic was washed with water (3 × 15 mL), dried and 
concentrated.  
The residue was purified by column chromatography eluted with ethyl acetate: hexane (4:6) to 
yield a clear oil (116 mg, 46%). 
 
1H NMR: į 1.26 (2H, t, J 7.2, CH2), 3.03 (1H, s, CCH), 3.4-3.56, (4H, m, 2x CH2), 6.80-6.85 
(1H, m, ArH), 6.94-6.96 (1H, m, ArH), 7.02-7.05 (1H, m, ArH), 7.16 (1H, t, J 7.8, ArH).  
13C NMR į 15.1 (CH2), 60.5 (CH2), 66.0 (CH2), 76.9 (CCH), 83.4 (CCH), 116.4 (ArCH), 
118.84 (ArCH), 123.14 (ArC), 124,31 (ArCH), 129.56 (ArCH), 155.89 (ArCO).  
Synthesis of (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(prop-2-yn-1-yl)quinuclidinium 
bromide 111a  
 
 Using general procedure 2 starting with (3R)-1-azabicyclo[2.2.2]oct-3-yl 
hydroxy(diphenyl)acetate 104 (75 mg, 0.22 mmol) and propargyl bromide solution (80% in 
toluene, 650 mg, 0.474 mL, 0.55 mmol) to yield a white solid (45%). 
1H NMR: į 1.59-1.61 (1H, m), 1.61-1.63 (1H, m), 2.04-2.10 (3H, m), 2.40-2.43 (2H, m), 2.59 
(1H, t, J 2.6, CCH), 2.72-2.75 (2H, m), 3.07-3.15 (2H, m), 3.35-3.41 (3H, m), 7.35-7.40 (5H, 
ArCH), 7.45-7.49 (5H, ArCH). 
13C NMR: į 19.16 (CH2), 24.05 (CH2), 25.01 (CH), 46.00 (CH2), 43.12 (CH2). 46.84 (CH2), 
54.64 (CH2), 72.25 (CCH), 73.81 (OCH), 77.29 (COH), 78.5 (CCH), 127.03 (ArC), 
127.45(ArC), 127.80 (ArC), 127.95 (ArC), 128.00 (ArC), 128.06 (ArC), 128.24 (ArC), 142.33 
(ArC), 174.16 (CO). 
mp – 175-176 qC 
  ? ? ?
FT-IR 3051(OH str), 2784, 1745 (ester), 1579, 1449 
HPLC Rt: 9.03 (System 1), 10.60 (System 2). 
ES-MS M-Br+ calc. For C24H26NO3 Calc 376.1907 found 376.1849 
Synthesis of (R)-1-(but-3-yn-1-yl)-3-(2-hydroxy-2,2-diphenylacetoxy)quinuclidinium 
bromide 111b  
 
 
Using general procedure 2 starting with (3R)-1-azabicyclo[2.2.2]oct-3-yl 
hydroxy(diphenyl)acetate 104 (50 mg, 0.14 mmol) and 4-bromo-1-butyne (36 Pl, 0.37 mmol) 
to yield a white solid (16 mg, 25%).  
 
1H NMR: į 1.59-1.61 (1H, m), 1.61-1.63 (1H, m), 1.79-1.81 (1H,m), 2.00-2.10 (3H, m), 2.40-
2.43 (1H, m), 2.60 (1H, t, J 2.6, CCH), 2.72-2.75 (2H, m), 3.05-3.12 (2H, m), 3.45-3.51 (3H, 
m), 5.21-5.30 (2H, m), 7.35-7.40 (5H, ArCH), 7.45-7.49 (5H, ArCH). 
13C NMR: į 19.16 (CH2), 24.05 (CH2), 25.01 (CH), 42.11 (CH2), 43.12 (CH2), 46.00 (CH2),. 
46.84 (CH2), 54.64 (CH2), 72.24 (CCH), 73.81 (OCH), 77.29 (COH), 78.5 (CCH), 127.03 
(ArC), 127.45 (ArC), 127.80 (ArC), 127.95 (ArC), 128.00 (ArC), 128.06 (ArC), 128.24 (ArC), 
142.33 (ArC), 174.16 (CO). 
Mpt: 185-186 qC. 
FT-IR: (KBr) 3075(OH), 2884, 1706 (ester), 1449, 1215. 
HPLC Rt: 12.37 (System 1), 15.55 (System 2). 
ES-MS M-Br+ Calc. For C25H28N03 390.2064 found 390.1799. 
  ? ? ?
Synthesis of (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(pent-4-yn-1-yl)quinuclidinium 
chloride 111c 
 
Using general procedure 2 starting with (3R)-1-azabicyclo[2.2.2]oct-3-yl 
hydroxy(diphenyl)acetate 104 (50 mg, 0.14 mmol) and  5-chloro-1-pentyne (0.36 mL, 3.5 
mmol) yielded a white solid (40 mg, 66%). 
 
1H NMR: į 1.59-1.61 (1H, m), 1.65-1.78 (3H, m), 2.05 (1H, t, J 2.5, CCH), 2.22-2.25 (2H, m), 
2,40 (1H, s), 2.95-3.05 (1H, m), 3.24-3.36 (5H,m), 3.40-3.50 (1H,m), 3.86-2.94 (1H, m), 4.40-
4.60 (3H, m), 5.21-5.30 (1H, m), 7.30-7.36 (5H, m, ArCH), 7.39-7.43 (5H, m, ArCH). 
13C NMR į 19.14 (CH2), 24.05 (CH2), 25.09 (CH), 35.60 (CH2), 42.14 (CH2), 43.12. 46.00 
(CH2), 46.84 (CH2), 54.64 (CH2), 60.81 (CH2) 72.21 (CCH), 73.81 (OCH), 77.29 (COH), 78.5 
(CCH), 127.03 (ArC), 127.45 (ArC), 127.80 (ArC), 127.95 (ArC), 128.00 (ArC), 128.06 (ArC), 
128.24 (ArC), 142.33 (ArC), 174.16 (CO.) 
Mpt: 188-190 qC. 
HPLC Rt: 12.37 (System 1), 15.55 (System 2). 
FT-IR: (KBr) 3141(OH), 2384, 1940, 1666 (ester), 1310. 
ES-MS M-Cl+ Calc. For C26H30NO3 Calc 404.2220 found 404.2230. 
 
 
 
  ? ? ?
Synthesis of (R)-1-(hex-5-yn-1-yl)-3-(2-hydroxy-2,2-diphenylacetoxy)quinuclidinium 
chloride 111d 
 
Using general procedure 2 starting with (3R)-1-azabicyclo[2.2.2]oct-3-yl 
hydroxy(diphenyl)acetate 104 (50 mg, 0.14 mmol) and 6-chloro-1-hexyne (0.43 mL, 3.5 
mmol) yielded a white solid (34 mg, 53%). 
 
1H NMR: į 1.52-1.58 (2H, m, CH2), 1.62-1.8 (4H, m, 2x CH2), 1.95-2.15 (2H, m, CH2), 2.28-
2.37 (2H, CH2), 2.42 (1H, s, CCH), 2.90-3.0 (1H, m, CH2), 3.0-3.5 (7H, m, CH2), 3.7-3.9 (2H, 
m, CH), 5.25-5.4 (1H,m, CHO), 7.32-7.49 (10H, m, ArH) 
13C NMR: į, 17.6, 25.7, 35.70, 42.19, 43.12, 46.91, 54.64, 59.8, 60.92 (CH2), 23.5 (CCH), 23.7 
(CCH), 68.4, 68.7 (CH), 142.2 (COHCOO), 127.03 (ArC), 127.45 (ArC), 127.80 (ArC), 
127.95 (ArC), 128.00 (ArC), 128.06 (ArC), 128.24 (ArC), 142.33 (ArC), 172.6 (CO). 
Mpt: 190-191 qC. 
FT-IR: (KBr) 3101 (OH), 2904, 1889, 1712 (ester). 
HPLC Rt: 9.72 (System 1), 11.34 (System 2). 
ES-MS M-Cl+ Calc. For C27H32NO3+ Calc 418.2378 found 418.2420. 
 
 
 
 
  ? ? ?
Synthesis of (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(2-oxo-2-(prop-2-yn-1-
ylamino)ethyl) quinuclidinium bromide 111e 
 
Using general procedure 2 starting with (3R)-1-azabicyclo[2.2.2]oct-3-yl 
hydroxy(diphenyl)acetate 104 (75 mg, 0.22 mmol) and 2-bromo N-(prop-2-ynyl) acetamide 
107 (97 mg, 0.56 mmol) yielded a white solid (75 mg, 66%). 
 
1H NMR: į 2.00-2.10 (2H,m), 237-2.43 (1H,m), 3.32-3.33 (1H, m), 3.36-3.44 (1H, m), 3.55-
3.65 (2H,m), 3.82-3.86 (2H, m), 3.96-4.02 (5H, m), 5.30-5.35 (1H,m), 4.10-4.14 (1H, m), 
7.32-7.48 (10H,m, ArH). 
13C NMR: į 19.16 (CH2), 24.05 (CH2), 25.01 (CH), 42.11 (CH2), 46.00 (CH2),. 46.84 (CH2), 
56.64 (CH2), 60.12 (CH2) 72.24 (CCH), 73.81 (OCH), 77.29 (COH), 78.5 (CCH), 127.03 
(ArC), 127.45(ArC), 127.80(ArC), 127.95(ArC), 128.00(ArC), 128.06(ArC), 128.24(ArC), 
142.33(ArC), 174.16 (CO). 
Mpt: 189-190 qC. 
FT-IR: (KBr) 3330, 3051(OH), 2784, 1726 (ester), 1670, 1449. 
HPLC Rt: 9.03 (System 1), 10.60 (System 2). 
ES-MS M-Br+ Calc. For C26H29N2O4+ Calc 433.2122 found 433.2179. 
 
 
 
  ? ? ?
Synthesis of (R)-1-(3-(3-ethynylphenoxy)propyl)-3-(2-hydroxy-2,2-diphenylacetoxy) 
quinuclidinium bromide 111f 
 
Using general procedure 2 starting with (3R)-1-azabicyclo[2.2.2]oct-3-yl 
hydroxy(diphenyl)acetate 104 (50 mg, 0.14 mmol) and 1-(3-bromopropoxy)-3-ethynylbenzene 
110 (83 mg, 3.48 mmol) yielded a white solid (34 mg, 53%). 
 
1H NMR: į 1.70-1.74 (1H,m), 1.95-2.03 (2H, m), 2.75-2.76 (2H, m), 2.98 (1H, s), 3.40-3.55 
(5H, m), 3.72-3.78 (1H,m), 4.04-4.15 (1H, m), 4.37-4.42 (2H, m), 5.20-5.26 (1H, m), 7.29-
7.45 (14H, m, ArCH). 
13C NMR į 19.14 (CH2), 24.05 (CH2), 25.09 (CH),35.60 (CH2), 42.14 (CH2), 43.12 (CH2), 
46.00 (CH2), 46.84 (CH2), 54.64 (CH2), 72.21 (CCH), 73.81 (OCH), 77.29 (COH), 78.5 
(CCH),125.51 (ArC),  127.03 (ArC), 127.45 (ArC), 127.80 (ArC), 127.95 (ArC), 128.00 (ArC), 
128.06 (ArC), 128.24 (ArC), 1290.33 (ArC), 131.11 (ArCH), 142.33 (ArC), 174.16 (CO). 
Mpt: 165-167 °C. 
FT-IR: (KBr) 3101 (OH), 2904, 1889, 1712 (ester), 1459, 1201. 
HPLC Rt: 11.20 (System 1), 12.95 (System 2). 
ES-MS M-Br+ calc. C32H34NO4+ 496.2482 found 496.2449. 
 
 
  ? ? ?
Synthesis of (R)-1-((4,4-difluoro-8-(4-(3-propoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-
s-indacene -1H-1,2,3-triazol-4-yl)methyl)-3-(2-hydroxy-2,2-diphenylacetoxy) 
quinuclidinium bromide 112a 
 
Using general procedure 1 starting with (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(prop-2-yn-
1-yl)quinuclidinium bromide 111a and 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-
dimethyl-4-bora-3a,4adiaza-s-indacene 46 yielded a red solid (1.0 mg, 50%). 
 
HPLC Rt: 12.90 (System 1). 
ES-MS M-Br+ calc. For C46H50BF2N6O4 799.3949 found 799.3915. 
Synthesis of (R)-1-((4,4-difluoro-8-(4-pentyl)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)methyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium bromide 112b 
 
Using general procedure 1 starting with (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(prop-2-yn-
1-yl)quinuclidinium bromide 111a and 4,4-difluoro-8-(4-(5-azidopentyl))phenyl-2,6-dimethyl-
4-bora-3a,4adiaza-s-indacene 61 yielded a red solid (2.2mg, 40%). 
 
HPLC Rt: 13.46 (System 1), 15.17 (System 2). 
  ? ? ?
ES-MS M-Br+ calc. For C48H54BF2N6O4 827.4262 found 827.4321. 
Synthesis of (R)-1-((4,4-difluoro-8-(2-ethoxy)ethoxy)phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)methyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium bromide 112c 
 
Using general procedure 1 starting with (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(prop-2-yn-
1-yl)quinuclidinium bromide 111a and 4,4-difluoro-8-(4-(2-azidoethoxy)ethoxy))phenyl-2,6-
dimethyl-4-bora-3a,4adiaza-s-indacene 65 yielded a red solid (3.3 mg, 33%). 
 
HPLC Rt: 12.78 (System 1), 15.00 (System 2). 
ES-MS M-Br+ calc. For C47H52BF2N6O5 829.4055 found 829.4056. 
Synthesis of (R)-1-(2-(4,4-difluoro-8-(4-(3-propoxy))phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)ethyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium bromide 113a 
 
Using general procedure 1 starting with (R)-1-(but-3-yn-1-yl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium bromide 111b and 4,4-difluoro-8-(4-(3-
  ? ? ?
azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 46 yielded a red solid 
(0.8mg, 39%). 
 
HPLC Rt: 12.75 (System 1), 15.22 (System 2). 
ES-MS M-Br+ calc. For C47H52BF2N6O4 813.4106 found 813.4292. 
Synthesis of (R)-1-(2-(4,4-difluoro-8-(4-pentyl)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)ethyl)-3-(2-hydroxy-2,2-diphenylacetoxy)quinuclidinium 
bromide 113b 
 
Using general procedure 1 starting with (R)-1-(but-3-yn-1-yl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium bromide 111b and 4,4-difluoro-8-(4-(5-azidopentyl))phenyl-
2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 61 yielded a red solid (0.4 mg, 20%). 
 
HPLC Rt: 15.80 (System 2). 
ES-MS M-Br+ calc. For C49H56BF2N6O4 841.4419 found 841.4412. 
 
 
 
 
  ? ? ?
Synthesis of (R)-1-(2-(4,4-difluoro-8-(2-ethoxy)ethoxy)phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)ethyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium bromide 113c 
 
Using general procedure 1 starting with (R)-1-(but-3-yn-1-yl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium bromide 111b 4,4-difluoro-8-(4-(2-
azidoethoxy)ethoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 65 yielded a red solid 
(1.3mg, 65%). 
 
HPLC Rt: 12.70 (System 1), 15.07 (System 2). 
ES-MS M-Br+ calc. For C48H54BF2N6O5 843.4211 found 843.4338. 
Synthesis of (R)-1-(3-(4,4-difluoro-8-(4-(3-propoxy))phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium chloride 114a 
 
Using general procedure 1 starting with (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(pent-4-yn-
1-yl)quinuclidinium chloride 111c and 4,4-difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-
dimethyl-4-bora-3a,4adiaza-s-indacene 46 yielded a red solid (1 mg, 50%). 
  ? ? ?
HPLC Rt: 12.80 (System 1), 15.02 (System 2) 
ES-MS M-Cl+ calc. For C48H54BF2N6O4 827.4262 found 827.4254. 
 
Synthesis of (R)-1-(3-(4,4-difluoro-8-(4-pentyl)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)propyl)-3-(2-hydroxy-2,2-diphenylacetoxy)quinuclidinium 
chloride 114b 
 
Using general procedure 1 starting with (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(pent-4-yn-
1-yl)quinuclidinium chloride 111c and 4,4-difluoro-8-(4-(5-azidopentyl))phenyl-2,6-dimethyl-
4-bora-3a,4adiaza-s-indacene 61 yielded a red solid (0.5 mg, 25%). 
 
HPLC Rt: 13.35 (System 1), 15.90 (System 3). 
ES-MS M-Cl+ calc. For C50H58BF2N6O4 855.4574 found 855.4575. 
 
 
 
 
  ? ? ?
Synthesis of (R)-1-(4-(4,4-difluoro-8-(4-(3-propoxy))phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)butyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium chloride 115a 
 
Using general procedure 1 starting with (R)-1-(hex-5-yn-1-yl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium chloride 111d and 4,4-difluoro-8-(4-(3-
azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 46 yielded a red solid (1.2 
mg, 64%). 
 
HPLC Rt: 12.87 (System 1), 15.53 (System 2). 
ES-MS M-Cl+ calc. For C49H56BF2N6O4 841.4419 found 841.4412. 
Synthesis of (R)-1-(4-(4,4-difluoro-8-(4-pentyl)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)butyl)-3-(2-hydroxy-2,2-diphenylacetoxy)quinuclidinium 
115b 
 
Using general procedure 1 starting with (R)-1-(hex-5-yn-1-yl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium chloride 111d and 4,4-difluoro-8-(4-(5-azidopentyl))phenyl-
2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 61 yielded a red solid (1.3 mg, 59%). 
 
HPLC Rt: 13.39 (System 1), 15.90 (System 2). 
  ? ? ?
ES-MS M-Cl+ calc. For C51H60BF2N6O4 869.4732 found 869.4749. 
Synthesis of (R)-1-(4-(4,4-difluoro-8-(2-ethoxy)ethoxy)phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)butyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium 115c 
 
Using general procedure 1 starting with (R)-1-(hex-5-yn-1-yl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium chloride 111d and 4,4-difluoro-8-(4-(2-
azidoethoxy)ethoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 65 yielded a red solid 
(0.98 mg, 20%). 
 
HPLC Rt: 12.72 (System 1), 14.98 (System 2). 
ES-MS M-Cl+ calc. For C50H58BF2N6O5 871.4524 found 871.4324. 
Synthesis of (R)-1-((2-(4,4-difluoro-8-(4-(3-propoxy))phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)methyl)amino)-2-oxoethyl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium bromide 116a 
 
Using general procedure 1 starting with (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(2-oxo-2-
(prop-2-yn-1-ylamino)ethyl)quinuclidinium bromide 111e and 4,4-difluoro-8-(4-(3-
azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 46 yielded a red solid (0.7 
mg, 35%). 
  ? ? ?
 
HPLC Rt: 12.60 (System 1), 14.87 (System 2). 
ES-MS M-Br+ calc. For C48H53BF2N7O5 856.4164 found 856.4100. 
Synthesis of (R)-1-((2-(4,4-difluoro-8-(4-pentyl)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene -1H-1,2,3-triazol-4-yl)methyl)amino)-2-oxoethyl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium bromide 116b 
 
Using general procedure 1 starting with (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(2-oxo-2-
(prop-2-yn-1-ylamino)ethyl)quinuclidinium bromide 111e and 4,4-difluoro-8-(4-(5-
azidopentyl))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 61 yielded a red solid (0.9 mg, 
36%). 
 
HPLC Rt: 13.15 (System 1), 15.60 (System 2). 
ES-MS M-Br+ calc. For C50H57BF2N7O5 884.4477 found 884.4481. 
  
  ? ? ?
Synthesis of (R)-1-((2-(4,4-difluoro-8-(2-ethoxy)ethoxy)phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)methyl)amino)-2-oxoethyl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium bromide 116c 
 
Using general procedure 1 starting with (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(2-oxo-2-
(prop-2-yn-1-ylamino)ethyl)quinuclidinium bromide 111e and 4,4-difluoro-8-(4-(2-
azidoethoxy)ethoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 65 yielded a red solid 
(0.94 mg, 47%). 
 
HPLC Rt: 12.47 (System 1), 14.62 (System 2). 
ES-MS M-Br+ calc. For C49H55BF2N7O6 886.4269 found 8846.4222. 
  
  ? ? ?
Synthesis of (R)-1-(3-(3-(4,4-difluoro-8-(4-(3-propoxy)phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)phenoxy)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium bromide DS117a 
 
Using general procedure 1 starting with (R)-1-(3-(3-ethynylphenoxy)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidin-1-ium bromide 111f and 4,4-difluoro-8-(4-(3-azidopropoxy)) 
phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 46 yielded a red solid (1.4 mg, 60%). 
 
HPLC Rt: 13.62 (System 1), 15.99 (System 3). 
ES-MS M-Br+ calc. For C54H58BF2N6O5 919.4524 found 919.457. 
  
  ? ? ?
Synthesis of (R)-1-(3-(3-(4,4-difluoro-8-(4-pentyl)phenyl-2,6-dimethyl-4-bora-3a,4adiaza-
s-indacene -1H-1,2,3-triazol-4-yl)phenoxy)propyl)-3-(2-hydroxy-2,2-diphenylacetoxy) 
quinuclidinium bromide 117b 
 
 
Using general procedure 1 starting with (R)-1-(3-(3-ethynylphenoxy)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidin-1-ium bromide 111f and 4,4-difluoro-8-(4-(5-
azidopentyl))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 61 yielded a red solid (1.2 mg, 
60%). 
 
HPLC Rt: 14.15 (System 1). 
ES-MS M-Br+ calc. For C56H62BF2N6O5 947.4837 found 947.4821. 
Synthesis of (R)-1-(3-(3-(4,4-difluoro-8-(2-ethoxy)ethoxy)phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)phenoxy)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium bromide 117c 
 
Using general procedure 1 starting with (R)-1-(3-(3-ethynylphenoxy)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidin-1-ium bromide 111f and 4,4-difluoro-8-(4-(2-
azidoethoxy)ethoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 65 yielded a red solid 
( 1.1 mg, 40%). 
 
  ? ? ?
HPLC Rt: 13.34 (System 1), 15.67 (System 2). 
ES-MS M-Br+ calc. For C55H60BF2N6O6
 949.4630 found 949.4693. 
Synthesis of (R)-1-(2-((N-(2 azidoethyl)-2-(4,4-difluoro-4,4a-dihydro-5-(thiophenyl)-4-
bora-3a,4a-  diaza-s  indacene 3-yl)vinyl)phenoxy)acetamide -1H-1,2,3-triazol-4-
yl)ethyl)-3-(2-hydroxy-2,2-diphenylacetoxy)quinuclidinium bromide 118a 
 
Using general procedure 1 starting with (R)-1-(but-3-yn-1-yl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidinium bromide 111b and N-(2  azidoethyl)-2-(4,4-difluoro-4,4a-
dihydro-5-(thiophenyl)-4-bora-3a,4a- diaza-s indacene 3-yl)vinyl)phenoxy)acetamide 85 
yielded a blue solid (0.7mg, 35%). 
 
HPLC Rt: 12.22 (System 1), 14.62 (System 2). 
ES-MS M-Br+ calc. For C50H49BF2N7O5S
 908.3572 found 908.3566. 
 
 
 
 
 
  ? ? ?
(R)-1-(3-(N-((2  azidoethyl)-2-(4,4-difluoro-4,4a-dihydro-5-(thiophenyl)-4-bora-3a,4a-
 diaza-s  indacene 3-yl)vinyl)phenoxy)acetamide -1H-1,2,3-triazol-4-yl)propyl)-3-(2-
hydroxy-2,2-diphenylacetoxy)quinuclidinium chloride 118b 
 
Using general procedure 1 starting with (R)-1-(3-(3-ethynylphenoxy)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy)quinuclidin-1-ium bromide 111c and N-(2  azidoethyl)-2-(4,4-difluoro-4,4a-
dihydro-5-(thiophenyl)-4-bora-3a,4a- diaza-s indacene 3-yl)vinyl)phenoxy)acetamide 85 
yielded a blue solid (0.98 mg, 25%). 
 
HPLC Rt: 12.48 (System 1), 15.28 (System 2). 
ES-MS M-Br+ calc. For C57H55BF2N7O6S 1014.3990 found 1014.3925. 
Synthesis of Sodium 2-Sulfonate-1,3,5,7-tetramethyl-8-(4-(3-azidopropoxy))phenyl -4,4- 
difluoro-4-bora-3a, 4a-diaza-s-indacence 119 
 
4,4-Difluoro-8-(4-(3-azidopropoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 46 
(135 mg, 0.31 mmol) was dissolved in anhydrous DCM (20 mL) and cooled to -40 °C under a 
nitrogen atmosphere. Chlorosulfonic acid (230 ȝL, 0.34 mmol) was added dropwise and stirred 
at -40 °C for tenminutes. The reaction mixture was then warmed to room temperature and 
stirred for 30minutes. Sodium hydrogen carbonate (310 mg, 0.36 mmol) was added to the 
  ? ? ?
reaction mixture and the organic layer was separated. The aqueous layer was collected and 
concentrated. The residue was purified by reverse phase HPLC and yielded an orange solid 
(100 mg, 62%). 
 
1H NMR: į 1.48 (3H, s, CH3), 1.72 (3H, s, CH3) 2.08-2.12 (2H, m, CH2CH2CH2N3), 2.53 (2H, 
s, CH3), 2.77 (2H, s, CH3), 3.55 (2H, t, J 6.8, CH2CH2CH2N3), 4.09 (2H, t, J 6.2, 
CH2CH2CH2N3), 5.96 (2H, s, CH), 7.15 (2H, d, J 9.0, ArH), 7.25 (2H, d, J 9.0, ArH).  
13C NMR: į 14.50, 15.45, 16.43, 17.22 (CH3), 28.99 (CH2CH2N3), 48.21 (CH2N3), 64.82 
(OCH2), 115.11 (phenyl CH), 121.27 (pyrrole CH), 127.20 (Phenyl C), 129.21 (NCCCH3), 
132.44 (Phenyl CH), 141.88 (CH3CC), 143.28 (PhenylC-C), 155.46 (NCCH3), 159.40 (Phenyl 
CO). 
Mpt: 156-158 °C. 
FT-IR: 3431 (br, pyrrole ring), 2933, 2737, 2676, 2092 (N3), 1607(conjugated C=N), 1353 
(S=O str). 
Synthesis of methyl 2-azido-4-bromobutanoate 121 
 
To a solution of methyl 2,4-dibromobutyrate 120 (5 g, 19.3 mmol) in DMF (10 mL), sodium 
azide (1.32 g, 20.26 mmol) was added at 0 °C and gently warmed to room temperature. The 
reaction was stirred for three hours was was poured into water (100 mL) and washed with ether 
(3 x 30mL). The organics were combined, washed with brine, dried and concentrated to yield 
clear oil (3.9 g, 91%). The product was used without further purification. 
 
1H NMR: į 2.12-2.20 (1H, m, CHCH2), 2.26-2.34 (1H, m, CHCH2), 3.40-3.50 (2H, m, CH2Br), 
3.79 (3H, s, OCH3), 4.18-4.22 (1H, m, CH).
 
13C NMR: į 33.94, (CHCH2), 28.71 (CH2Br), 60.21 (OCH3), 65.82 (CH), 162.52 (CO).  
  ? ? ?
Synthesis of methyl 2-azido-4-(4-formylphenoxy)butanoate 122 
 
4-Hydroxybenzaldehyde (395 mg, 3.23 mmol) and K2CO3 (892 mg, 6.46 mmol) was dissolved 
in DMF (20 mL) to which methyl 2-azido-4-bromobutanoate 121 (1 g, 4.5 mmol) was added 
and heated to 60 °C for three hours. The reaction mixture was cooled and poured into water 
(100mL) The product was extracted with ether (3 x 30mL). The organics were combined, 
washed with brine, dried and concentrated to yield a clear oil (500 mg, 58%). The product was 
used without further purification. 
 
1H NMR: į 2.12-2.20 (1H, m, CHCH2), 2.32-2.39 (1H, m, CHCH2), 3.40-3.50 (2H, m, OCH2), 
3.76 (3H, s, OCH3), 4.14-4.18 (2H, m, OCH2),  4.20-4.26 (1H, m, CH), 6.96 (2H, d, J 8.9, 
ArCH), 7.81 (2H, d, J 8.9, ArCH). 
13C NMR: į 33.94, (CHCH2), 42.54 (OCH2), 60.21 (OCH3), 65.82 (CH), 114.88 (ArC), 130.27 
(ArC), 132.13 (ArC), 163.79 (ArCO), 162.52 (CO), 190.89 (Ar-C=O). 
Synthesis of 4,4-difluoro-8-(methyl 2-azido-4-(4-formyl))phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene 123 
 
Methyl 2-azido-4-(4-formylphenoxy)butanoate 122 (500 mg, 1.9 mmol) and 2,4-
dimethylpyrrole (39 ȝL, 3.8 mmol) were dissolved in anhydrous DCM (200 mL) under a 
nitrogen environment. TFA (2 drops) were added and the reaction mixture was stirred 
overnight. DDQ (431 mg, 1.9 mmol) was added in a single portion and stirred for one hour. 
Triethylamine (2 mL, 1.46 mmol) and BF3.OEt2 (2 mL, 1.88 mmol) were added to the reaction 
  ? ? ?
mixture which was stirred for 12 hr. The reaction mixture was poured into water (200 mL) and 
extracted with DCM (3 x 50mL). The organics were combined and washed with brine, dried 
and concentrated. The product was purified by reverse phase HPLC to yield a red solid (209 
mg, 23%). 
 
1H NMR: į 1.43 (6H, s, CH3), 2.12-2.20 (1H, m, CHCH2), 2.32-2.39 (1H, m, CHCH2), 2.55 
(6H, s, CH3), 3.76 (3H, s, OCH3), 4.14-4.18 (2H, m, OCH2), 4.20-4.26 (1H, m, CH), 5.97 (2H, 
s, 6.96, CH), (2H, d, J 8.9, ArCH), 7.81 2H, d, J 8.9, ArCH. 
Mpt: 144-146 °C. 
ES-MS MH+ calc. For C24H27BF2N5O3 482.2170 found 482.2175 
Synthesis of 4,4-difluoro-8-(4-(2-azido-4-(4-formyl)phenoxy))phenyl-2,6-dimethyl-4-bora-
3a,4adiaza-s-indacene 124 
 
4,4-Difluoro-8-(methyl 2-azido-4-(4-formyl))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene 123 (20 mg, 0.42 mmol) was dissolved in MeOH/water (2:5 mL). LiOH (5 mg, 2.1 
mmol) was added over ice and the reaction was stirred for three hours. The MeOH was 
evaporated and the aqueous phase was washed with DCM (2 x 10mL). The aqueous layer was 
acidified with 1M HCl and the product was extracted with DCM (3 x 10mL). The organics 
were washed with brine, dried and concentrated to yield a red solid (34 mg, quantitative yield). 
 
1H NMR: į 1.43 (6H, s, CH3), 2.20-2.22 (1H, m, CHCH2), 2.40-2.47 (1H, m, CHCH2), 2.55 
(6H, s, CH3), 4.16-4.20 (2H, m, OCH2), 4.20-4.26 (1H, m, CH), 5.97 (2H, s, 6.96, CH),7.00 
(2H, d, J 8.9, ArCH), 7.81 (2H, d, J 8.9, ArCH). 
  ? ? ?
13C NMR: į 14.60 (CH3), 22.62 (CH2CHN3), 41.34 (CHN3), 63.36 (OCH2), 115.05 (phenyl 
CH), 121.11 (pyrrole CH), 127.64 (Phenyl C), 129.34 (NCCCH3), 131.8 (Phenyl CH), 141.40 
(CH3CC), 143.14 (PhenylC-C), 155.37 (NCCH3), 158.87 (Phenyl CO), 174.80 (COOH). 
Mpt: 136-138 °C 
ES-MS MH+ calc. For C23H25BF2N5O3
 468.2013 found 468.2175 
Synthesis of 4,4-difluoro-8-(4-(2-(2-azido-4-(4-formyl)phenoxy)butanamido))phenyl-2,6-
dimethyl-4-bora-3a,4adiaza-s-indacene 127 
 
4,4-difluoro-8-(4-(2-azido-4-(4-formyl)phenoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-
indacene 126 (15 mg, 0.32 mmol) and HBTU (12 mg, 0.35 mmol) were dissolved in DCM (5 
mL). DIPEA (12.3 ȝL, 0.35 mmol) was added and the reaction mixture was stirred for 30 
seconds before the addition of glycine methyl ester 125 (3.6 mg, 0.035 mmol). The reaction 
mixture was stirred overnight and the reaction mixture was concentrated. Deprotection of the 
methyl ester with LiOH (15mg, 6.3 mmol) dissolved in water/MeOH (2:5mL) and stirred for 
six hours. The MeOH was evaporated and the aqueous phase was washed with DCM (2 x 
10mL). The aqueous layer was acidified with 1M HCl and the product was extracted with 
DCM (3 x 10mL). The organics were washed with brine, dried and concentrated to yield a red 
solid (16 mg, 16%). 
 
1H NMR: į 1.42 (6H, s, CH3), 2.54 (6H, s, CH3), 2.82 (2H, s, CH2COOH), 4.16-4.20 (2H, m, 
OCH2), 4.20-4.26 (1H, m, CH), 5.97 (2H, s, 6.96, CH), 7.00 (2H, d, J 8.9, ArCH), 7.81 (2H, d, 
J 8.9, ArCH). 
  ? ? ?
13C NMR: į 14.60 (CH3), 22.62 (CH2CHN3), 41.34 (CHN3), 63.36 (OCH2), 115.05 (phenyl 
CH), 121.11 (pyrrole CH), 127.64 (Phenyl C), 129.34 (NCCCH3), 131.8 (Phenyl CH), 141.40 
(CH3CC), 143.14 (PhenylC-C), 155.37 (NCCH3), 158.87 (Phenyl CO), 174.80 (COOH). 
Mpt: 154-156 °C. 
Synthesis of (R)-1-(3-(4,4-difluoro-8-(4-(2-azido-(4-formyl)phenoxy)phenyl-2,6-dimethyl-
4-bora-3a,4adiaza-s-indacene -1H-1,2,3-triazol-4-yl)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium chloride 128a 
 
Using general procedure 1 starting with 4,4-difluoro-8-(4-(2-azido-4-(4-
formyl)phenoxy))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 124 (1eq) and (R)-3-(2-
hydroxy-2,2-diphenylacetoxy)-1-(pent-4-yn-1-yl)quinuclidinium chloride 111c (1.1eq) yielded 
a red solid after HPLC purification (3.9mg, 57%). 
 
HPLC Rt: 12.48 (System 1), 15.28 (System 2). 
ES-MS M-Cl+ calc. For C49H56BF2N6O6 872.4239 found 872.4245 
 
 
 
 
 
  ? ? ?
Synthesis of (R)-1-(3-(4,4-difluoro-8-(4-(2-(2-azido-4-(4-
formylphenoxy)butanamido)))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene -1H-
1,2,3-triazol-4-yl)propyl)-3-(2-hydroxy-2,2-diphenylacetoxy) quinuclidinium chloride 
128b 
 
Using general procedure 1 starting with 4,4-difluoro-8-(4-(2-(2-azido-4-(4-
formyl)phenoxy)butanamido))phenyl-2,6-dimethyl-4-bora-3a,4adiaza-s-indacene 127 (1eq) 
and (R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(pent-4-yn-1-yl)quinuclidinium chloride 111c 
(1.1eq) yielded a red solid after HPLC purification (2.9mg, 47%). 
 
HPLC Rt: 12.48 (System 1), 15.28 (System 2). 
ES-MS M-Cl+ calc. For C51H58BF2N7O7 929.4448 found 929.4427 
Synthesis of (R)-1-(3-(2-sulfonate-1,3,5,7-tetramethyl-8-(4-(3-azidopropoxy))phenyl -4,4- 
difluoro-4-bora-3a, 4a-diaza-s-indacence -1H-1,2,3-triazol-4-yl)propyl)-3-(2-hydroxy-2,2-
diphenylacetoxy) quinuclidinium 129 
 
 
  ? ? ?
Using general procedure 1 sodium 2-sulfonate-1,3,5,7-tetramethyl-8-(4-(3-
azidopropoxy))phenyl -4,4-difluoro-4-bora-3a, 4a-diaza-s-indacence 119 (1eq) and (R)-3-(2-
hydroxy-2,2-diphenylacetoxy)-1-(pent-4-yn-1-yl)quinuclidinium chloride 111c (1.1eq) yielded 
a red solid after HPLC purification (2.9mg, 47%). 
 
HPLC Rt: 10.70 (System 1), 12.15 (System 2). 
ES-MS M-Cl+ calc. For C51H58BF2N7O7 908.3909 found 908.3910 
 
 
  ? ? ?
Pharmacology 
Whole Cell Culture 
All reagents used were obtained from Sigma chemicals (Poole, Dorset, UK), unless otherwise 
stated. All plates were obtained from Corning Costar (Corning Incorporated, Corning, NY, 
USA), unless otherwise stated. 
CHO-K1-ȕ1, CHO-K1-ȕ2 and CHO M3 cells were used throughout this study. CHO-K1 cells 
were obtained from Dr Jillian Baker who performed the transfection, dilution cloning and 
isolation of a stable clone. CHO M3 cells were obtained from Dr Lauren May who performed 
the transfection, dilution cloning and isolation of a stable clone.  
All cell lines were cultured in Dulbecco’s modified Eagle’s medium/nutrient mix F12 
(DMEM/F12) supplemented with 2mM L-glutamine and 10% heat-inactivated foetal calf 
serum (FCS) (PAA Laboratories, Teddington, Middlesex, UK). CHO cells were incubated at 
37 °C, 5% CO2. All cell culture procedures were performed in a class II laminar flow hood 
using sterile techniques. 
Passaging of cells 
All CHO cell lines were passaged once they had grown to confluence in a T75 flask. Media 
was removed and the cells were washed with warm Dulbecco’s phosphate buffered saline 
(PBS) (5-10 mL). PBS was removed and cells were then incubated with warm trypsin/EDTA 
(T/E) (1 mL) for 2-3minutes or until cells were loosened from the bottom of the flask. Once 
detached, the T/E was neutralised with media (10 mL) and the resulting suspension was spun at 
1000 rpm for fiveminutes. The pellet was re-suspended in media (1 mL); this step involved 
rapid agigtation to ensure a uniform suspension was produced. The media was then added to 
make the volume 20mL and the resulting suspension was dispensed as appropriate into 75 mL 
flasks. All CHO cell lines were generally split 1:20. 
Seeding into cell plates 
All CHO  cells from confluent T75 flasks were removed from the flask and centrifuged as 
described above. Cell required for radioligand binding assays were seeded 24 hours prior to 
  ? ? ?
experiments. One T75 flask was used to set up a maximum of four 96-well. Cells required For 
intracellular calcium assays were seeded 24 hours prior to experiment One T75 flask was used 
to set up a maximium of six 96 well plates.  
 
Cell freezing and thawing 
Cells from confluent T150 flasks were removed from the flask and centrifuged as described 
previously. One pellet from a T150 flask was carefully re-suspended in the freezing medium (5 
mL, 10% DMSO in FCS). 1 mL of cell suspension was transferred to each cryovail (Nalgene, 
Rochester, NY, USA) and cooled in an isopropanol filled freezing chamber to reduce the 
temperature at a rate of approximately 1 °C/min for 24 hours. The following day, cryovials 
were transferred to the liquid nitrogen dewars for freezing.  
Cells were thawed by removing one cyrovial from the storage in liquid nitrogen and rapidly 
warmed to 37 °C. The contents of the vial were suspended into growth media (10 mL) and the 
resulting suspension was spun at 1000rpm for fiveminutes. The pellet was resuspended in 
media (1 mL) and transferred to a 75 mL flask containing 20 mL of media. After 8-12 hours, 
growth media was removed and replaced wth fresh growth media, removing the cell debris that 
did not survive the freezing/thawing process. 
 
Assays 
Radioligand binding assays 
Cells were seeded into 96-well white sided plates 24 hours prior to the assay. On the day of 
experimentation, all media was aspirated and different concentrations of the ligand were added 
(100ȝl/well) in triplicate. Total and non-specific binding was defined by adding serum free 
media in triplicate (total binding) and 1 ȝl propranolol (non specific binding). [3H]-CGP 12177 
was made at a concentration of 0.5 nM in serum free media and as added to all wells (100 
ȝl/well). The cells were incubated for 2 hours at 37 °C, 5% CO2. After 2 hour incubation, the 
cells were washed twice with cold PBS (200 ȝl/well) in order to wash any unbound ligand 
from the cells. White backing was added to each plate and 100 ȝl of microscintillent was added 
to each well. Finally the plates were sealed and counted on a Topcount Microplate Illuminator.  
 
  ? ? ?
Data Analysis 
All data are represented as mean ± s.e. of triplicate determinations unless otherwise stated. The 
n in the text refers to the number of separate experiments (a separate experiment requires cells 
plated from a separate plate and separate drug dilution used throughout the experiment). 
In order to determine the actual concentration of radioligand, 50 ȝl was added in triplicate to 
scintillation vials. Scintillation fluid (10 mL) was added to each vial and the vial was counted 
on a scintillation counter. 
The dpm was then converted to concentration of [3H]-CGP 12177 from the following: 
1 Ci = 2.22 x 1012. Specific activity of 3H-CGP 12177 = 45 Ci/mmol 
therefore 1dpm = 1/(45 x 2.22 x1012) mmol. 
Kd values were then determined from the IC50 values and concentration of radioligand 
according to the expression141 D?H?ൌ D?D?H?H?ሺ ? ൅D?D?H?ሺH?H?H?ሻൗ  
Where [A] is the concentration of [3H]-CGP 12177 used in the displacement and Kd is the 
dissociation constant (Kd) of [
3H]-CGP 12177. 
 
Intracellular calcium assay 
Cells were seeded into 96-well black sided plates 24 hours prior to the assay. On the day of 
experimentation, all media was aspirated and different concentrations of the ligand were added 
(20 ȝl) with assay buffer (Hank’s Buffered Salt Solution, brilliant black (0.5mM), fura-2 (2 
mM) and probenacid (2 mM). The plates were incubated for 0.5 hours at 37 °C, 5% CO2 then 
assay plates were then placed onto the flexstation 1 fluorescence plate reader for measuring the 
changes of intracellular calcium in response to the GPCR activation. The fluorescent signal 
was recorded for 200 seconds with carbachol (10 ȝl) added at 20 seconds.  
Data analysis 
 
All data are represented as mean ± s.e.m of triplicate determinations unless otherwise stated. 
The n in the text refers to the number of separate experiments (a separate experiment requires 
cells plated from a separate plate and separate drug dilution used throughout the experiment). 
  ? ? ?
Kd values were determined from the IC50 values and concentration of carbachol according to 
the expression171 
D?D? ൌ  ? ൅ሾD?ሿD?H? 
Where DR (dose ± ratio) is the ratio of the concentrations of agonist required to produce an 
identical response in the presence and absence of antagonist, [A] is the concentration of 
antagonist and Kb is the antagonist inhibitory constant.  
 
Binding kinetic assays 
Cell Membranes were pre-prepared using established procedures37 by Mr David Sykes 
(Novartis Institute for Biomedical Research). 
On the day of experimentation, different concentrations using of antagonist were diluted in 
assay buffer (10 mM HEPES, 1 mM MgCl2, pH 7.4) and were added (100 ȝl/well) in triplicate. 
Assay buffer (200 ȝl) was added to each well. Non specific was defined by adding assay buffer 
in triplicate and 100 ȝl atropine (5 ȝM). [3H]-NMS was made at a concentration of 1 nM in 
buffer and was added (100ȝl/well). Membranes were prepared and at each time point cell 
membranes (100 ȝl (10 ȝg/well) were added. The plates were sealed and shaken at 37 °C. 
Termination of reaction by rapid vacuum filtration onto pretreated unfiltered GF/B plates and 
washed three times with ice cold buffer. Plates were dried at 48 °C for two hours in a 
controlled temperature incubator. White backs were placed onto the filter plates and 40 ȝl of 
microscintillent was added to each well. Finally the plates were sealed and counted on a 
Topcount Microplate Illuminator.  
In order to determine the actual concentration of radioligand, 50 ȝl was added in triplicate to 
scintillation vials. Scintillation fluid (5 mL) was added to each vial and the vial was counted on 
a scintillation counter. 
Data analysis 
The dpm was then converted to concentration of [3H]-NMS from the following: 
1 Ci = 2.22 x 1012. Specific activity of [3H]-NMS = 82 Ci/mmol 
therefore 1dpm = 1/(82 x 2.22 x1012) mmol. 
The association (k3) and disassociation rate (k4) for antagonists were calculated in line with 
  ? ? ?
Sykes et al.37 
 
Confocal microscopy 
 Confocal microscopy was performed using a Zeiss LSM510 laser-scanning microscope. All 
experiments used a Zeiss 40 x 1.3 NA oil immersion lens. 
 
Imaging 
Cells were seeded into 8-well plates 24 hours prior to experiment. (If wells needed 
preincuation with poly- L -lysine, (1mg/mL) was incubated for one hour, followed aspiration 
and washing with PBS.) On the day of the experiment, all media was aspirated and the cells 
were washed twice with warmed 500 ȝl HBS. HBS (300 ȝl) was added to each well which 
provided a media into which the antagonists could be added. The holder was transferred to a 
heated stage on the microscope, which allowed cells to be maintained at 37 °C throughout the 
experiments. Cells were allowed to settle for 15minutes before each antagonist (30 ȝl) was 
added. When competition antagonist were used, cells were incubated for 15minutes before 
addition of fluorescent antagonist. All images were taken at 1024 x 1024 pixels. 
 
 
Stability Experiments 
Antagonists were diluted from DMSO stock solution to 10-4 M concentration in serum free 
media and incubated for a maximum of six hours. This incubation time was chosen as it above 
and beyond the time length in which the antagonists would be in solution for. HPLC analytical 
traces were performed with 20 PL of antagonist/serum free media and were injected at 0 hr, 0.5 
hr, 1 hr, 2 hr 3 hr and 6 hr in order to observe if the media had caused any decomposition of the 
ligands. Results showed that there was no decomposition of any antagonists.  
  
  ? ? ?
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